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Summary
This thesis advances the understanding of mitochondrial dynamics in adipocytes. 
Chapter 1 outlines mitochondrial dynamics, health, function and quality control in the 
context of obesity  and T2DM. Chapters 2 and 3 are concerned with characterising 
mitochondrial dynamics in human abdominal subcutaneous adipose tissue and how 
the balance of this process may be augmented by adiposity and bariatric surgery. As 
an extension of this, Chapter 4 explores the potential regulatory role of p38 within 
adipogenesis in the 3T3-L1 cell line model together with the interplay  between p38 
and mitochondrial dynamics throughout differentiation. As part of this study, the 
impact of modulating p38 by chemical means or via the introduction of an 
overexpression vector was used to investigate the functional consequences of this 
gene on mitochondrial bioenergetics. The subtle balance of mitochondrial fusion and 
fusion markers is critical, not only for controlling the abundance and bioenergetic 
health of mitochondria but also, for overall cellular health. Finally, Chapter 5 extends 
analysis of the regulatory  role of p38 on mitochondrial dynamics through 
computational modelling of the p38β	  . From the entire AstraZeneca compound collec-
tion, a series of novel and putative p38β inhibitors were selected for further functional 
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21.1 Obesity and T2DM.
1.1.1 Definition of Obesity and T2DM.
Obesity is a key contributory factor in the development of insulin resistance 
(Fernandez-Sanchez, Madrigal-Santillan et al. 2011). The excess accumulation of fat 
in both overweight (BMI ≥	  25 kg/m2) and obese	   (BMI ≥	  30 kg/m2) individuals results 
in 2.8 million deaths per year (World Health Organization.). The co-existence of insu-
lin resistance and obesity are known as significant risk factors for the development of 
Type 2 Diabetes Mellitus (T2DM) (Bastard, Maachi et al. 2006, Abdullah, Peeters et 
al. 2010).
Figure 1.1. Central vs peripheral fat depots. Central fat accumulation (subcutane-
ous or visceral adipose tissue) is referred to colloquially  as an ‘apple’	   shape (left) 
whilst peripheral deposition of fat (thighs, hips, buttocks) is termed as a ‘pear’ 	  body 
type (	  right). Image taken from http://averaorg.adam.com.
31.1.2.	  Prevalence and financial impact of obesity.
T2DM accounts for 90% of all diagnosed cases of diabetes (Diabetes UK). T2DM 
develops by  one of two mechanisms, an inability  of pancreatic beta cells to produce 
sufficient insulin or the development of cellular insensitivity  to insulin (i	   	  nsulin resis-
tance (IR)) (DeFronzo 2004). The consequence of IR is the inability to control blood 
glucose (Nesher, Della Casa et  al. 1987, Covey, Wideman et al. 2006, Bao, Jacobson 
et al. 2008) and onset  of hyperglycaemia (Mah and Bruno 2012). Typically, T2DM 
develops and is diagnosed in Caucasians over 40 years of age (1994, Sharp, Grunwald 
et al. 2003, Gujral, Pradeepa et al. 2013). However, in south Asians, T2DM can occur 
as early as 25 (Diabetes UK). South Asians exhibit a greater tendency than Caucasian 
cases towards central lipid storage in the abdominal and visceral adipose tissue depots 
(Morris, Velkoska et al. 2005, Nystad, Melhus et  al. 2010, Cai 2013, Ali, Cerjak et al. 
2014). Meta-analysis of the risk factors for the development of diabetes, indicate that 
80-85% can be explained by obesity (Abdullah, Peeters et al. 2010). Between 1993 
and 2011, obesity increased from 13 to 24% in men and 16 to 26% of women (NHS). 
Together with the trend towards increasing adiposity, cases of diabetes are set  to dou-
ble, in percentage terms, from 5% of the UK population in 2011, to 5 million people 
(~12% of today’s population) (Statistics from World Health Organisation, WHO). In 
conjunction with the requirement for pharmacological control of diabetes and treat-
ment of obesity, these conditions are often associated with secondary complications 
including vascular diseases such as coronary artery disease, peripheral vascular dis-
ease, renal diseases and ophthalmological disease, which could lead to blindness and 
peripheral nerve damage causing neuropathy (Sharp, Grunwald et al. 2003). In 2035, 
the financial cost of treating diabetes and its associated complications is estimated to 
4reach £39.8 billion (Farzadfar, Finucane et al. 2011). Given the public health burden 
of diabetes and obesity globally, understanding at a molecular level, the regulation of 
insulin sensitivity and diabetes, is of vital significance.
1.1.3. Adipose tissue; central vs peripheral obesity. 
Adipose tissue is the primary storage depot for excess nutritional intake. During con-
ditions of nutrient  excess, adipocytes store excess dietary lipids as triglycerides (Ra-
jala and Scherer 2003). Excess dietary intake can be stored centrally (subcutaneous or 
visceral AT) or in peripheral regions (hips, thighs, buttocks) (Rosen and Spiegelman 
2006) (	  Figure 1.1). Deposition of excess triglycerides centrally  is a major risk factor 
for the onset of metabolic conditions including but not limited to, cardiovascular dis-
ease and T2DM (Jung and Choi 2014). 
1.1.4. Adipose tissue remodelling in obesity.
Adipocytes are capable of cellular remodelling. The inherent flexibility  of adipocytes 
enables them to dynamically increase their number	   and size in response to conditions 
of nutrient excess (Lemoine, Ledoux et al. 2012). Adipose tissue remodelling can oc-
cur in one of two ways; through increased adipose tissue number	  (hyperplasia) or vol-
ume (hypertrophy) (Figure 1.2). The ability of adipocytes to store excess dietary  in-
take as triglycerides is finite and this capacity differs between individuals (Figure 
1.3.) (Scherer 2006, Sun, Kusminski et al. 2011) (Figure 1.3). Once this expansion 
capacity has been reached, triglycerides must seek new sites of fat  deposition (Jung 
and Choi 2014). 
5Figure 1.2. Hypertrophy vs Hyperplasia.
Adipose tissue remodelling can occur in one of two ways, through increased adipo-
cyte 	  number (hyperplasia) or volume (hypertrophy). The ability of adipocytes to store 
excess dietary  intake as triglycerides is finite and this capacity differs between indi-
viduals (expansion limit). Hyperplasia is accompanied by increased adiponectin se-
cretion and reduction in inflammatory  adipokines. Conversely, hypertrophy  decreases 
adiponectin whilst increasing inflammatory adipokines. In obesity, hypertrophy pre-
vails. Figure adapted from Queiroz, J.C. et al. (2009) Arg Bras Endocrinol Metabol.
6Figure 1.3. Healthy and unhealthy adipose tissue expansion.
(A) The conversion of preadipocytes to mature adipocytes is accompanied with acti-
vation of angiogenesis, thereby maintaining sufficient oxygen supply. Continued at-
tempts to store excess nutrient supply as triglycerides above the expansion limit of 
adipocytes results in the onset of hypoxia and inflammation	   . Hypoxia occurs in re-
gions of adipose tissue with insufficient oxygen supply. (B) In contrast, unhealthy 
adipose tissue expansion is accompanied by  significant enlargement of adipocytes 
under conditions of limited angiogenesis and corresponding development of hypoxia. 
Together with the induction of hypoxia inducing factor 1 (HIF-1 alpha), fibrosis is 
initiated. Furthermore, inflammation increases as a result of the recruitment of M1 
macrophages into adipose tissue. M1 macrophages are a pro-inflammatory phenotype. 
Conversely, M2 macrophages are anti-inflammatory and have been proposed to be 
involved in tissue repair. Overall the contribution of macrophages in this adipose tis-
sue, is towards a pro-inflammatory bias, which is strongly associated with insulin re-
sistance. Figure taken from (Sun, Kusminski et al. 2011).
7These excess lipids remain in the circulation and are deposited in secondary organs 
such as the liver and heart resulting in lipotoxicity  and cardiac damage (Vigouroux, 
Caron-Debarle et al. 2011). During obesity and T2DM, these circulating lipids acti-
vate the innate immune system and maintain a state of chronic low grade or meta-
inflammation within adipose tissue (Creely, McTernan et al. 2007). Taken together, 
these conditions have negative implications for cellular metabolism (Bastard, Maachi 
et al. 2006, Hotamisligil 2006, Hotamisligil and Erbay 2008). A reduction in insulin 
sensitivity and metabolic function are two cornerstones of metabolic syndrome (Vir-
tue and Vidal-Puig 2010). As a condition, Metabolic Syndrome (MetS) is defined as 
the co-existence of conditions including obesity, insulin resistance and dyslipidemia 
within patients (Abella, Scotece et al. 2014). Individuals exhibiting Metabolic Syn-
drome display sustained insulin resistance during fasting and post-prandially (Harte, 
Varma et al. 2012, Piya, Harte et al. 2013). Finally, additional evidence for the func-
tional link between lipid and IR is, that humans with lipodystrophy due to genetic mu-
tations, also present with insulin resistance (Simha and Garg 2009). 
1.1.5. Metabolic flexibility is compromised in obesity.
Cells are programmed to exhibit metabolic flexibility  (Mingrone, Manco et al. 2005). 
In response to substrate availability  and cellular demand, cells are capable of switch-
ing between lipid or glucose oxidation (Astrup, Buemann et al. 1996, Blaak and Saris 
2002). Under homeostatic conditions, glucose oxidation is more commonly used as a 
cellular substrate. The randall hypothesis was proposed to explain the etiology  of 
T2DM during obesity. During obesity and T2DM, the excess circulating free fatty ac-
ids (substrates in fatty acid oxidation), considered to originate from the more metab-
8olically active abdominal adipose depots, may contribute to the impairment of glyco-
lysis and development of glucose intolerance. One process by which this may occur is 
the stimulation of gluconeogenesis in hepatocytes (stimulated by free fatty acids and 
results in the creation of glucose from predominantly  pyruvate, glycerol or lactate) 
further compounding the situation. In an attempt to return these elevated glucose lev-
els to a homeostatic level, the pancreas releases insulin to promote the conversion of 
the glucose to glycogen. The impairment of glycolysis and continued release of insu-
lin to control glucose levels in the blood, places significant pressures on energy ho-
meostasis regulation. Research has suggested that it  is the impairment of carbohydrate 
metabolism and development of glucose intolerance, orchestrated by these circulating 
free fatty acids, which are responsible for the pathophysiology of T2DM.
1.2. Energy homeostasis in adipose tissue.
1.2.1.    Regulation of energy metabolism in a	  	  dipose tissue.
Previously dismissed as nothing but a passive site for excess energy  storage (Ahima 
2006), the identification that adipokines secreted from a	   	  dipose tissue can modulate 
energy homeostasis, insulin action and whole body metabolic processes including 
glucose and lipid metabolism (Antuna-Puente, Feve et al. 2008, Abella, Scotece et  al. 
2014, Knights, Funnell et al. 2014), has brought the role of a	   	  dipose tissue as an en-
docrine organ to the fore. The origin of the term adipokines, was coined to collec-
tively represent the group of hormones generated from adipocytes and the stromal 
vascular fraction within the adipose tissue (Antuna-Puente, Feve et al. 2008). A multi-
tude of cell types including preadipocytes, macrophages and fibroblasts are contained 
within the stromal vascular fraction (Kim, Choi et al. 2010, Peinado, Jimenez-Gomez 
9et al. 2010, Liu, Guo et al. 2014). Collectively, these cell types work in coordination 
with the adipokines secreted from them, to support the a	   	  dipose tissue within energy 
homeostasis (Lehr, Hartwig et al. 2012, Abella, Scotece et al. 2014).
Figure 1.4. Energy homeostasis and hepatic glucose metabolism.
Energy homeostasis is regulated through balancing dietary intake with cellular re-
quirements for energy in the form of ATP. This model displays the different mecha-
nisms involved in coordinating and monitoring availability of nutrients. Signals gen-
erated from circulating nutrients or adipose related adipokines e.g. leptin and insulin 
are transduced to the hypothalamus. As a consequence, changes in energy intake, ex-
penditure and glucose production occur. Under conditions of nutrient excess, glucose 
production is lowered and nutrients are stored as triglycerides resulting in an increase 
in body fat mass. Conversely, during starvation, leptin secretion is reduced promoting 
an enhancement in appetite. Together with a feedback loop from leptin, insulin secre-
tion is lowered reducing storage of essential energy in adipocytes. 	  Figure taken and 
legend adapted from (Schwartz and Porte 2005).
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1.2.2. Role of adipokines in energy homeostasis.
Adipose tissue can respond to both central and peripheral metabolic signals via adi-
pokines (Trayhurn and Wood 2004, Antuna-Puente, Feve et al. 2008). Adipokines can 
regulate appetite (leptin, 1.2.2.2)	    as well as energy expenditure	    (adiponectin,1.2.2.3 
thereby extending their role from a cellular level to whole body homeostasis (Dyck 
2009). A description of a few critical adipokines and their role within energy homeo-
stasis are given 	  below	  :
1.2.2.1. TNFα: is a pro-inflammatory cytokine and is primarily secreted from macro-
phages. Insulin resistance induced through TNFα action, has been proposed to involve 
dysregulation of fatty acid metabolism together with impairment of insulin signalling 
(Dyck 2009).
1.2.2.2. Leptin: is a 16kDa non-glycosylated hormone (Kamohara, Burcelin et al. 
1997). As a critical regulator of appetite, it works with the central nervous system as a 
signalling molecule between adipose tissue and the brain. Leptin is secreted from adi-
pocytes and is capable of initiating lipolysis through its stimulatory and feedback ac-
tivity on the sympathetic nervous system (Kennedy 1953). Furthermore, it  is capable 
of lowering food intake whilst concurrently increasing energy expenditure (Friedman 
and Halaas 1998). These functions are achieved through signalling to hypothalamic 
nuclei via neuronal circuits, resulting in the promotion of anorexigenic factors (appe-
tite suppressant) together with the inhibition of the opposing orexigenic (appetite 
promoting) neuropeptides (Elmquist, Maratos-Flier et al. 1998). In 1994, following 
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characterisation of the murine obese (ob) gene or human LEP gene, leptin protein was 
identified as an ob gene product (Zhang, Proenca et al. 1994). Through its appetite 
suppressing action, leptin is capable of promoting weight loss (Pelleymounter, Cullen 
et al. 1995). Conversely, during conditions of nutrient deprivation, a key energy sen-
sor AMPK	   is activated by leptin (Wu, Chao et al. 2013). The detection of high AMP: 
ATP ratio by AMPK, results in the activation of fatty acid oxidation to enhance shut-
tling towards oxidative phosphorylation. The ATP generated via oxidative phosphory-
lation, maintains the capability  of mitochondria to meet the energy demands of the 
cell (Covey, Wideman et al. 2006). 
1.2.2.3. Adiponectin: originally  identified in 1995 (Scherer, Williams et al. 1995) is 
secreted in serum	    and is an insulin sensitising, anti-inflammatory and anti-apoptotic 
protein (Dridi and Taouis 2009). During obesity and T2DM, adiponectin binds to tthe 
adiponectin receptor 	  (Hara, Yamauchi et al. 2005). As a result, energy expenditure is 
reduced resulting in weight gain (Hara, Yamauchi et al. 2005, Tajtakova, Petrasova et 
al. 2006). Two forms of adiponectin, globular and full-length adiponectin are capable 
of binding and thereby activating both adiponectin receptors, adipoR1 and adipoR2 
(Guillod-Maximin, Roy et al. 2009). Nevertheless, the binding affinity of adipoR1 is 
greater for the globular compared to the full-length form of adiponectin (Yamauchi, 
Kamon et al. 2003). Following their activation, a	  diponectin receptors transduce their 
signal to a number of signalling messengers including MAPK, PPAR-α and AMPK 
(Trayhurn and Wood 2004, Iwabu, Yamauchi et  al. 2010, Chen, Zhang et al. 2013). 
Insulin resistance and obesity have been shown to be inversely  proportional to plasma 
adiponectin expression levels (Trayhurn and Wood 2004). Furthermore, observational 
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studies revealed that the reduction of adiponectin expression was linked to a greater 
incidence of metabolic syndrome (Kozlowska and Kowalska 2006, Miczke, Szulinska 
et al. 2006, Shimomura, Maeda et al. 2006, Tajtakova, Petrasova et  al. 2006, Mo-
jiminiyi, Abdella et al. 2007). Finally, observation studies have concluded that human 
adiponectin levels in those with T2DM are greatly reduced compared to their non-
diabetic counterparts (Vasseur, Meyre et al. 2006). Administration of adiponectin in 
mice with obesity and insulin resistance boosted their low basal circulating adipo-
nectin levels and corresponded with an improvement in their insulin sensitivity to-
gether with enhanced glucose tolerance (Yamauchi, Kamon et al. 2003).
1.2.3. Energy homeostasis dysregulation in obesity and T2DM.
Obesity is often associated with dysregulated adipokine secretion (Nawrocki, Rajala 
et al. 2006). In obese and insulin resistant patients, adiponectin is downregulated, 
whilst leptin is increased	    (Qi, Takahashi et al. 2004). Mutations in the ob gene are 
accompanied by insufficient expression of leptin. It is this downregulation of leptin, 
which is responsible for the 3-fold increase in the weight of ob/ob mice compared to 
wild type	    mice (Schafer, Halle et al. 2004). Leptin and insulin signalling are known 
as the adipo-insular axis and are integral for regulating nutrient and energy balance 
(Perry and Wang 2012). The exact mechanisms responsible for coordinating both the 
local and global effects of leptin in promoting insulin sensitivity  are unknown and re-
quire further characterisation.
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1.3. Mitochondrial health and function.
Mitochondrial health is vitally important for cellular viability and function (Magal-
haes, Venditti et al. 2014). As the powerhouse of the cell, mitochondria are responsi-
ble for liberation of the energetic substrate, ATP via the fatty acid cycle and oxidative 
phosphorylation (Figure 1.8) 	  (Hafner, Brown et al. 1990).The symbiotic relationship 
between the mitochondria and nucleus enables nuclear synthesis of the majority of the 
1500 mitochondrial proteins (37 are encoded in the mitochondrial genome, 13 of 
which are required for oxidative phosphorylation) (Anderson, Bankier et al. 1981, 
Gaston, Tsaousis et al. 2009).These include subunit 6 (mt-ND6) of NADH dehydro-
genase (complex I) and subunit 6 (mt-ATP6) of ATP synthase (complex V) (Van Ber-
gen, Blake et al. 2014). Given the critical role of mitochondria 	  to cellular health, the 
process of nuclear synthesis of mitochondrial proteins may have arisen to minimise 
the effect of the greater mitochondrial mutation rate, as much as 10-20 times that of 
the nuclear genome (De Pauw, Demine et al. 2012). Coupled with this, mitochondrial 
DNA repair enzymes 	  have a low activity status (Linnane, Marzuki et al. 1989, Wang, 
Lin et al. 2009). Therefore, quality control mechanisms have evolved within the mito-
chondria in an attempt to overcome some of the limitations of this inefficient DNA 
repair system. One example of these quality control mechanisms is mitochondrial 
biogenesis (Attardi and Schatz 1988, Medeiros 2008, Ren, Pulakat et al. 2010, Weck-
becker and Herrmann 2013).
1.3.1. Mitochondrial biogenesis.
Mitochondrial biogenesis protects mitochondrial health through the maintenance of 
mtDNA quality (Scarpulla, Vega et al. 2012). This process is achieved via cycles in-
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volving the coalescence of old mitochondria and their subsequent division (Ren, Pu-
lakat et  al. 2010). As a result, functional mitochondrial DNA is retained whilst com-
promised mitochondrial DNA is selectively  eliminated (Ren, Pulakat et al. 2010). Mi-
tochondrial DNA synthesis occurs de novo during the cell cycle to return mitochon-
dria mtDNA abundance to their homeostatic levels (Sheng and Cai 2012). However, 
during obesogenic conditions, mitochondrial biogenesis is impaired thereby  contribut-
ing to mitochondrial dysfunction. Mitochondrial biogenesis is coordinated at a tran-
scriptional level by peroxisome proliferator activated receptor co-activator 1 alpha 
(PGC1α) (Fernandez-Marcos and Auwerx 2011) and nuclear respiratory  factor 1 
(NRF-1) (Escriva, Rodriguez-Pena et al. 1999). Together these promote the induction 
of the catalytic subunit  of the mitochondrial DNA polymerase (POLG) and expression 
of other biogenesis transcription factors i.e. mitochondrial transcription factor A 
(Tfam) and oxidative phosphorylation (OXPHOS) genes required for mitochondrial 
replication (Murholm, Dixen et al. 2009, Elachouri, Vidoni et al. 2011). Previous 
studies have identified that patients who possess mutations in either a mitochondrial 
or nuclear gene involved in mitochondrial function, exhibit disturbances in their respi-
ratory  capacity (Pich, Bach et al. 2005). Thus 	  respiratory or oxidative capacity is a 
reflection of both mitochondrial biogenesis and mitochondrial morphology regulated 
via mitochondrial dynamics.
1.3.2. Mitochondrial dysfunction.
Mitochondrial dysfunction is most commonly defined as the inability  of mitochondria 
to produce ATP in response to cellular demand (Bournat and Brown 2010). Neverthe-
less, this definition can be extended to incorporate changes to mitochondrial biogene-
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sis, reduction in fatty acid oxidation or increased production of reactive oxygen spe-
cies (ROS) (Lowell and Shulman 2005, Zorzano, Liesa et al. 2009). 
Figure 1.5. Origins of mitochondrial dysfunction. 
Mitochondrial quality control involves surveillance and protection strategies to limit 
mitochondrial damage and ensure mitochondrial integrity. This quality  control occurs 
at the following molecular, organelle and cellular levels. Figure and legend taken 
from (Sheng and Cai 2012).
Importantly, mitochondrial dysfunction has been proposed to account for the genera-
tion of toxic lipid metabolites via the fatty acid cycle and hampering of metabolic fit-
ness, which accompany  the stunted adipogenic capacity and Adipose tissue dysfunc-
tion (Vankoningsloo, Piens et al. 2005, Liu, Lin et al. 2012). Finally, 	  evidence in fa-
vour of the role of mitochondrial dysfunction in those individuals with T2DM  is the 
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co-association of reduced mitochondrial oxidative phosphorylation capacity and insu-
lin resistance in elderly or obese individuals (Petersen, Dufour et al. 2004). Further-
more, mitochondrial dysfunction extends beyond the inability to synthesise sufficient 
ATP, to processes of mitochondrial DNA abundance and mitochondrial morphology 
(Okamoto and Shaw 2005, Yu, Robotham et al. 2006). In the skeletal muscle of obese 
and T2DM, a reduction of mitochondrial copy number together with enhanced mito-
chondrial fission have been observed (Barthelemy, Ogier de Baulny et al. 2001, Jeng, 
Yeh et al. 2008). Mitochondrial dynamics, which involves mitochondria fission, is 
discussed in further detail in section 1.4.2.
1.3.3. Causes of mitochondrial dysfunction.
Despite multiple studies in skeletal muscle implicating a connection between insulin 
resistance and mitochondrial dysfunction, little data is available in white adipose tis-
sue (WAT), regarding the involvement of mitochondria during conditions of insulin 
resistance or AT dysfunction. 
1.3.4. Mitochondrial dysfunction in adipose tissue.
In humans, insulin resistance has been found to co-exist with a lower mitochondrial 
oxidative phosphorylation activity (Petersen, Dufour et al. 2004). Nevertheless, 
whether insulin resistance is a primary or secondary effect of mitochondrial dysfunc-
tion is unknown (Shulman 1999, Shulman 2000, Guilherme, Virbasius et al. 2008, 
Amati, Dube et al. 2011, Koliaki and Roden 2014). In an attempt to address this ques-
tion, studies performed in skeletal muscle of obese and T2DM subjects found that 
these cells are often exposed to a high fat load (Sparks, Xie et al. 2005, Catta-Preta, 
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Martins et al. 2012). Recapitulating this scenario and analysis of mitochondrial dy-
namics in skeletal muscle biopsies from either morbidly  obese (Semple, Crowley et 
al. 2004), following a high fat  feed in humans with an ideal BMI (Richardson, 
Kashyap et al. 2005, Sparks, Xie et al. 2005) or mice (Rong, Qiu et al. 2007) resulted 
in the downregulation of the mitochondrial biogenesis gene, PGC1α (Puigserver and 
Spiegelman 2003, Mitra, Nogee et al. 2012). As mentioned earlier in section 1.3.1, the 
respiratory capacity of mitochondria is a reflection of both mitochondrial biogenesis 
and morphology that are regulated via mitochondrial dynamics.
1.4. Mitochondrial dynamics.
In response to changes in their cellular environment, mitochondria are able to alter 
their morphology and abundance through the balance of “fusion”	  and “fission”	  events 
(Liesa, Palacin et al. 2009). Together with mitophagy, mitochondrial dynamics genes 
selectively identify and eliminate dysfunctional mitochondria (Twig, Elorza et al. 
2008, Twig, Hyde et al. 2008). 
1.4.1. Fusion.
Mitochondrial fusion is characterised by two independent events culminating in the 
coordinated fusion of inner and outer mitochondrial membranes from separate mito-
chondria to form a single larger mitochondrion (Huang, Galloway et al. 2011). The 
mitochondrial membrane proteins involved are Opa1 (inner mitochondrial membrane 
protein) and Mfn1/2 (outer mitochondrial membrane protein).
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Opa1: Optic atrophy 1 is a dominant autosomal mutation resulting in atrophy  of the 
optic nerve and often progresses to visual blindness (Figure 1.9) (Eiberg, Kjer et al. 
1994, Alexander, Votruba et al. 2000, Olichon, Landes et al. 2007, Song, Chen et al. 
2007, Akepati, Muller et al. 2008). The regulation of Opa1 occurs at a post-
transcriptional level through alternative splicing (Song, Chen et al. 2007). Splicing at 
exons 4,4b and 5b can generate a total of 8 mRNA isoforms (Satoh, Hamamoto et al. 
2003, Akepati, Muller et al. 2008). Opa1 isoforms that include exon 4 (Opa1 isoform 
1, the most abundant in mice and humans) have been shown to influence mitochon-
drial fusion activity and maintain membrane potential (Akepati, Muller et  al. 2008). 
Following the generation of Opa1 isoforms, proteolytic cleavage represents a secon-
dary level of Opa1 regulation (Satoh, Hamamoto et al. 2003, Duvezin-Caubet, Jagasia 
et al. 2006, Ishihara, Fujita et al. 2006, Ehses, Raschke et al. 2009). Proteolytic cleav-
age generates shorter Opa1 isoforms, at the expense of a reduction in the abundance 
of the longer isoforms (Olichon, Emorine et al. 2002, Ishihara, Fujita et al. 2006, 
Ehses, Raschke et  al. 2009, Quiros, Ramsay et al. 2012). Only these longer isoforms 
possess the capacity  to redress defective mitochondrial fusion in Opa1 knockout cells 
(Guillery, Malka et al. 2008).
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Figure 1.6. Proteins involved in mitochondrial dynamics.
Mitochondrial fission involves the translocation of Drp1 from its cytosolic location to 
the outer mitochondrial membrane. Fis1 together with the other integral membrane 
proteins of Mff, MiD49 and MiD51 have been proposed to assist in the recruitment  of 
Drp1 to the outer mitochondrial membrane. Nevertheless, the role and mechanism of 
these putative Drp1 receptors are still under investigation. Drp1 creates a concentric 
ring around the mitochondria restricting the mitochondrial tubule and mediating fis-
sion to generate two asymmetric daughter mitochondria. Fusion, involves Mfn1/2 and 
Opa1. Opa1 mediates the tethering of inner mitochondrial fusion whilst Mfn mediate 
outer mitochondrial fusion. Together these contribute to the coalescence of two mito-
chondria to a single mitochondrion. This coalescence allows mixing of mitochondrial 
contents including protein and DNA. Complete mitochondrial fusion is dependent on 
GTP hydrolysis. Mitochondrial fission factor (Mff), mitochondrial dynamics proteins 
of 49 and 51kDa (MiD49/51), Guanosine triphosphate (GTP), optic atrophy 1 (Opa1), 
dynamic related protein (Drp1), mitochondrial fission protein 1 (Fis1), Mfn (mito-
fusin). Figure taken from (Osellame, Blacker et al. 2012).
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Mfn2: Mitofusin 2 is localised within the outer mitochondrial membrane and assists 
with mitochondrial fusion (Figure 1.9) (Chen, Detmer et al. 2003, Bach, Naon et al. 
2005). Mutations within Mfn2 gene cause the autosomal dominant neurodegenerative 
disease Charcot-Marie-Tooth type 2A (CMT) resulting in weakness and loss of mus-
cle control particularly in the lower extremities e.g. the feet. (Zuchner, Mersiyanova et 
al. 2004) Knockdown of Mfn2 is associated with lower mitochondrial oxygen con-
sumption together with diminished mitochondrial membrane potential (Pich, Bach et 
al. 2005). These observations also exist within patients with known Mfn2 mutations 
within their fibroblasts. Fibroblasts from patients with amino acid substitutions from 
R364Q or A166T have greater oxygen consumption at rest together with a diminished 
mitochondrial membrane potential (Loiseau, Chevrollier et al. 2007). 
Mfn1: Mitofusin 1 is a human homolog of Mfn2 (Santel, Frank et al. 2003).  In keep-
ing with their homologous nature, Mfn1 shares 80% sequence identity  with Mfn2 
(Detmer and Chan 2007). Likewise, the functional domains of the GTPase, Coiled-
coil regions, GTPase effector domain and transmembrane domain are conserved 
across Mfn1 and 2 (Ishihara, Eura et al. 2004). A localisation sequence located within 
the carboxy terminus of the protein directs the localisation of the transmembrane 
GTPase protein to the outer mitochondrial membrane (Santel, Frank et al. 2003). Mi-
tochondrial fusion is initiated through formation of a dimeric anti-parallel coiled-coil 
structure (Koshiba, Detmer et al. 2004). Formation of this complex, engages the teth-
ering of two mitochondria and signifies that mitochondrial fusion has begun (Ko-
shiba, Detmer et al. 2004). Loss of function mutations in Mfn1 is lethal to developing 
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embryos, as it results	   in defects within placenta formation (Chen, McCaffery et al. 
2007).
FOXC2: Forkhead transcription factor 2 is capable of inducing mitochondrial fusion 
(Lidell, Seifert et  al. 2011) and is associated with a lean and insulin sensitive pheno-
type (Cederberg, Gronning et  al. 2001). Furthermore, its critical role as a metabolic 
regulator is evidenced by  its ability to transactivate Tfam and initiate mitochondrio-
genesis resulting in elongated mitochondrial morphology (Bergman, Van Citters et  al. 
2001). Correlation analyses between FOXC2 and mitochondrial fusion genes (Mfn2, 
Mfn1 and Opa1) have confirmed a positive association and provide support to sugges-
tions that the regulation of fusion by FOXC2 extends from mice to humans (Lidell, 
Seifert et al. 2011).
1.4.2. Fission.
Fission involves the segregation of one mitochondrion into two smaller mitochondria 
(James, Parone et al. 2003). This process is unequal, and is used to segregate the 
compromised mitochondrial membrane and its components from an otherwise func-
tional organelle (Figure 1.9) (Twig, Elorza et al. 2008, Galloway, Lee et al. 2012, El-
gass, Pakay et al. 2013). Where possible, components such as lipids within the mito-
chondrial membrane are recycled and the remainder of the defective mitochondrial 
membrane is tagged for degradation by ubiquitylation (Praefcke and McMahon 2004). 
Similar to the ubiquitylation of misfolded proteins, compromised mitochondria are 
shuttled via the lysosome pathway  towards mitophagy (mitochondrial equivalent of 
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cellular autophagy) (Twig, Elorza et al. 2008, Twig, Hyde et al. 2008). Mitochondrial 
fission requires Drp1 and Fis1 proteins.
Drp1: is a key  protein required	  for fission and translocates from the cytosol to the mi-
tochondria with assistance from Fis1 (Figure 1.9) (Smirnova, Shurland et al. 1998). 
Once localised to the outer mitochondrial membrane, Drp1 punctuate holes within the 
mitochondria required for initiation and assembly  of future sites of fission (Smirnova, 
Griparic et al. 2001). Importantly, these scission sites are created as a concentric ring 
within the outer mitochondrial membrane (Taguchi, Ishihara et al. 2007). Together 
with the scission sites and a GTP hydrolysis reaction, mitochondrial membranes can 
become severed and physically separated from one another (Liesa, Palacin et al. 
2009). Nevertheless, the mitochondrial fission proteins involved in the division of the 
inner mitochondrial membranes remain unresolved. 
Fis1: is a 17kDa protein and functions as the mechanical scissors to finalise and coor-
dinate the creation of two separated mitochondria (Stojanovski, Koutsopoulos et  al. 
2004). Ubiquitously expressed and dispersed throughout the mitochondrial network 
and is thought to be the limiting factor for mitochondrial fission (Yoon, Krueger et al. 
2003).
1.4.3. Dysregulation of mitochondrial dynamics.
How mitochondrial dynamics become	   dysregulated is unknown. Understanding the 
molecular mechanisms that underlie this phenomenon, offers a key opportunity  to de-
velop  therapeutics or biomarkers for diabetes and insulin resistance. In diabetic mice, 
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their adipocyte expression, abundance of mtDNA and mitochondrial dynamics pro-
teins is lower than non-diabetic mice (Rong, Qiu et al. 2007). The balance of mito-
chondrial fusion and fission are key to maintaining mitochondrial health and mor-
phology (Zorzano, Liesa et al. 2009, Liesa and Shirihai 2013). Over-activation of fis-
sion or an absence of balanced fusion initiates the fragmentation of mitochondria 
(Ferrier 2001, James, Parone et al. 2003, Huang, Galloway et al. 2011). Mitochondrial 
fragmentation results in the generation of smaller and greater numbers of mitochon-
dria. Depending on the duration and severity of the imbalanced fission, the mitochon-
drial population may become compromised or reduced	   in abundance through their 
removal by mitophagy (Jheng, Tsai et al. 2012). Both mitochondrial fragmentation 
and a reduction in mitochondrial membrane potential must occur before mitochondria 
are shuttled towards mitophagy (Lee, Jeong et al. 2004). Under conditions of transient 
or acute cellular stress, mitochondrial fusion can be upregulated to compensate for 
damage induced within the mitochondria (Huang, Galloway et al. 2011). Investigation 
of the effect of cellular stress within cultured cells have revealed that mitochondria 
display  the ability to resolve damage such as misfolded mitochondrial proteins or the 
effects of cellular stress such as production of reactive oxygen species (ROS) (Michel, 
Wanet et  al. 2012). If unresolved, damage induced to cells would require their re-
moval by apoptosis (Ferrier 2001). 
1.5. Mitochondrial bioenergetics.
Mitochondrial bioenergetics is a measure of mitochondrial capacity. Measurement of 
oxidative phosphorylation enables quantification of the rate of ATP synthesis within 
cells and thereby provides a snapshot of the energetic demands of cells in real time.
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Figure 1.7. Quality control pathway: The life cycle of a mitochondrion and the 
involvement of mitochondrial dynamics proteins. 
Local control is exerted at the level of the G0 phase of the cell cycle (resting phase). 
During this phase, mitochondrion undergo fusion, fission, depolarisation and auto-
phagic degradation. Global control is governed by the cellular metabolism and thus 
demand for energy needed to perform cell division and re-organisation of cellular 
components between cells during metaphase. Examples of these global signal effects 
on mitochondria include, the presence of hyperfused mitochondrial network (cell 
growth-synthesis, G1-S phase) or mitochondrial fragementation (cellular synthesis 
and mitosis, S and M phases). Figure from Ferree,A. and Shirihai,O. Chapter 2. Mito-
chondrial oxidative phosphorylation: (748). Advances in Experimental Medicine and 
Biology (2012).
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1.5.1. Quantitative measurement of OXPHOS can be performed in situ.
Measuring mitochondrial bioenergetics can be performed in situ (Gerencser, Chino-
poulos et al. 2012) within a cell or following isolation of the mitochondrial fraction 
from cells (Hafner, Brown et al. 1990). Recent developments in mitochondrial bio-
energetics have enabled in situ measurements of intracellular mitochondria. Despite a 
slight compromise in precision for in situ analyses, this significantly outweighs the 
damage and time required to perform bioenergetic analyses on isolated mitochondria 
(Hafner, Brown et al. 1990). Additional advantages include the physiological rele-
vance of maintaining mitochondria within their cellular environment (Nicholls 2002, 
Nicholls, Johnson-Cadwell et al. 2007). Mitochondria exhibit inter-organelle contacts 
with the ER and interact with their cytoplasmic environment.
Maintaining mitochondria within its surrounding environment permits a more realistic 
recapitulation of its interaction with other organelles and cellular role (Affourtit, Jas-
troch et al. 2011). The measurement in real time allows determination of the dynamic 
flux of mitochondrial ATP production in response to energy  demand. Mitochondrial 
dysfunction is most commonly defined as the inability  of mitochondria to produce 
ATP in response to cellular demand (Nicholls 2002). Through parallel measurement 
of mitochondrial potential and respiration, the effect of chemical, genetic treatment on 
mitochondrial function together with the target site (within the mitochondrial com-
plexes of the oxidative phosphorylation chain) and distribution of this effect can be 
more accurately determined (Brand and Nicholls 2011). 
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Figure 1.8. The oxidative phosphorylation cycle.
Oxidative phosphorylation cycle involves electron transfer (e-) sequentially through 
complexes I to V. Accompanying this are a series of redox reactions culminating at 
the ATP synthase in the generation of ATP (adenosine triphosphate). Complex inhibi-
tors (given in orange boxes) Oligomycin is an ATP synthase inhibitor. Through its in-
hibition of this mitochondrial membrane bound complex, it is capable of blocking 
oxidative phosphorylation from proceeding past this point of the electron transport 
chain. As a consequence, only electrons generated through mitochondrial uncoupling, 
allow protons to diffuse using UCP1 (uncoupling protein 1) from the outer to inner 
mitochondrial membrane.
 FCCP (carbonyl cyanide-p-trifluoromethoxyphenylhydrazone) is a mitochon-
drial uncoupling agent, used to increase mitochondrial permeability to protons 
through depolarisation of the mitochondrial membrane potential. FCCP measures the 
maximal oxygen consumption rate of cellular mitochondria. Antimycin inhibits com-
plex III of the electron transport chain resulting in leaking of electrons to molecular 
oxygen resulting in the generation of superoxides. Rotenone inhibits Complex I of the 
electron transport chain (specifically the NADH dehydrogenase enzyme). The cock-
tail of antimycin/rotenone quantifies non-mitochondrial respiration rate within the as-
sayed cells. 
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Maintaining mitochondria within its surrounding environment permits a more realistic 
recapitulation of its interaction with other organelles and cellular role (Affourtit, Jas-
troch et al. 2011). The measurement in real time allows determination of the dynamic 
flux of mitochondrial ATP production in response to energy  demand. Mitochondrial 
dysfunction is most commonly defined as the inability  of mitochondria to produce 
ATP in response to cellular demand (Nicholls 2002). Through parallel measurement 
of mitochondrial potential and respiration, the effect of chemical, genetic treatment on 
mitochondrial function together with the target site (within the mitochondrial com-
plexes of the oxidative phosphorylation chain) and distribution of this effect can be 
more accurately determined (Brand and Nicholls 2011). 
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1.6. Summary.
In summary, adiposity  and T2DM are often accompanied by mitochondrial dysfunction. 
Whilst, the role of mitochondrial dynamics in the regulation of mitochondrial abundance 
have been previously  addressed and is known to influence mitochondrial abundance and 
morphology, its link to the regulation of mitochondrial function in adipocytes remains 
largely uncharacterised. As the primary energy storage tissue, adipose tissue functions 
together with mitochondrial dynamics to maintain energy homeostasis. As such, investi-
gating both theconsequences of adiposity  on the balance of markers of mitochondrial dy-
namics together with regulation of this process at a molecular level is of vital importance 
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and may provide the basis for future research into novel therapeutic interventions for obe-
sity and T2DM.
1.7 Aims and Objectives.
Aim: Assess the regulation of mitochondrial dynamics in adipocytes and adipose tis-
sue.
The four key objectives of my thesis were as follows:
1. Define mitochondrial dynamics within human adiposity.
2. Bariatric surgery; implications of the surgical procedure and weight loss on 
mitochondrial dynamics. 
3. To study the regulation of mitochondrial dynamics by signalling pathways in 
adipocytes.
4. Modelling the interaction between putative p38 beta isoform inhibitors and 
their effects on mitochondrial morphology and bioenergetics.
Based on previous literature, I wished to test and examine the following hypotheses:
1. Mitochondrial dynamics proteins are differentially  expressed in the subcuta-
neous a	  	  dipose tissue of lean, overweight and obese individuals.
2. Mitochondrial dynamics can be redressed through weight  loss induced by 
bariatric surgery in T2DM individuals.
3. p38 positively regulates mitochondrial dynamics and adipocyte differentiation.
4. Modelling of p38	   and selection of putative p38 β isoform inhibitors.
5. p38 inhibition diminishes mitochondrial bioenergetics and is accompanied by 
mitochondrial fragmentation in adipocytes.
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Chapter 2:
The role of adiposity in mitochondrial dynamics.
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2.1. Introduction.
Obesity is a key contributory  factor in the development of insulin resistance. 
(Fernandez-Sanchez, Madrigal-Santillan et al. 2011) Obesity is defined as an individ-
ual whose body mass index is above 30 kg/m2 (World Health Organisation). The co-
existence of insulin resistance and obesity are known significant risk factors for the 
development of T2DM (Bastard, Maachi et al. 2006, Abdullah, Peeters et  al. 2010). 
During periods of excess nutritional intake, which if continuous would result in obe-
sity, cellular substrates are converted for storage into cells as triglycerides (Scherer 
2006). However, the site of fat  storage also has metabolic implications for the indi-
vidual (Sun, Kusminski et  al. 2011). In particular, central obesity, characterised by the 
deposition of fat  in the abdominal region (Rosen and Spiegelman 2006) (subcutane-
ous and visceral adipose tissue), is a greater risk factor for the development of T2DM 
compared to that  posed by peripheral obesity  (accumulation of fat around the hips and 
thighs) (Kraunsoe, Boushel et al. 2010). Mitochondria are indispensable for energy 
homeostasis (Liesa and Shirihai 2013) (Magalhaes, Venditti et al. 2014) and are re-
sponsible for generating the essential cellular substrate, ATP via oxidative phosphory-
lation (Robertson 2014). Tasked with maintaining energy homeostasis, mitochondria 
are capable of adapting their abundance and thus capacity to meet the energetic needs 
of the cell, through mitochondrial biogenesis (Medeiros 2008) and dynamics (Zor-
zano, Liesa et al. 2009, Picard and Turnbull 2013). Mitochondrial dynamics regulates 
mitochondrial abundance (Jeng, Yeh et al. 2008), morphology (da Silva, Mariotti et al. 
2014) and health through fusion and fission (Okamoto and Shaw 2005, Palaniyandi, 
Qi et al. 2010). Fusion generates a larger mitochondrion from two smaller mitochon-
dria, through coalescence of mitochondrial membranes and contents (Mouli, Twig et 
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al. 2009). In contrast, fission generates two smaller mitochondria from a large/fused 
mitochondrion (Chan 2006). Furthermore, insulin resistance and compromised lipid 
metabolism have been shown to correlate with a reduction in both mitochondrial copy 
number (Michel, Wanet et al. 2012) and function (Nunnari and Suomalainen 2012). 
As a consequence downstream mitochondrial functions such as oxidative phosphory-
lation are impaired in skeletal muscle as a consequence of insulin resistance (Jheng, 
Tsai et al. 2012). This is supported by evidence of the diminished oxidative phospho-
rylation capacity shown in pre- diabetic and age-related insulin resistant subjects 
(Sparks, Xie et al. 2005, Mustelin, Pietilainen et al. 2008, Fernandez-Sanchez, 
Madrigal-Santillan et al. 2011). Furthermore, previous findings have indicated that 
inhibiting mitochondrial fission in the skeletal muscle of mice with genetic or diet-
induced obesity, reversed the insulin resistance and development of smaller and frag-
mented mitochondria normally present in obese mice (Bach, Pich et al. 2003). To 
date, most studies have focused on characterisation of mitochondrial processes in 
skeletal muscle, due to its role as the primary site of glucose uptake and utilisation 
within the body (Dyar, Ciciliot et al. 2014). Recently, adipose tissue has received 
greater recognition for its role not only in energy storage but its role as an endocrine 
organ within glucose homeostasis, (Rosen and Spiegelman 2006) involving amongst 
others, adiponectin (Dridi and Taouis 2009) (see introduction section 1.2.2.3) for a 
more detailed description). Therefore, adipose tissue is a more representative model in 
which to investigate mitochondrial dynamics (Tseng, Cypess et al. 2010). In support 
of this, human fibroblasts from patients with naturally occurring mutation (A166T or 
R364Q) in the mitochondrial fusion protein, Mfn2, correspond with greater basal 
oxygen consumption under conditions of unaltered mitochondrial mass and normal 
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functionality of their oxidative phosphorylation complexes (Loiseau, Chevrollier et al. 
2007). 
The purpose of this study was to investigate whether mitochondrial dynamics 
were	    influenced by adiposity  thereby offering a potential explanation for the inci-
dence of mitochondrial dysfunction in obesity.
2.2. Research design and methods.
2.2.1. Selection and description of participants:
A female cohort consisting of lean (Age 38±8yr; BMI: 22.9±0.9 kg/m2, n = 10), 
overweight (Age 38±9yr; BMI: 26.8±1.5kg/m2, n = 10) and obese (Age 42±10yr; 
BMI: 34.1±2.1kg/m2, n = 10) subjects participated in our study. Ethical approval was 
obtained from the local research ethics committee (LREC). Prior to enrolment, all 
participants provided written informed consent and completed a comprehensive medi-
cal evaluation. Detailed medical drug histories were taken and those subjects on 
medication considered to alter inflammatory status were excluded, including thia-
zolidinediones. Abdominal subcutaneous adipose tissues (AbSc AT) were collected, 
flash frozen immediately and stored in -80°c freezers until use. Fasted blood samples 
were taken prior to surgery and sera were analysed as detailed below. 
2.2.2. Analyses of blood samples.
Fasted blood samples were used to assess the metabolic profiles of all participants. 
The lipid and fasted plasma glucose were determined using routine laboratory meth-
ods, undertaken by colleagues in the biochemistry laboratory, at University Hospital 
Coventry  and Warwickshire. In brief, the routine b	  lood tests included glucose and a 
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full lipid	    profile (TGs, HDL-cholesterol	    and LDL-cholesterol	   ), as noted in Table 1. 
Insulin measurements were performed by a solid phase enzyme amplified sensitivity 
multiplex immunoassay (Millipore, UK) and glucose was measured by a glucose oxi-
dase method (YSL 200 STAT plus).
2.2.3. Isolation of mRNA and qPCR.
Figure 2.1. RNA extraction: RNeasy lipid tissue 
kit protocol (Qiagen).
A tissue sample (50mg, 1ml Qiazol) was homoge-
nised (1 min) and incubated at  room temperature 
(RT, 5 mins). Chloroform (200μl) was added to the 
sample,vigourously shaken (15s) and incubated at 
RT (3 mins). All flow throughs were discarded. 
Centrifugation ensured optimal separation of the 
organic and aqueous phases (12,000g for 15min at 
4c). The upper aqueous phase containing RNA was 
removed and placed in a new tube. A 1:1 equivalent 
of 70% ethanol was added to aqueous phase and 
vortexed. The sample was centrifuged (8,000g for 
15s at RT), binding the RNA to the column. A se-
ries of wash steps remove non specifically bound 
carbohydrates, fatty acids and proteins (RW1), and 
guadinine salts (RPE). which would interfere with 
RT-PCR reactions whilst  retaining RNA > 200 
bases on the silica column. DNase treatment fol-
lowing elution removed contaminating sources of 
DNA from the RNA sample.
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Figure 2.2. DNase treatment: removing sources of DNA contamination from the 
RNeasy lipid tissue kit eluant (based on Invitrogen DNase protocol).
RNA eluant from RNeasy lipid kit (30μl) was incubated with DNase I reaction buffer 
(3μl, 10x stock solution), DNase I (3μl, 1U/μl). DNase treatment (Invitrogen) was 
performed to remove any source of contaminating genomic DNA after elution of ge-
nomic material from the RNeasy lipid mini kit  (Figure 2.1 following RNA elution and 
2.2 for protocol).  The reaction mix was incubated (10min at room temperature). Fol-
lowing incubating the DNase I was inactivated through addition of EDTA (1μl of 
2 5 m M ) a n d h e a t t r e a t e d ( 5 5 c , 5 m i n ) . I m a g e a d a p t e d f r o m 
http://www.tataa.com/wp-content/uploads/2012/11/Heat-and-Run-Workflow.jpg.
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RNA was quantified using the Nanodrop ND-100 Spectrophotometer (Labtech, UK). 
Ribosafe RNase inhibitor, (1μl) was added after RNA quantification to preserve RNA 
integrity  and minimise RNA degradation and loss of quality upon storage at -80c. 
The priming premix was prepared on ice. Briefly, 500ng of each RNA sample was 
reverse transcribed to cDNA (Bioline) using random hexmaers (1μl, 40μM stock), 
dNTP (1μl,10mM) and DEPC-treated water (up to final volume of priming mix of 
10μl). Samples were incubated in these RNase free reaction tubes (70c, 10min) before 
being chilled on ice (10min). A reaction premix was prepared, with volumes described 
here given per reaction, 5x RT buffer (4μl), Ribosafe RNase inhibitor (1μl), Bioscript 
reverse transcriptase (1μl) and diethyl pyrocarbinate (DEPC)-treated water (up to a 
final reaction premix of 10μl). DEPC is a nonspecific inhibitor of RNases. The reac-
tion premix was added to the priming premix and mixed by pipetting. Samples were 
incubated as follows; 10min at 25c then 42c, 30 min). The synthesis reaction was 
terminated by  heat inactivation (85c for 5 min). The cDNA sample was chilled on ice 
for 15min before further use. cDNA samples were amplified using Taqman primers 
and probes (Applied Biosystems, UK, OPA1; Hs_00323399_m1, Mfn2; 
Hs_00208382_m1, Fis1; Hs_00211420_m1, Drp1; Hs_00247147_m1, FOXC2; 
Hs_00270951_s1, CD68; Hs02836816_g1) and universal PCR master mix (Applied 
Biosystems, UK) in an ABI 7500 thermocycler (Life Technologies). 
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2.2.4. Quantitative reverse transcription polymerase chain reaction program and 
gene expression analyses
Gene expressions were determined using quantitative real-time PCR (qRT-PCR) and 
were normalised to a housekeeping gene (18s, Applied Biosystems). Each sample was 
measured in triplicate. The expression of each gene was defined as a delta threshold 
cycle (ΔCt) value (where ΔCt = Ct of gene of interest –	  Ct of 18S). The data was 
transformed from ΔCt to 2-ΔΔCt to allow the trend in gene expression to be expressed 
as relative fold change in arbitrary  units (AU) of averaged overweight and obese sub-
jects compared to average mitochondrial dynamics gene expression of lean subjects. 
Bar charts were selected to represent the mRNA expression of mitochondrial dynam-
ics genes, with error bars indicating the standard error of the mean across the subjects 
of each BMI category (lean,overweight.obese).
	  Experimental conditions:
qRT-PCR master mix per reaction:
Taqman gene expression master mix: 12.5μl
Taqman gene expression assay: 1.25μl
House keeping gene: 1.25μl
cDNA: 1μl




Hold: 50c , 2 min
Hold: 95c, 10 min
Cycle (40 cycles): 95c, 15s
Cycle: (40 cycles) 60c, 1 min
2.2.5. Protein determination and western blot analysis.
Human adipose tissue was homogenised and resuspended in 1x RIPA lysis buffer 
(Millipore) containing protease inhibitor (Roche) and phosphatase inhibitor (100μl of 
100mM Sodium fluoride and 100μl of 100mM Sodium vanadate, Sigma Aldrich). 
Protein concentrations were assessed by Biorad assay (detergent compatible protein 
assay kit, Bio-Rad laboratories, CA) using BSA as a standard (Sigma). Concentrations 
were quantified using a nanospectrophotometer (Geneflow, UK) A595. 20μg of protein 
samples were loaded per well. For OPA1 (7.5% sodium dodecyl sulphate poly-
acrylamide gel, SDS-PAGE) and Fis1 (12.5%), the percentages of SDS-PAGE gel 
used are given in brackets	  . Protein expression of OPA1 (1:1000, anti-rabbit, abcam, 
ab42364) and MFN2 (1:1000, anti-mouse, abcam, ab56889) were measured using the 
primary antibodies given in the brackets	   . Anti-mouse and anti-rabbit (1:1000, cell 
signalling technology, #7074 and #7076 and anti-mouse (1:10,000, the binding site) 
secondary  antibodies were used to detect primary antibodies ( anti-rabbit for Opa1 
and anti-mouse for Mfn2 probed westerns)	   . All antibodies were diluted in 0.2% 
iBlock. Equal protein loading was confirmed by examining β-actin protein expres-
sion. ECL was used to determine chemiluminescence and to visualise protein bands 
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(GE healthcare, UK). The intensity  of each band was determined by densitometry 
(ImageQuant, Amersham).
2.2.6. Mitochondrial copy number determination.
Total DNA was extracted from paired subcutaneous adipose tissue using DNeasy 
blood and tissue kit (Figure 2.3) (Qiagen). RNase treatment was performed to prevent 
co-purification of RNA with genomic DNA. The relative amounts of nuclear and mi-
tochondrial DNA were determined by  PCR. DNA was amplified using SYBR green in 
an ABI 7500 thermocycler (Life technologies). The abundance of each gene was cal-
culated as the ratio between mitochondrial threshold cycle (Ct) value and nuclear 
threshold cycle. Each sample was measured in duplicate against a mitochondrial (m) / 
nuclear (n) DNA primer set.	  The following primer sequences were used: Cytochrome 
b forward (mitochondrial), 5’-GCGTCCTTGCCCTATTACTATC-3’, and Cytochrome b 
reverse, 5’-TATCCGCCATCCCATACATT-3’. β-actin forward (nuclear), 5-
A C C C A C A C T G T G C C C A T C T A C ’ - 3 a n d β - a c t i n r e v e r s e 5 ’ -
TCGGTGAGGATCTTCATGAGGTA-3 as previously published (Ferber, Peck et al. 
2012). ND1 forward (mitochondrial), 5’-ATGGCCAACCTCCTACTCCT-3’ and ND1 
reverse, 5’-GCGGTGATGTAGAGGGTGAT-3’ and BECN1 forward (Nuclear), 5’-
C G A G G C T C A A G T G T T T A G G C - 3 ’	   a n d B E C N 1 r e v e r s e , 5 ’ -
ATGTACTGGAAACGCCTTGG-3’	  (Hsieh, Weng et al. 2011). Melt  curve analyses to 
confirm the production of a single, primer specific product.
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Figure 2.3 DNA extraction: DNeasy Blood and tissue 
protocol (Qiagen).
Adipose tissue (25mg) was placed in a microcentrifuge 
tube (1.5ml) containing buffer ATL (180μl). Proteinase K 
was added (20μl) to the tube and mixed with the ATL and 
tissue by vortexing. Using a heat block the adipose tissue 
sample was lysed by incubation (56c, 2hr) and regular 
vortexing (every 15min). Upon completion of lysis, 
RNase A (4μl,100mg/ml working stock) was added to the 
reaction tube, vortexed and incubated (room temperature, 
2min). The lysed and RNase free adipose tissue sample 
was vortexed (15s). Following this, buffer AL (200μλ) 
and ethanol (96-100% HPLC grade, 200μλ) were added 
to the reaction tube and the sample was vortexed. The 
mixture was transferred to a DNeasy mini spin column 
and centrifuged (6000g, 1min). At each stage the flow 
through and collection tube were discarded and replaced. 
The column was washed with buffer AW1 (500μλ) and 
centrifuged (6000g, 1min). The DNeasy mini spin column 
was placed in its fresh collection tube and washed a sec-
ond time to dry the membrane and remove residual etha-
nol (500μl, buffer AW2, 20000g, 3min). DNA was eluted 
in a minicentrifuge tube (2ml) using buffer AE (200μl, 




Data were examined for normality  according to the Shapiro-Wilks criteria (originally 
published in 1965, this normality test is appropriate for sample sizes of less than 50). 
Non-normally distributed data were log-transformed prior to statistical analyses. 
Analyses were performed in SPSS version 21 (IBM) and figures were generated using 
Numbers for Mac (version 3.2). Analysis of variance (ANOVA) was used to evaluate 
differences in between the BMI categories (lean, overweight and obese). An unpaired 
student’s t-test  was used to compare mRNA expression of mitochondrial dynamics 
genes in AbSc AT between obese or overweight patients and the lean controls. A p 
value of 0.05 or less was considered statistically significant. All data are presented as 
means ± S.E.M unless otherwise stated. 
2.3. Results.
2.3.1 Effect of adiposity on clinical parameters of the human AbSc AT cohort
Unpaired t-test analyses were performed to identify differences in the clinical parameters 
between lean versus overweight and lean versus obese. Fasted Glucose levels were sig-
nificantly higher in obese compared to the lean cohort (Table 1, p < 0.05). No differences 
were noted between the fasted glucose levels of lean and overweight subjects. Total-
cholesterol, triglycerides, LDL-cholesterol and HDL-cholesterol were not significantly 
different between all three cohorts (lean, overweight, obese). Insulin levels were signifi-
cantly higher in obese compared to lean subjects (Table 1. p < 0.05). Glucose and insulin 
were measured in fasted plasma samples. These clinical parameters are consistent 
with previous studies (Bastard, Maachi et al. 2006, Neff 2013) and define these sub-
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jects as a representative cohort for the investigation of adiposity and mitochondrial 
dynamics. 
Table 1. Comparison of the clinical parameters within the cohort.
Data are presented as mean ±	  SD. ANOVA was used to compare between BMI groups. 
p < 0.05 was considered statistically  significant. p < 0.05*, p < 0.01** and p < 0.001***. 
lean; n = 10, overweight; n = 10 and obese; n = 10. Age was not included as it was not 
available for all subjects. Glucose (glucose oxidase method) and insulin (enzyme ampli-
fied sensitivity multiplex immunoassay) data are from fasted blood samples. Lipid, glu-
cose and insulin profiling were performed by colleagues in the biochemistry  lab and pre-
vious diabetes research staff at University Hospital Coventry and Warwickshire. 
43
2.3.2. Effect of adiposity on markers of mitochondrial fission.
mRNA expression of genesinvolved in mitochondrial fission; Fis1 and Drp1 were meas-
ured by qRT-PCR in AbSc AT. Fis1 expression increased in AbSc AT with BMI (Figure 
2.4. lean vs obese: p = 0.008). Furthermore, mRNA Drp1 expression with adiposity also 
significantly  increased	  with BMI (Figure 2.4. lean vs overweight: p  = 0.06 and lean vs 
obese; p = 0.018). Taken together, markers of mitochondrial fission were higher in obe-
sity.
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Figure  2.4. Markers of mitochondrial fission increased with adiposity.
mRNA expression of genes involved in mitochondrial fission; A) Fis1 and B) Drp1. All 
experiments were performed in triplicate. Unpaired t-tests were performed to assess the 
effect of BMI on either Drp1 or Fis1 expression. p < 0.05 was considered statistically  sig-
nificant.  p = 0.06§	  , p  < 0.05*, p < 0.01** and p  < 0.001***. lean; n = 10, overweight; n 
= 10 and obese; n = 10. Data are represented as means ±	  S.E.M.
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2.3.3. Effect of adiposity on markers of mitochondrial fusion.
mRNA expression of genes involved in mitochondrial fusion; FOXC2, Mfn2 and Opa1 
were measured by qRT-PCR in AbSc AT. Mfn2 and Opa1 increased at both an mRNA 
and protein expression level whilstthe transcriptional regulator of fusion, FOXC2 expres-
sion decreased in mRNA expression with adiposity. Mfn2 increased significantly in ex-
pression in obese subjects (Figure 2.5A-B. lean versus obese, mRNA: p = 0.04, protein: p 
= 0.03). Furthermore the second mitochondrial fusion gene Opa1 expression was sig-
nificantly higher in obese compared to lean (Figure 2.5C-D. lean vs obese: mRNA: p = 
0.004 and protein: p = 0.001). Conversly, FOXC2 mRNA expression was significantly 
lower in obese compared to lean subjects (Figure 2.5E. FOXC2: lean vs obese; p < 
0.001).                                                                
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Figure  2.5. Markers of mitochondrial fusion increased with adiposity.
mRNA and protein expression of genes involved in mitochondrial fusion; A-B) Mfn2. All 
experiments were performed in triplicate. Unpaired t-tests were performed to assess the 
effect of BMI on Mfn2 expression. p < 0.05 was considered statistically significant. 
p < 0.05*.  lean; n = 10, overweight; n = 10 and obese; n = 10. L1-L4 represent 4/10 
lean subjects. O1-4 represent 4/10 obese subjects. These subjects were selected to 
highlight that despite differential expression of Mfn2 amongst the 10 patients, collec-
tively a significant increase in Mfn2 protein expression was identified. Data are repre-
sented as means ±	  S.E.M.
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Figure 2.5 continued. Markers of mitochondrial fusion increased with adiposity.
mRNA and protein expression of genes involved in mitochondrial fusion; C-D) Opa1.All 
experiments were performed in triplicate. Unpaired t-tests were performed to assess the 
effect of BMI on Opa1 expression. p  < 0.05 was considered statistically significant. 
p < 0.05*, p < 0.01** and p  < 0.001***.  lean; n = 10, overweight; n = 10 and obese; 
n = 10. L1-L4 represent 4/10 lean subjects. O1-4 represent 4/10 obese subjects. These 
subjects were selected to highlight that despite differential expression of Opa1 
amongst the 10 patients, collectively  a significant increase in Opa1 protein expression 
was identified. Data are represented as means ±	  S.E.M.
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Figure 2.5 continued. Transcriptional regulator of mitochondrial fusion, FOXC2 
decreased with adiposity
mRNA expression of genes regulating mitochondrial fusion; FOXC2 (E). All experi-
ments were performed in triplicate. Unpaired t-tests were performed to assess the effect of 
BMI on FOXC2 expression. p < 0.05 was considered statistically significant. p < 0.05*, 
p < 0.01** and p < 0.001***.  lean; n = 10, overweight; n = 10 and obese; n = 10. Data 
are represented as means ±	  S.E.M.
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2.3.4 Balance of mitochondrial dynamics in adiposity
The balance of mitochondrial fusion and fission genes is essential to the maintenance of 
mitochondrial number, structure and morphology. Correlation analyses between markers 
of mitochondrial fusion and fission genes were performed to assess if the regulation of 
mitochondrial dynamics was altered by adiposity. Parametric analyses of Mfn2 vs Opa1 
identified that  these genes were positively  and significantly  associated in lean subjects 
(Figure 2.6. Mfn2 vs Opa1 mRNA; lean: R2 = 0.655, p  = 0.04). Conversely, in obese sub-
jects, Mfn2 and Opa1 were no longer significantly positively  associated (Figure 2.3. 
Mfn2 vs Opa1; obese: R2 = 0.407, p = 0.243). No significant correlations were noted for 
the fission genes (Drp1 and Fis1) for either the lean or obese subjects.
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Figure 2.6. Balance of markers of mitochondrial dynamics in adiposity.
Parametric correlation analyses were performed to assess the relationship  between the 
mitochondrial fusion markers, Mfn2 and Opa1 and mitochondrial fission markers, Drp1 
and Fis1 and whether these were altered by adiposity. All mRNA expression data are an 
average of triplicate measurements. p < 0.05 was considered statistically significant. 
p < 0.05*, p < 0.01** and p < 0.001***.  lean; n = 10 and obese; n = 10. Data are repre-
sented as means ±	  S.E.M.
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2.3.5 Mitochondrial copy number in abdominal subcutaneous adipose tissue (AbSc AT) 
of lean, overweight and obese cohorts
Total genomic DNA was extracted from all the adipose tissuesamples and abundance of 
mitochondria specific (Cytochrome B (CytB)) and nucleus specific (β-actin) genes were 
measured using PCR. Approximate mitochondrial DNA content was calculated as the 
ratio of mitochondrial gene : nuclear gene. Mitochondrial DNA content did not alter sig-
nificantly by BMI in our cohort (Figure 2.7, lean vs obese; p > 0.05).
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Figure 2.7. Mitochondrial DNA content did not alter significantly with adiposity.
Amplification of mitochondrial (CytB) and nuclear genes (Beta actin) were performed by 
PCR to assess the relative mitochondrial DNA content in abdominal subcutaneous adi-
pose tissue of all patients in our cohort. The relative mitochondrial DNA content was de-
fined as a ratio between mitochondrial gene : nuclear gene expression. All experiments 
were performed in triplicate. Unpaired t-tests were performed to assess the effect  of BMI 
on mitochondrial abundance. p < 0.05 was considered statistically significant.  lean; n = 
10, overweight; n = 10 and obese; n = 10. All data were non significant. Data are repre-
sented as means ±	  S.E.M.
53
2.3.6. Correlation analyses between mitochondrial  DNA content and mitochondrial 
dynamics genes.
Parametric correlation analyses were performed to evaluate whether the relationship be-
tween mitochondrial DNA content and markers of mitochondrial dynamics was affected 
by adiposity. This was not the case,as a positive and significant relationship between 
FOXC2 and mitochondrial abundance in lean subjects (Figure 2.8. FOXC2 vs mito; lean: 
R2 = 0.744, p = 0.03) and a less positive but still significant correlation in obese subjects 
(Figure 2.8. FOXC2 vs mito; obese: R2 = 0.704, p = 0.03). 
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Figure 2.8. Correlation analyses between mitochondrial DNA content and markers 
of  mitochondrial dynamics genes
Parametric correlation analyses were performed to assess the relationship  between the 
mitochondrial DNA content and markers of mitochondrial dynamics gene expression. All 
mRNA expression data are an average of triplicate measurements. p < 0.05 was consid-
ered statistically significant. p < 0.05*, p  < 0.01** and p < 0.001***.  lean; n = 10 and 
obese; n = 10.
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2.4. Discussion.
Previous studies have noted metabolic dysfunction within obesity (Virtue and Vidal-Puig 
2010, Picard and Turnbull 2013). With the critical role of mitochondrial dynamics in con-
trolling the abundance and health of mitochondria, any disturbance could result in nega-
tive implications for metabolism (Kelley, He et al. 2002, Szewczyk and Wojtczak 2002, 
Bakkman, Fernstrom et al. 2010). The results of this study demonstrate that markers of 
mitochondrial dynamics are	   altered with adiposity in AbSc AT and the expression of 
genes involved in fusion and fission, with the exception of FOXC2,were more highly ex-
pressed in overweight and obese individuals compared to lean individuals. 
 Mitochondrial dynamics during adiposity was studied by evaluating expression 
levels of gene markers of fission as well as fusion. This approach offers the ability  to ex-
plore whether a single or multiple mitochondrial fission genes were altered by adiposity. 
Our data demonstrates that markers of mitochondrial fission increased with adiposity, as 
evidenced by  the significantly increased expression levels of Fis1 and Drp1 in obese 
compared to lean controls (Figure 2.4	  ). These data are consistent with previous studies in 
endothelial cells, which found a higher expression of Fis1 compared to healthy volunteers 
(Shenouda, Widlansky et al. 2011). Based on our and others observations that markers of 
mitochondrial fission are increased, it may  be expected that mitochondrial DNA content 
would also increase, in the absence of any changes to mitochondrial fusion. Nevertheless, 
upon evaluation of the mitochondrial DNA content in our human AbSc AT revealed no 
significant change in mitochondrial DNA content with adiposity was observed (Figure. 
2.7	  ). 	  Considering this result, the lack of significant increase in mitochondrial DNA 
content as a consequence of enhanced markers of mitochondrial fission is not only 
unexpected but is also in contradiction with the reduction in mitochondrial DNA con-
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tent and size described in the skeletal muscle of obese subjects compared to their lean 
counterparts (Jheng, Tsai et al. 2012). A number of potential explanations can be of-
fered to support our observations. Firstly, the increase in the expression of markers of 
mitochondrial fission may be compensated by an equivalent upregulation of expres-
sion of the markers of mitochondrial fusion. This possibility  was investigated and will 
be discussed in further detail, later in this discussion. Secondly, others have suggested 
that a change in mitochondrial abundance may not necessarily indicate the full extent 
of changes to mitochondrial function (Jeng, Yeh et al. 2008). In light of this, even in 
the absence of changes to mitochondrial DNA content, the functional capacity  of the 
individual mitochondria in obese individuals may differ from those of lean subjects. 
Indeed others have shown in islet cells, that knockout of Opa1, a gene involved in mi-
tochondrial fusion did not affect mitochondrial DNA content (Jeng, Yeh et al. 2008, 
Picard and Turnbull 2013) but that their mitochondria displayed a significant decrease 
in electron transport chain complex IV and stunting of insulin secretion (Picard and 
Turnbull 2013).Furthermore, previous studies have highlighted that the presence of 
compromised mitochondria result in negative metabolic consequences for these indi-
viduals (Shenouda, Widlansky et al. 2011) possibly exerted through the induction of 
mitochondrial fragmentation (Jheng, Tsai et  al. 2012). In order to consider the impli-
cations of our enhanced expression of markers of mitochondrial fission and consis-
tency of mtDNA content, further studies would be required to assess the metabolic 
health of mitochondria in our subjects (Bakkman, Fernstrom et al. 2010, Brand and 
Nicholls 2011, Cabrera, Ziemba et al. 2012). 
Returning to gene expression analysis of the opposing arm of mitochondrial 
dynamics from mitochondrial fission, markers of mitochondrial fusion also increased 
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with adiposity. In our study, Opa1 and Mfn2 mRNA and proteins expressions were 
significantly increased in obese compared to lean subjects (Figure 2.5 C and D). 
Whilst the mechanism for induction of Opa1 expression is unknown, others have 
shown that ob/ob mice fed with a high fat diet, had a lower Opa1 expression in their 
islets prior to the development of diabetes (Keller, Choi et al. 2008). In contrast, the 
increase in Opa1 expression in our AbSc AT study may present an earlier stage than 
the pre-diabetic status shown in the mice. In line with this study, FOXC2 expression 
in our AbSc AT samples were significantly diminished in obese subjects compared to 
lean controls (Figure 2.5E). As a transcriptional regulator of mitochondrial fusion, 
FOXC2 has been shown to represent a lean and insulin sensitive phenotype (Lidell et 
al. 2011).	   
In summary, mRNA and protein expression of markers of mitochondrial dynamics 
geneswere significantly increased with adiposity. Optimal mitochondrial dynamics re-
quires balanced mitochondrial fusion and fission, in order to prevent the development of 
mitochondrial dysfunction (Zorzano, Liesa et al. 2009, Zorzano, Liesa et al. 2009, Liesa 
and Shirihai 2013). The balance of markers of mitochondrial fusion genes was different 
between lean and obese subjects. Parametric analyses of Mfn2 vs Opa1 identified that 
these genes were positively and significantly associated in lean subjects (Figure 2.6). 
However, the significance of the relationship between fusion gene expression was not 
upheld within the obese cohort. This result may indicate that the balance of mitochondrial 
dynamics is affected by adiposity and would support the known essential role of optimal 
mitochondrial dynamics in preventing the development of mitochondrial dysfunction.. 
The ex vivo treatment of our AbSc AT with palmitate , previously identified to inhibit 
mitochondrial fusion, would allow manipulation of fusion. Fusion has been character-
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ised as selective and an essential pre-requisite for the subsequent intiation of mito-
chondrial fission, required to detect and remove dysfunctional mitochondrial compo-
nents by mitophagy (Twig et al. 2008). Through the treatment of palmitate in obese sub-
jects, would allow us to explore if the reduction of mitochondrial fusion was accompa-
nied by  changes in mitochondrial fission and how their mitochondria compared metaboli-
cally  to those of the lean individuals whose fusion was already expressed at a lower level 
than those of the obese subjects.
The present study extends our understanding of mitochondrial dynamics in adipo-
cytes as an entire system. The observation that markers of mitochondrial dynamics ex-
pression are altered in obese AbSc AT offers a potential explanation for the reduction in 
metabolism and dysregulation of energy homeostasis known to accompany adiposity 
(Kelley, He et al. 2002, Sparks, Xie et al. 2005). 
Bariatric surgery  is one of the most successful methods to resolve insulin resistance 
(Levy, Fried et al. 2007, Buchwald, Estok et al. 2009, Carlsson, Peltonen et al. 2012, 
Nijhawan, Richards et al. 2013). As a consequence, up to 85% of patients ameliorate their 
T2DM status following bariatric surgery (Bloomston, Zervos et al. 1997, Scopinaro 2002, 
Sjostrom 2005, Pories 2008). As a novel extension of this study, markers of mitochondrial 
dynamics was studied in pre and post bariatric surgery adipose tissue samples together 








In Chapter 2, higher adiposity was shown to increase the expression of mitochondrial 
fission (Drp1 and Fis1) and fusion genes (Mfn2 and Opa1) in overweight and obese 
AbSc AT (Figures 2.4 and 2.5). Obesity  is known to be a prominent risk factor for the 
development of insulin resistance and T2DM. By 2035, the financial cost of treating 
diabetes and its associated secondary complications is estimated at £39.8 billion 
(WHO, 2013). Given the public health burden of T2DM  and obesity  globally, under-
standing at a molecular level, the regulation of insulin sensitivity and T2DM, is of 
vital significance (DeFronzo 2004). Currently, bariatric surgery represents the most 
effective treatment for long-term resolution of T2DM and control of obesity  above 
that which can be achieved through lifestyle alone e.g. exercising and dieting (Levy, 
Fried et al. 2007, Cunneen 2008, Pories 2008). Previous studies have identified that 
weight loss induced following surgery provides beneficial effects within cellular me-
tabolism including resolution of insulin resistance and remission of T2DM (Niskanen, 
Uusitupa et al. 1996, Guldstrand, Ahren et al. 2003, Villareal, Banks et al. 2008). 
Weight loss (Ziccardi, Nappo et al. 2002, Gumbs, Modlin et al. 2005) has also been 
shown to correspond with significant changes in beta cell function and endoplasmic 
reticulum stress (ER) (Gregor, Yang et al. 2009, Bradley, Conte et al. 2012).
 Several studies show that mitochondrial dysfunction is present in metabolic 
disorders such as insulin resistance and T2DM  (Lowell and Shulman 2005, Zorzano, 
Liesa et  al. 2009, Bournat and Brown 2010, Jheng, Tsai et al. 2012). As the regulators 
of energy metabolism (Rosen and Spiegelman 2006, Liesa and Shirihai 2013), mito-
chondria and their health are tightly  regulated. Mitochondrial dysfunction can result 
from an imbalance in mitochondrial fusion and fission or an overactivation of mito-
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chondrial fission (Figure 1.5) (Lowell and Shulman 2005, Zorzano, Liesa et al. 2009, 
Jheng, Tsai et al. 2012). Mitochondrial dynamics contributes to the maintenance of 
mitochondrial abundance and function through the selective sequestering of compro-
mised mitochondria that  are shuttled towards mitophagy and thus removed from the 
mitochondrial population (Figure 1.7) (Twig, Hyde et al. 2008). Without balanced mi-
tochondrial dynamics, compromised mitochondria would accumulate. The presence of 
imbalanced mitochondrial dynamics within these individuals could provide an expla-
nation for diminished metabolic health of cells, which often accompanies T2DM 
(Mouli, Twig et al. 2009). 
 Despite the critical role of the mitochondria within cellular metabolism, the 
regulation and balancing of mitochondrial dynamics in adipose tissue remain poorly 
characterised. Without mitochondrial dynamics, cells would continually  accumulate 
damaged mitochondria, which if allowed to persist, would compromise cellular me-
tabolism and survival (Lowell and Shulman 2005, Michel, Wanet et al. 2012). To 
date, most research has focused on investigation of insulin resistance and mitochon-
drial dynamics within skeletal muscle. Therefore, the aim of this study was to address 
whether mitochondrial dynamics were imbalanced in our T2DM  cohort and if the type 
of surgical procedure or weight loss induced after surgery could influence mitochon-
drial dynamics in AbSc AT.
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3.2. Materials and Methods.
3.2.1 Selection and description of participants:
29 female Caucasian patients who were scheduled to undergo Bariatric Surgery (Gas-
tric banding, (GB), n = 8; 54 ±	  11 years old, Sleeve Gastronectomy (SG) like gastric 
plication surgery (n = 13; 55 ±	  6 years old) or Biliopancreatic diversion (BPD), n = 8; 
52 ±	  3 years old) procedures at ISCARE Clinic Centre in the Czech Republic partici-
pated in this study under ethical approval. Prior to enrolment, all participants provided 
written informed consent and completed a comprehensive medical evaluation. All pa-
tients had a BMI > 35 kg/m2 and T2DM. Samples of abdominal subcutaneous adipose 
tissues (AbSc AT) were taken at  time of surgery and 6 months after surgery. These 
samples were collected as a surgical biopsy. The post surgical sample was taken at 6 
months after surgery as the weight loss for patients across all surgical procedures was 
estimated from previous studies to correspond to a around 20% weight loss. A follow-
up is planned by our collaborators to collect a further AbSc AT biopsy from each pa-
tient, by the same surgical method, 1 year after their  bariatric surgery.
All groups were matched for age (54 ± 7 years), BMI (Pre 41.9 ± 6) and duration of 
diabetes. Aspirin and medications for diabetes were discontinued, under medical su-
pervision, 3 days before each proposed study test. 
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3.2.2. Body composition and basal metabolic variables.
Body fat compositions were measured pre-operatively and 6 months after surgery by 
dual energy  x-ray absorptiometry  (DEXA) using a whole body Hologic QDR 2000 
scanner (Hologic Europe, Vilvoorde, Belgium). 
3.2.3. Surgical procedures.
For the current study we used adipose tissue from three different  types of bariatric 
surgical procedure. They are explained as follows:
Figure 3.1. Types of bariatric surgery:Gastric Banding (GB), Sleeve Gastronec-
tomy (SG) and Biliopancreatic Diversion (BPD). Clinical observations have high-
lighted that the more extensive structural remodelling of the gastrointestinal tract dur-
ing bariatric surgery, the more significant the correlation with diabetes resolution. Im-
ages taken from (Neff 2013).	    BPD > SG > Band for post surgical remission of 
T2DM.
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GB, or laproscopic adjustable gastric banding (LAGB) involves placement of a sili-
cone band immediately below the gastro-oesophageal junction at the upper part of the 
stomach (Dixon, Straznicky et  al. 2012). This results in physical division of the upper 
and lower part of the stomach. Restriction of the opening between the two parts of the 
stomach using the silicone band can influence hunger and satiety (Burton and Brown 
2011). The size of the opening can be altered post operatively  (Cherian, Tentzeris et 
al. 2010). Adjusting the band appears to promote reduction in food consumption by 
lowering feelings of hunger. The advantages of the procedure are its reversibility and 
adjustability, maintenance of normal digestive processes and absorption of nutrients 
and vitamins (Schouten, Wiryasaputra et  al. 2010). The disadvantages are the greater 
lag time between surgical procedure and initial weight loss. Lower proportions of pa-
tients lose 50% of their excess body  weight compared to other bariatric procedures 
and issues with band adjustment/positioning (Aarts, Dogan et al. 2014).
Sleeve Gastronectomy (SG) procedure, 75% of the stomach’s capacity is removed, 
reducing the amount of food that can be consumed. Whilst stomach function is virtu-
ally unchanged, remodelling involves resection of the greater curvature of the stom-
ach at 4cm proximal to the pylorus (Skrekas, Antiochos et al. 2011, Neff 2013). The 
advantages of this procedure include the rapid, significant and sustained weight loss 
of more than 50% based on 3-5+ year follow up data (Himpens, Dobbeleir et al. 2010) 
and improved satiety, reduction in hunger and appetite via changes in the secretion of 
gut hormomes (accessed on 17.6.14:
http://asmbs.org/obesity-and-surgery-learning-center/bariatric-surgery-procedures/#sl
eeve). Nevertheless, like all surgical procedures, SG presents a number of disadvan-
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tages including the irreversible nature of the procedure and possibility of long-term 
vitamin deficiencies (Pech, Meyer et al. 2012).
Biliopancreatic diversion (BPD) involves extensive remodeling of the stomach and 
bypassing of the small intestine (Ferrannini, Rosenbaum et al. 2014). A small pouch is 
created which is attached to the colon bypassing the small intestine. Unlike SG and 
GB, this diversion results in a significant decrease in the absorption of nutrients, calo-
ries and fat-soluble vitamins (Levy, Fried et al. 2007, Tice, Karliner et  al. 2008). This 
procedure is considered to resolve T2DM  most effectively (Buchwald, Estok et al. 
2009). Further advantages include up to 70% excess weight loss 5 years after surgery 
and up to 70% lower absorption of dietary fat  ((Dolan, Hatzifotis et al. 2004) accessed 
17.6.14:http://asmbs.org/obesity-and-surgery-learning-center/bariatric-surgery-proced
ures/#sleeve). Given the complicated nature of the BPD procedure, post-surgical dis-
advantages may include greater propensity for vitamin, mineral and protein deficien-
cies and longer post-surgical recuperation (Topart, Becouarn et al. 2014).
3.2.4. Analyses of blood samples and adipose tissue.
Fasted serum and plasma samples were used to assess the metabolic, hormonal and 
inflammatory profiles of all participants (e.g. glucose, cholesterol, triglycerides, HDL, 
HbA1c, insulin). Fasted glucose and insulin (Roche, Modular Analytics E170, Mann-
heim, Germany) measurements undertaken by  our Czech collaborators allowed calcu-
lation of Homeostasis Model Assessment indices (HOMA-insulin resistance) (Mat-
thews, Hosker et al. 1985). 
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HOMA-IR was calculated as follows: [HOMA-IR= Fasted Insulin (μU/l) x Fasted 
glucose (mmol/l))/22.5]. LDL Cholesterol was calculated using the Friedewald for-
mula (Friedewald, Levy et al. 1972).
Adipose tissue samples were flash frozen in liquid nitrogen, immediately  after collec-
tion, and then placed directly  at  -80°c freezer for storage until use, to ensure minimal 
damage or degradation.
3.2.5. Isolation of mRNA and qPCR.
See adiposity chapter 2, section 2.2.3 for description
3.2.6. Protein determination and western blot analysis.
See adiposity chapter 2, section 2.2.5 for description
3.2.7. Mitochondrial copy number determination.
See adiposity chapter 2, section 2.2.6 for description
3.2.8 Statistical analyses.
Data were examined for normality according to the Shapiro-Wilks criteria. Non-
normally distributed data were log-transformed prior to statistical analyses. Analyses 
were performed in SPSS version 21 (IBM) and figures were generated using Numbers 
(Mac version 3.2). Analysis of variance (ANOVA) was used to evaluate differences in 
weight loss induced changes between the 3 surgical procedures (GB, SG and BPD). A 
paired student’s t test was used to compare mRNA and protein expression of mito-
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chondrial dynamics markers in AbSc AT before and after weight loss. A P value of 
0.05 or less was considered statistically significant. All data are presented as means ± 
S.E.M unless otherwise stated. Power analysis revealed that 29 samples were suffi-
cient to determine a statistically significant difference in mitochondrial copy number 
that may arise due to Bariatric Surgery. The sample size calculation was done using 
G*Power version 3.1.9 (Dusseldorf, Germany). An assay, the details of which are 
provided in: Mitochondrial copy number determination section 2.2.6 generated mito-




3.3.1. Clinical parameters following bariatric surgery.
On average, subjects lost 25% of their initial body weight 6 months after bariatric 
surgery (GB, BPD and SG; Table 2, p  < 0.01). Bariatric surgery  resulted in an average 
percentage excess BMI loss across subjects of 33% ± 13 (p < 0.05, Table 2). Across 
all surgical procedures, values of insulin sensitivity determined through homeostatic 
model assessment of insulin resistance (HOMA-IR) were more than halved from 
11.90±8.63 to 5.11±2.95 (p < 0.01, Table 2). HbA1c levels decreased significantly 
post-surgery from 5.6±0.94 to 4.5± 0.82 (p < 0.01, Table 2). Furthermore, fasted lev-
els of plasma markers of glucose homeostasis were markedly improved following 
surgery (glucose (9.26±2.48 to 7.22±1.65 mmol/L) and insulin (28.8±18.57 to 
























































































































































































3.3.2. Influence of the different surgical procedures on clinical parameters follow-
ing bariatric surgery.
Stratification of subjects based on their surgical procedure revealed distinct differ-
ences in their post-surgical clinical and mitochondrial gene expressions (Table 2). 
BPD patients saw the greatest number of biochemical parameters significantly im-
prove following surgery  including glucose, insulin, HbA1c and percentage excess 
BMI loss. Whilst BPD provided the most consistent improvement in clinical parame-
ters following surgery, no single surgical procedure could account for all the signifi-
cant reductions in clinical parameters observed following bariatric surgery. Taken to-
gether, weight loss rather than the type of surgical procedure provides a more com-
prehensive explanation for the changes observed in clinical parameters in abdominal 
subcutaneous adipose tissue (AbSc AT) 6 months after surgery.
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3.3.3. mRNA expression of the mitochondrial fission markers, Fis1 and Drp1 be-
fore and after bariatric surgery	   	  
Fis1 and Drp1 play important roles in mitochondrial fission. After 6 months, follow-
ing weight loss accompanying bariatric surgery, mRNA expressions of Drp1 and Fis1 
were significantly reduced when all patients were included in the analysis irrespective 
of the surgical procedure (Figure 3.2 A and B. pre vs post, p  < 0.05). Upon stratifica-
tion of the data by surgical procedure, all the surgeries showed a trend towards re-
duced expression but only  patients undergoing GB surgery displayed a significant de-
crease in Fis1 mRNA expression (Figure 3.3A. GB; p = 0.02), while Drp1 was consis-
tently and significantly  downregulated across all surgical procedures (Figure 3.2A. 
overall pre vs post-surgery; p < 0.04, Figure 3.3A. GB; p = 0.02, 3.3B. SG; p = 0.04 
and 3.3C. BPD; p  = 0.03). These data lend support  to the observation that although 
the surgical procedure may influence the outcome of mitochondrial fission marker 
expression	  , weight  loss may be the biggest factor involved	   in this process. Figure 3.4 
shows the mRNA expressions of Drp1 and Fis1 for each patient pre and post bariatric 
surgery.
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Figure 3.2. Markers of mitochondrial fission, Drp1 and Fis1 decrease signifi-
cantly after bariatric surgery.
mRNA expression of genes involved in mitochondrial fission; A) Drp1 and B) Fis1. All 
experiments were performed in triplicate. Paired t-tests were performed at an individual 
subject level between mRNA expression values of either Drp1 or Fis1 in their pre and 
post surgical sample (n = 29 pre, n = 29 post). p  < 0.05 was considered statistically sig-
nificant. p < 0.05*, p < 0.01** and p < 0.001***. p values were compared to before sur-
gery mRNA expression level. Data are represented as means ±	  S.E.M.
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Figure 3.3. mRNA expression of the markers of mitochondrial fission, Drp1 and 
Fis1 stratified by surgical procedure.
mRNA expression of genes involved in mitochondrial fission; Gastric Banding (GB), 
Sleeve Gastronectomy  (SG) and Biliopancreatic diversion (BPD). All experiments were 
performed in triplicate. Paired t-tests were performed at an individual subject level be-
tween mRNA expression values in their pre and post surgical sample (n = 29 pre, n = 29 
post). p < 0.05 was considered statistically  significant. p < 0.05*, p  < 0.01** and p < 
0.001***. p values were compared to before surgery mRNA expression level.
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Figure 3.4. Individual patient Drp1 and Fis1 mRNA expressions pre and post 
bariatric surgery.
mRNA expression of genes regulating mitochondrial fission; A) Drp1 and B) Fis1. All 
experiments were performed in triplicate. Data for each individual patient is shown as 
1/dCt expression. Patient number is given as numerical value before notation of surgical 
procedure. Patients undergoing the same surgical procedure have their 1/dCt mRNA ex-
pression colour coded as follows: grey (Gastric banding, LAGB and band), black (Sleeve 
gastronectomy, SG) and dashed (Biliopancreatic diversion, BPD). Paired t-tests were per-
formed at an individual subject level between mRNA expression values of either Drp1 or 
Fis1 in their pre and post  surgical sample (n = 29 pre, n = 29 post). p < 0.05 was consid-
ered statistically significant. p < 0.05*, p  < 0.01** and p < 0.001***. p  values were com-
pared to before surgery mRNA expression level.
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3.3.4. mRNA and protein expression of the mitochondrial fusion markers, Mfn2 
and Opa1 before and after bariatric surgery 
Mfn2 and Opa1 play an important role in the regulation of mitochondrial fusion. 
Therefore, their expression was evaluated next to understand the complete regulation 
of mitochondrial dynamics in adipose tissue. Both Mfn2 mRNA, protein and Opa1 
mRNA revealed a significant overall reduction in expression following bariatric sur-
gery (Figure 3.5A. p = 0.004 and B. protein; p = 0.03). Opa1 protein expression did 
not alter significantly post-surgery (Figure 3.5D.). Upon stratification of the data by 
surgical procedure, only patients undergoing SG displayed a significant decrease in 
Mfn2 (Fig. 3.6A) mRNA expression, despite a general trend across all patients to-
wards a reduction in fusion expression regardless of the surgical procedure. These 
data lend support to the observation that although the surgical procedure may influ-
ence the outcome of mitochondrial fission marker expression	  , weight loss may  be the 
biggest factor involved	   in this process. Figure 3.7 shows the mRNA expressions of 
Mfn2 and Opa1 for each patient pre and post bariatric surgery. 
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Figure 3.5. Mfn2, a marker of mitochondrial fusion decreases in mRNA and pro-
tein expression after bariatric surgery.
Expression of Mfn2 gene involved inmitochondrial fusion; A) mRNA and B) protein. All 
experiments were performed in triplicate. Paired t-tests were performed at an individual 
subject level between mRNA expression values of Mfn2 in their pre and post surgical 
sample (n = 29 pre, n = 29 post). p  < 0.05 was considered statistically  significant. 
p < 0.05*, p  < 0.01** and p < 0.001***. p values were compared to before surgery 
mRNA expression level. Data are represented as means ±	  S.E.M.
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Figure 3.5 continued. Opa1, a marker of mitochondrial fusion decreases in 
mRNA and protein expression after bariatric surgery	  .
Expression of Opa1 gene involved in mitochondrial fusion; C) mRNA and D) protein. All 
experiments were performed in triplicate. Paired t-tests were performed at an individual 
subject level between mRNA expression values of Opa1 in their pre and post surgical 
sample (n = 29 pre, n = 29 post). p  < 0.05 was considered statistically  significant. 
p < 0.05*, p  < 0.01** and p < 0.001***. p values were compared to before surgery 
mRNA expression level. Data are represented as means ±	  S.E.M.
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Figure 3.6. mRNA expression of the markers of mitochondrial fusion, Opa1 and 
Mfn2, stratified by surgical procedure.
mRNA expression of genes regulating mitochondrial fission; Gastric Banding (GB), 
Sleeve Gastronectomy  (SG) and Biliopancreatic diversion (BPD). All experiments were 
performed in triplicate. Paired t-tests were performed at an individual subject level be-
tween mRNA expression values in their pre and post surgical sample (n = 29 pre, n = 29 
post). p < 0.05 was considered statistically  significant. p < 0.05*, p  < 0.01** and p < 
0.001***. p values were compared to before surgery mRNA expression level.
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Figure 3.7. Individual patient Mfn2 and Opa1 mRNA expressions pre and post 
bariatric surgery	  . 
mRNA expression of genes regulating mitochondrial fission; A) Mfn2 and B) Opa1. All 
experiments were performed in triplicate. Data for each individual patient  is shown as 
1/dCt expression. Patient number is given as numerical value before notation of surgi-
cal procedure. Patients undergoing the same surgical procedure have their 	  1/dCt mRNA 
expression colour coded as follows: grey (Gastric banding, LAGB and band), black 
(Sleeve gastronectomy, SG) and dashed (Biliopancreatic diversion, BPD). Paired t-tests 
were performed at an individual subject level between mRNA expression values of either 
Drp1 or Fis1 in their pre and post surgical sample (n = 29 pre, n = 29 post). p < 0.05 was 
considered statistically significant. p < 0.05*, p  < 0.01** and p < 0.001***. p values were 
compared to before surgery mRNA expression level.
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3.3.5. Effect of bariatric surgery on mitochondrial DNA content. 
Mitochondrial DNA content in both assay methods (CytB/beta actin and ND1/
BECN1) increased significantly after surgery  (Figure 3.8; p < 0.001). Therefore, 
weight loss may  bring about changes in mitochondrial abundance through redressing 
the balance of mitochondrial dynamics. Fisher r-to-z transformation was performed to 
assess if there were any significant differences between the correlations obtained for 
the two-mitochondrial DNA expression assay  methods. Evaluation of the correlation 
coefficients revealed a non-significant z-score of -0.5 and p = 0.6. Therefore, the cor-
relations in both assays did not  differ significantly from one another (Figure 3.8). 
Figure 3.9. shows the mitochondrial DNA content in AbSc AT before and after bariat-
ric surgery according to surgical procedure.
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Figure 3.8. Mitochondrial DNA content before and following bariatric surgery.
Genomic DNA (gDNA) was isolated from AbSc AT taken before and after bariatric 
surgery (n = 29). Mitochondrial DNA content was defined as the relative 
mitochondrial/nuclear DNA expression: A) ND1/BECN1 pre vs post, B) CytB/Beta 
actin pre vs post. Data are represented as means ±	  S.E.M. Paired t-tests were per-
formed on an individual level between isolated genomic DNA from pre and post bari-
atric surgery.  p  < 0.05*, p < 0.01** and p  < 0.001***. p  values were compared to mito-
chondrial DNA content before surgery.
82
Figure. 3.9. Changes to mitochondrial DNA content by surgical procedure 
Genomic DNA (gDNA) was isolated from AbSc AT taken before and after bariatric 
surgery. Mitochondrial DNA content was defined as the relative mitochondrial/
nuclear DNA expression using the ND1/BECN1 assay. pre vs post for gastric banding 
(GB) (n = 8),  pre vs post for sleeve gastronectomy (SG) (n = 13) and pre vs post for 
biliopancreatic diversion (BPD) (n = 8). Data are represented as means ±	  S.E.M. 
Paired t-tests were performed on an individual level between isolated genomic DNA 
from pre and post bariatric surgery. p values were compared to mitochondrial DNA con-
tent before surgery. All data were non significant.
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3.3.7. Glucose correlates with markers of mitochondrial dynamics.
After weight loss, expression of the markers of mitochondrial dynamics Drp1, Opa1 
and Mfn2 became positively and significantly correlated with plasma glucose levels 
(Figure 3.10. A. Drp1; pre: R2 = -0.165, p  = 0.393, post: R2 = 0.394, p = 0.035, B. 
Mfn2; pre: R2 = 0.045, p  = 0.816, post: R2 = 0.499, p = 0.015, and C. Opa1; pre: R2 = 
0.052, p  = 0.788, post: R2 = 0.462, p = 0.012). The correlation coefficients by Fisher 
r-to-z transformation, used to determine if there is a statistically significant difference 
between two correlations revealed that all mitochondrial dynamics markers with the 
exception of Fis1 were significantly altered after bariatric surgery (Figure 3.10A. 
Glucose vs Drp1 z-score = 2.1, p = 0.03, 3.10C. Glucose vs Mfn2 z-score = -1.81, p = 
0.07 and 3.10D. Glucose vs Opa1 z-score = -1.61, p = 0.1). 
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Figure 3.10. Glucose correlates with mRNA expression of the mitochondrial fis-
sion gene Drp1 expression.
Parametric correlation analyses were performed to evaluate the relationship between fast-
ing glucose levels and mitochondrial dynamics gene expression (n = 29). All mRNA ex-
pression data are an average of triplicate measurements. p < 0.05 was considered statisti-
cally significant. p < 0.05*, p < 0.01** and p < 0.001***. 
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Figure 3.10. continued. Glucose correlates with mRNA expression of the mito-
chondrial fusion genes Mfn2 and Opa1.
 Parametric correlation analyses were performed to evaluate the relationship between 
fasting glucose levels and mitochondrial dynamics gene expression (n = 29). All 
mRNA expression data are an average of triplicate measurements. p < 0.05 was con-
sidered statistically significant. p < 0.05*, p < 0.01** and p < 0.001***.  
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3.3.8. Macrophage markers and bariatric surgery.
CD68 was used to characterise macrophage expression in AbSc AT (Figure 3.11. 
CD68 vs BMI). Following bariatric surgery, no statistically  significant change in 
macrophage gene expression was identified (Figure 3.12. mRNA, p = 0.11). In sup-
port of the hypothesis that changes in mitochondrial dynamics occurs independently 
of macrophages the expression of CD68 did not correlate with mRNA and protein ex-
pression of mitochondrial dynamics genes (Mfn2, Opa1, Fis1 and Drp1). These data 
demonstrate that macrophage infiltration into AbSc AT was not responsible for 
changes observed in mitochondrial dynamics.
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Figure 3.11. CD68 versus BMI.
CD68 was used to characterise macrophage expression in abdominal subcutaneous 
adipose tissue. Values for 1/dCt are an average of triplicate measurements of each sam-
ple. n = 29 pre, n = 29 post. 
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Figure 3.12. Macrophage markers and bariatric surgery.
CD68 was used to characterise macrophage expression in AbSc A.T. Values for 1/dCt 
are an average of triplicate measurements of each sample. n = 29 pre, n = 29 post. All 
data were non significant.
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3.4. Discussion.
This study sought to examine and evaluate the effects of weight loss induced by bari-
atric surgery on mitochondrial dynamics within AbSc AT of T2DM subjects. The re-
sults of this study demonstrate that weight loss accompanying bariatric surgery can 
positively influence the expression of markers of mitochondrial dynamics genes. 
Consistent with previous clinical studies BMI, HOMA-IR and plasma glucose 
markedly improved following bariatric surgery (Levy, Fried et al. 2007, Aarts, Dogan 
et al. 2014). Previous reports involving skeletal muscle biopsies taken before and after 
surgery, highlight that the rates of diabetes remission and return to normal glycaemic 
control vary according to the surgical procedure (Buchwald, Estok et al. 2009). In an 
attempt to address, whether the nature of the surgical procedure or weight loss could 
alter the expression of markers of mitochondrial dynamic gene in this study, we firstly 
examined the clinical parameters before and after surgery. The entire cohort repre-
sented three different types of elective bariatric surgery, Gastric banding (GB, Sleeve 
gastronectomy (SG) and Biliopancreatic diversion (BPD). The degree of surgical re-
modelling has often been hypothesised to be responsible for the differences in weight 
loss and diabetes remission (Pournaras, Osborne et al. 2010). In this study, subjects 
across all surgery types lost  an average of 33±13 % of their excess weight 6 months 
after surgery (Table 2). However, amongst the clinical parameters measured (HbA1c, 
BMI, glucose, insulin, HOMA-IR, triglycerides and cholesterol), no single surgical 
procedure could account for the significant reductions observed (Table 2). Therefore, 
we concluded that  weight loss rather than the surgical procedure might be responsible 
for the post-surgery improvements.
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Considering weight loss and diabetes remission by surgical procedure, BPD 
corresponded with the greatest  excess BMI loss 6 months after surgery (Table 2).In 
the context of the hypothesis that BPD, which involves the greatest degree of surgical 
remodelling should experience greater improvements in diabetes remission, it  would 
be expected that the HOMA-IR score should be most significantly  decreased.  Indeed, 
despite the pre bariatric HOMA-IR score of BPD patients of appoximately 13 com-
pared to 11 for GB and SG patients, the post bariatric surgery  for the BPD patients 
were lower than those of the other two surgical procedures (HOMA-IR: 5.03 com-
pared to 5.26 (GB) and 5.06 (SG)).  These data lend support to the hypothesis that the 
greater the surgical remodelling the greater the rate of diabetes remission. One poten-
tial explanation for this physiological improvement, is the reduction in lipid absorp-
tion, which mainly occurs in the large intestine that is largely  bypassed due to the 
BPD remodelling surgery. As a consequence, these lipids do not reach the circulation 
is such greater concentrations and minimise the activation of hepatic gluconeogenesis 
and secretion of pancreatic insulin, that have been proposed in the Randall hypothesis 
to contribute to the disruption of glycolysis and glucose homeostasis (section 1.1.5). 
Further investigation of the impact of weight loss on mitochondrial dynamics required 
analysis of mRNA expression. 
Fission involves the segregation of one mitochondrion into two smaller mito-
chondria and involves proteins, Drp1 and Fis1 (Ferrier 2001). Drp1 translocates from 
the cytosol to the mitochondria with assistance of Fis1 (Smirnova, Griparic et al. 
2001, Lee, Jeong et al. 2004) (Figure 1.5). Once localised to the outer mitochondrial 
membrane, Drp1 punctuate holes within the mitochondria required for the initiation 
and assembly of future sites of fission. Fis1 are the mechanical scissors that finalise 
91
and coordinate the creation of two smaller separated mitochondria (James, Parone et 
al. 2003, Stojanovski, Koutsopoulos et  al. 2004). Expression analyses of	    markers of 
mitochondrial fission, Drp1 and Fis1, revealed a significant reduction in mRNA ex-
pression after surgery  (Figures 3.2-3.4). This is a critical post surgical improvement, 
as evidence of the negative effects of over-activation of fission have been presented 
both in human and mouse studies including a significantly higher expression of Fis1 
in endothelial cells of T2DM individuals compared to healthy control subjects (She-
nouda, Widlansky et al. 2011). Furthermore, the enhancement of Fis1 expression in 
these endothelial cells resulted in mitochondrial fragmentation (Shenouda, Widlansky 
et al. 2011). Unlike control subjects, mitochondria of T2DM subjects are known to be 
smaller and punctuate (Shenouda, Widlansky et al. 2011). These findings together 
with the use of diet  induced or genetic mouse induction models of obesity (Jheng, 
Tsai et al. 2012), demonstrate a possible link between increased markers of mitochon-
drial fission and insulin resistance. The opposing arm of mitochondrial dynamics, mi-
tochondrial fusion, allows mixing of mitochondrial contents including metabolites, 
protein and DNA across the mitochondrial population (Twig, Hyde et al. 2008) and 
involves the proteins, Mfn2 (Chen, Detmer et al. 2003, Bach, Naon et  al. 2005) and 
Opa1 (Akepati, Muller et al. 2008) (Figure 1.5). Following its initiation, mitochon-
drial fusion promotes the formation of multimeric Mfn2 complexes, which enable 
physical tethering of outer mitochondrial membranes between surrounding mitochon-
dria (Olichon, Emorine et al. 2002). Opa1 performs a similar functional role within 
the inner mitochondrial membrane to promote and enable fusion to progress (Cipolat, 
Martins de Brito et al. 2004, Olichon, Landes et al. 2007). Expression analysis of mi-
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tochondrial fusion genes highlighted a significant decrease in Mfn2 and Opa1 mRNA 
levels following bariatric surgery (Figures 3.5-3.7).
Thus far, the data clearly shows an overall alteration in the expression of 
markers of mitochondrial dynamics. In particular, markers of mitochondrial fission 
expression diminished following surgery  as judged by the significant reductions in 
Fis1 and Drp1 mRNA expression induced after weight loss (Figures 3.2-3.4). There-
fore, in order to better understand the implications of this for cellular metabolism, mi-
tochondrial DNA content in AbSc AT of pre and post bariatric samples was under-
taken (Figure 3.8-3.9). Power analysis revealed that the sample size of this study  is 
sufficient to determine a statistically significant difference in mitochondrial DNA ex-
pression that may arise after bariatric surgery. Analyses of mitochondrial DNA ex-
pression by two previously published methods (Hsieh, Weng et al. 2011, Ferber, Peck 
et al. 2012), revealed no significant difference in mitochondrial DNA content before 
and after bariatric surgery(Figure 3.8). Furthermore, both assays exhibited no signifi-
cant differences in their correlation coefficients for determination of the mitochondrial 
DNA content in AbSc A.T before and following bariatric surgery  (Figure 3.9). The 
lack of change in mitochondrial DNA content is likely to have arisen due to the 
equivalent proportional increase in mitochondrial fusion and fission gene expression. 
Nevertheless, this result generates only half the picture of the implications of changes 
in markers of mitochondrial dynamics gene expression, as the metabolic activity  of 
the individual mitochondria may be profoundly changed even in the absence of 
changes to mitochondrial DNA content. Therefore, in order to provide a more com-
plete picture of the effects of bariatric surgery on markers of mitochondrial dynamics 
it may be necessary to perform bioenergetic assay profiling of pre and post bariatric 
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samples across the entire cohort (n = 29 patients, paired pre and post samples). Given 
the improved expression of the mitochondrial dynamics markers and 	  lack of change 	  
in mitochondrial 	   	  DNA content	   after bariatric surgery, we sought to identify  if glu-
cose could explain in part at least, the improvements in the expression of mitochon-
drial dynamics markers. Debate still exists as to the effect of bariatric surgery on insu-
lin sensitivity  when non-diabetic and diabetic patients are compared (Garcia-Fuentes, 
Garcia-Almeida et al. 2006, Lin, Davis et al. 2009, Pournaras, Osborne et al. 2010, 
Dixon, Straznicky  et al. 2012). Firstly, comparisons of the pre and post-surgery fasted 
glucose levels were completed. Fasted glucose decreased significantly following sur-
gery. Secondly, correlation analyses were undertaken to compare the relationship be-
tween markers of mitochondrial dynamics gene expression and glucose. Drp1, Opa1 
and Mfn2 became positively and significantly  correlated with plasma glucose follow-
ing bariatric surgery (Figure 3.11A-C). Taken together, the positive correlation be-
tween glucose and Drp1, Opa1 and Mfn2 after surgery  identifies that glucose metabo-
lism and mitochondrial dynamics may be under similar regulatory control. 
Finally, the presence of macrophages in AbSc AT of pre and post bariatric 
samples was assessed to investigate the role of macrophage infiltration as a potential 
mechanism for overall improvement in expression of the markers of mitochondrial 
dynamics. In adipose tissue, macrophage infiltration has been shown to occur in obese 
individuals and those with T2DM  status (Weisberg, McCann et al. 2003, Curat, Mi-
ranville et al. 2004). CD68 (marker of macrophage) mRNA expression did not de-
crease in a significant manner following weight loss induced through surgery (Figure 
3.11.). In support of the hypothesis that, changes in mitochondrial dynamics occurs 
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independently of macrophages, the expression of CD68 did not correlate with mRNA 
expression of the mitochondrial dynamics genes (Figure 3.12 A-B.Fis1 and, Mfn2). 
In conclusion, the results from this study demonstrate that the expression of 
markers of mitochondrial fusion and fission in AbSc AT of T2DM individuals is 
mainly altered by weight loss.Taken together, the redressing of markers of mitochon-
drial dynamics gene expression reflects a possible mechanism through which mito-
chondrial dysfunction could be resolved following weight loss induced by bariatric 
surgery.
The observation that markers of mitochondrial fission are more highly  expressed in 
overweight and obese AbSc AT offers a potential explanation for the reduction in metabo-
lism known to accompany adiposity (Robertson 2014). Nevertheless, the upstream signal-
ing pathways and genes that regulate mitochondrial dynamics remain unknown. As a 
stress kinase, p38 has been previously  reported to be upregulated under conditions of cel-
lular stress. Given this context and evidence of the involvement of p38 in adipocyte matu-
ration (Engelman, Lisanti et al. 1998, Engelman, Berg et  al. 1999) and mitochondrial dy-
namics genes in triglyceride accumulation (Kita, Nishida et al. 2009), lead us to speculate 
that p38 may be involved in regulating mitochondrial dynamics. Assessment of the 








As a signal transduction mediator, p38 is involved in mediating a wide range of cellu-
lar processes including inflammation, the cell cycle, death, differentiation and senes-
cence in response to extracellular stimuli (Zarubin,T. and Han,J. 2005). p38 belongs 
to one of the four main groups of mitogen activated protein kinases (MAPKs); 1: ex-
tracellular singal regulated kinases (ERK) , 2: c-jun stress activated kinases (JNK), 3: 
ERK/big MAP kinase 1 (BMK1) and 4: p38 MAPK (Rouse J, Cohen P and Trigon S, 
et al.1994)
 Originally isolated following inflammatory stimulation via lipopolysaccharide 
(LPS), p38 alpha was isolated as a 38kDa tyrosine phosphorylated protein. The 
Threonine (Thr) - Glycine (Gly) - Tyrosine (Tyr) (abbreviated to TGY) dual phospho-
rylation motif is a key characteristic of p38 kinases (Han,J et al .1994).
 p38 activation may occur in response to extracellular stress (e.g. inflammatory 
cytokine release (TNF or IL-1, UV light or heat) or growth factor secretion (e.g those 
contained in foetal bovine serum used during cell culture, FBS) (Lee, JC. et  al.1994). 
Additional influences include the cell type such as 3T3-L1 adipocytes whose p38 is 
activated upon treatment with insulin. To date, the majority of research has worked on 
characterisation of the alpha and beta isoforms whose expression is most ubiquitous.
 Evidence of the biological consequences of p38 activation, which are trans-
duced through either MKK6 or MKK3 upon complexing of p38 with ATP and MK2, 
its cellular substrate, include a regulatory role in the proliferation and differentiation 
or immune system cells and as a regulator of oxidation (Sweeney, G et  al. 1999). Fur-
thermore, p38 plays an important role in control of senescence and tunour suppres-
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sion. Namely, that  activation of MKK6 and MKK3 following enhancement of p38 
activity promote the development of a senescent phenotype (Cuenda, A. et al. 1997). 
Conversely, under conditions where p38 activation is diminished including tumours, 
due to their ability to modulate p38 MAPK signalling, lead to the promotion of tumo-
rigenic conditions and subsequent induction of further tumour growth (Mahtani, KR. 
et al. 2001). Whilst knowledge of the involvement of p38 in signalling with the  mito-
chondrial proteins such as Bax and Bad (Bcl2 family  member, pro-apoptotic pro-
teins), and BCL-xL (anti-apoptotic protein and Bcl2), which assist in the regulation of 
apoptosis, little is known about the involvement of p38 in other mitochondrial proc-
esses such as mitochondrial dynamics. 
4.1.2. Mitochondrial biogenesis, dynamics and effect of p38 on these processes
The most important roles of mitochondria are to produce energy for the cell in the 
form of ATP through respiration, and to regulate cellular metabolism (Nunnari and 
Suomalainen 2012, Robertson 2014). Mitochondrial biogenesis (Attardi and Schatz 
1988), dynamics (Zorzano, Liesa et al. 2009) and bioenergetics are critical in coordi-
nating not only cellular abundance of mitochondria but also ensuring optimal mito-
chondrial function and health. With these mechanisms at their disposal, mitochondria 
are responsible for maintaining energy homeostasis. 
Mitochondrial biogenesis assists energy homeostasis through the maintenance 
of mitochondrial abundance thereby compensating for the normal mitochondrial turn-
over (Menzies and Hood 2012). Creation of new mitochondria occurs during the cell 
cycle by de novo synthesis and division of pre-existing mitochondria (Posakony, Eng-
land et al. 1977). Peroxisome proliferator-activated receptor-gamma coactivator α	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(PGC-1α) and Mitochondrial transcription factor A (Tfam) are key  regulators of mito-
chondrial biogenesis (Prigione and Adjaye 2010). During conditions of nutrient deple-
tion, the accompanying increase in the AMP/ATP ratio detected by  two energy sen-
sors, Sirtuin 1 (SIRT1) and AMP-activated protein kinase (AMPK), triggers initiation 
of a downstream signalling cascade, resulting in the activation of PGC-1α and libera-
tion of energy stored within triglycerides located predominantly within adipose tissue 
(Puigserver, Rhee et al. 2001). Functional studies of mitochondrial biogenesis have 
proposed that p38 is capable of phosphorylation and activation of PGC-1α 
(Puigserver, Rhee et  al. 2001). Treatment of C2C12 myocytes, a skeletal muscle cell 
line with the p38α and β isoform inhibitor, SB203580, resulted in inhibition of stimu-
lated PGC-1α promoter activity (Akimoto, Pohnert et al. 2005). 
4.1.3. p38 and adipogenesis
Furthermore, p38 is known to regulate adipogenesis (Engelman, Lisanti et al. 
1998). Adipocytes have been most extensively employed to investigate cell differen-
tiation. Previous studies have highlighted that  cellular differentiation regulated 
through p38 is accompanied by  an increase in the expression of mitochondrial bio-
genesis genes (Ducluzeau, Priou et al. 2011). During cellular differentiation, termi-
nally differentiated adipocytes are more metabolically  active compared to their 
preadipocyte precursors (Ducluzeau, Priou et al. 2011). In conjunction with their en-
hanced lipid storage capacity, mitochondria within adipocytes require extensive re-
modelling (Kita, Nishida et al. 2009) involving mitochondrial dynamics and biogene-
sis to support the greater metabolic requirements of adipocytes (De Pauw, Demine et 
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al. 2012). In coordination with mitochondrial biogenesis, mitochondrial function, 
health and abundance are regulated by mitochondrial dynamics. 
4.1.4. Mitochondrial  dynamics and potential role of p38. Mitochondrial dynamics 
(Liesa, Palacin et al. 2009, Zorzano, Liesa et al. 2009, Shenouda, Widlansky et al. 
2011, Liesa and Shirihai 2013) involves the opposing processes of fusion (coales-
cence of two mitochondria to form a larger mitochondrion) and fission (division of 
mitochondria to form two smaller mitochondria). Through dynamic remodelling of 
mitochondria, the abundance (through mitochondrial dynamics and biogenesis (Ren, 
Pulakat et al. 2010)) and optimal health of the mitochondrial population (through se-
lective mitophagy of compromised mitochondria) are maintained. The GTPase pro-
teins (Hoppins, Lackner et al. 2007), Mfn2 and Opa1 are involved within mitochon-
drial fusion (Legros, Lombes et al. 2002), whilst Drp1 and Fis1 participate in mito-
chondrial fission (Dikov and Reichert 2011, Elgass, Pakay et al. 2013). Central to this 
study is exploration of mitochondrial morphology (Okamoto and Shaw 2005) and 
whether p38 is capable of exerting influence on the balance of mitochondrial dynam-
ics (Zorzano, Liesa et al. 2009). A number of key lines of evidence from observational 
studies have led us to propose a role for p38 within mitochondrial dynamics of adipo-
cytes. In addition to the insulin resistance that accompanies T2DM, patients often ex-
hibit a reduction in mitochondrial metabolism (Gerencser, Chinopoulos et al. 2012) 
and expression of mitochondrial biogenesis genes (Mustelin, Pietilainen et al. 2008). 
Cellular differentiation, which is regulated through p38, is known to enhance mito-
chondrial biogenesis suggesting that p38 may also be affected in patients with dimin-
ished mitochondrial metabolism. Firstly, mtDNA copy number (Shay, Pierce et al. 
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1990, Jeng, Yeh et al. 2008) in diabetic subjects is lower as compared to their Lean 
counterparts. This reduction in abundance has been linked with diminished mitochon-
drial oxidative phosphorylation capacity (Brand and Nicholls 2011, Saada 2014) of up 
to 40% (Petersen, Dufour et al. 2004) and ATP synthesis. Secondly, PGC-1α of mor-
bidly  obese AbSc AT (Semple, Crowley et al. 2004), which regulates mitochondrial 
biogenesis (Rong, Qiu et al. 2007) is reduced by 3-fold compared to healthy controls. 
Finally, mitochondrial dysfunction (Michel, Wanet et al. 2012) observed in skeletal 
muscle of Obese and T2DM  patients, is associated with a significant reduction of mi-
tochondrial area (Kelley, He et al. 2002) and respiration in adipose tissue (Kraunsoe, 
Boushel et al. 2010).
In summary, this study sought to address whether p38 was involved in the 
regulation of mitochondrial dynamics and bioenergetics in adipocytes.
4.2. Methods.
4.2.1. Cell culture of 3T3-L1 (Category II HEPA filtered cell culture hood); 
4.2.1.1 Preadipocytes for markers of mitochondrial dynamics gene expression as-
says
3T3-L1 preadipocytes were seeded at  1x106/2ml in a 6 well plate (6WP) and incu-
bated at  37C, 5% CO2. Media was replaced every 48 hours (2ml per well). After 2 
days, 3T3-L1 preadipocytes reached confluency (100%). Any protein or RNA sam-
ples were harvested for further expression analyses. Individual protein samples (per 
well) were harvested by removing culture media, washing the monolayer twice with 
cold PBS, addition of RIPA lysis buffer (250μl), shaking incubation on ice, scraping 
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and storage in eppendorfs (2 ml) at -20C until required. RNA samples were harvested 
by removing culture media, washing the monolayer twice with cold PBS, addition of 
Qiazol (250μl), shaking incubation on ice, scraping and storage in eppendorfs (2 ml) 
at -20C until required. RNA was extracted using RNeasy kit (Qiagen, see 2.1).
4.2.1.2. Optimisation of seeding density and culture conditions for mitochondrial 
bioenergetics assay:
This decision was taken to optimise the mitochondrial bioenergetics assay prior to the 
evaluation of any mitochondrial stress reagents or drug treatments. The optimal basal 
oxygen consumption rate, in the absence of any treatments is < 400pmol/min/mg. 
Therefore, the cell seeding density  which corresponded most closely to this optimal 
oxygen consumption rate was selected for future mitochondrial bioenergetics assays.
Assay protocol:
Day before the assay:
Cell seeding: 3T3-L1 fibroblast cells (preadipocytes) were seeded at  3 densities in the 
morning; 1 x 104, 2 x 104and 3x104/well (100ul, 37C pre warmed 10% FBS DMEM-
F12) in an mitochondrial bioenergetics specific seahorse bioscience 24 well plate 
(24WP) cell culture plate and incubated (5% CO	  2 and 37C). After 4 hours, the cells 
had adhered to the culture plate, and the volume of media was increased to 250ul 
(37C pre warmed 10% FBS DMEM-F12) before returing the 24WP to the incubator 
overight. 
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Figure 4.1. Seeding of 3T3-L1 preadipocytes. 3T3-L1 fibroblast cells (preadipo-
cytes) were seeded at 3 densities; 1 x 104, 2 x 104and 3x104/well (pre warmed 10% 
FBS DMEM-F12) seahorse bioscience 24 well plate (24WP) cell culture plate and 
incubated (5% carbon dioxide and 37C). After 4 hours, media (150ul) was added (37C 
pre warmed 10% FBS DMEM-F12) before returing the 24WP to the incubator 
overight. 
Equilibration of the seahorse assay cartridge containing the fluorescent probes:
Hydrate all wells of the seahorse assay cartridge with provided equilibration buffer 
(1ml/well). Incubate at 37C in the seahorse carbon dioxide free incubator overnight.
Preparation of running assay media (1L, final concentrations are given below):




MilliQ water up to 1L
*DMEM  (Sigma D3050, no L-glutamine, glucose, phenol red, sodium pyruvate or 
sodium bicarbonate supplements). 
103
No buffering capacity, essential requirement for running media for use in the bioener-
getics assay. Pre warm to 37c in a 5% C02 incubator using a 25ml (T25) vented cul-
ture flask. Transfer an aliquot of the 1L solution (50ml per assay) into a conical flask. 
Using a pH meter, stirrer plate and magnetic stirrer bar, carefully titrate dropwise us-
ing a pasteur pipette either hydrochloric acid (HCl, ImM  stock,if solution too alka-
line) or sodium hydroxide (NaOH 1mM  stock, if solution too acidic) until the running 
assay media is at pH to 7.4. Sterile filter the solution in the cell culture hood by pass-
ing the solution through a 0.2um filter attached to a 50ml syringe into a fresh and ster-
ile T25 flask. Store the solution in the fridge for use in the assay the following day.
Day of the assay:
Remove the stress reagents and any drug treatments from -20C to allow these to 
thaw.The seahorse 24WP containing the pre-seeded 3T3-L1 preadipocytes was exam-
ined for cellular adherence. The media (200ul of the 250ul 10% FBS DMEM-F12) 
was removed and the cells were washed twice with seahorse running assay media (se-
rum free, 1ml per wash and discarded). The cells in the assay  plate were examined 
under the light microscope, both before removal of the growth media and after re-
placement with the seahorse running media change. 
 No disturbance of the cell monolayer was identified. Plating the 3T3-L1, 16 
hours prior to the assay, resulted in an 80% confluent cellular monolayer on the day of 
the assay, as determined by examination under the light microscope. Once the cells 
were washed using the seahorse running media, a final addition of  running media was 
added and the cells were incubated in a CO2 free, 37C incubator (provided by  Sea-
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horse bioscience) for 1 hour. During this time, all the stress reagents and drug treat-
ments were prepared.
Figure 4.2. Flow chart of mitochondrial bioenergetics assay protocol.
The stock compounds include mitochondrial stress reagents (oligomycin, FCCP, an-
timycin, rotenone) and any drug treatments (e.g. SB203580, p38 inhibitor). XF sensor 
cartridge contains the fluorescent probes which measure oxygen and pH. The hydra-
tion solution is provided by Seahorse bioscience. XF24 TC is the tissue culture plate 
in which cells are seeded into and the plate on which the sensor cartridge sits when 
the assay is performed. The XF assay  media is an unbuffered, serum and phenol free 
basic DMEM  that has been supplemented with sodium chloride, sodium pyruvate and 
d-glucose (see 4.2.1.2 for exact  concentrations). XF24 is the instrument which the mi-
tochondrial bioenergetics assay is performed at 37C.
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4.2.1.3.. Optimisation of treatment conditions of 3T3-L1 preadipocytes with mito-
chondrial inhibitors and uncouplers: 
Mitochondrial stress reagents were purchased from sigma aldrich: Oligomycin 
(75351), FCCP (carbonyl cyanide-p-trifluoromethoxyphenylhydrazone, C2920), An-
timycin and Rotenone (A8674 and R8875). 
Mitochondrial stress test reagents and drug treatment preparation: The mitochon-
drial stress test reagents were assessed individually within 3T3-L1 preadipocytes 
seeded at 2 x 104/well. Oligomycin was assayed at 0.25, 0.5, 0.75 and 1 μM (final 
concentration in well, 1ml of 2.5, 5.0, 7.5 and 10μM working stocks were prepared in 
running media). Oligomycin is an ATP synthase inhibitor. Through its inhibition of 
this mitochondrial membrane bound complex, it  is capable of blocking oxidative 
phosphorylation from proceeding past this point of the electron transport chain. As a 
consequence, only  electrons generated through mitochondrial uncoupling, allow pro-
tons to diffuse using uncoupling protein (UCP1) from the outer to inner mitochondrial 
membrane. Therefore, oxygen consumption-rate changes following oligomycin ad-
ministration were used to semi-quantitatively measure ATP production and proton 
leak. FCCP (carbonyl cyanide-p-trifluoromethoxyphenylhydrazone) was assayed at 
0.25, 0.5, 0.75 and 1 μM (final concentration in well, 1ml of 2.5, 5.0, 7.5 and 10μM 
working stocks were prepared in running media). FCCP is a mitochondrial uncoupling 
agent, used to increase mitochondrial permeability to protons through depolarisation 
of the mitochondrial membrane potential. FCCP measures the maximal oxygen con-
sumption rate of cellular mitochondria. FCCP concentration should be tightly  titrated, 
as treatment of cells with supra-concentrations of this compound is known to initiate 
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apoptosis. Antimycin/Rotenone were assayed at 0.25, 0.5, 0.75 and 1μM  (final con-
centration of each in well, 1ml of 2.5, 5.0, 7.5 and 10μM working stocks were pre-
pared in running media).Antimycin inhibits complex III of the electron transport 
chain resulting in leaking of electrons to molecular oxygen resulting in the generation 
of superoxides. Rotenone inhibits Complex I of the electron transport chain (specifi-
cally the NADH dehydrogenase enzyme). The cocktail of antimycin/rotenone quanti-
fies non-mitochondrial respiration rate within the assayed cells. 
Loading the seahorse cartridge with drug treatments and/or stress reagents:
Figure 4.3. Loading pattern for use of mitochondrial stress reagent or drug 
treatment in mitochondrial bioenergetics assay. The contents of the ports are re-
leased alphabetically throughout the bioenergetics assay and should be loaded as fol-
lows A: Oligomycin or drug treatment (SB203580) (75ul), B: FCCP (carbonyl 
cyanide-p-trifluoromethoxyphenylhydrazone, 75ul), C: Antimycin/Rotenone cocktail 
(75ul).All ports included as part of the assay protocol should be occupied. For the un-
treated wells, i.e. those not receiving either a mitochondrial stress reagent or drug 
treatment, running media solution should be placed (75ul) in these relevant ports. In 
the case of the standard stress reagent assay i.e. oligomycin, FCCP and then 
antimycin-rotenone, the port D can remain unoccupied  and excluded from the bio-
energetics assay  protocol. However, in the case where a drug treatment is preadminis-
tered in port A before the commencement of the mitochondrial stress assay (Oligomy-
cin, FCCP, antimycin/Rotenone), all ports A-D will be required.
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Figure 4.4. Mitochondrial stress test bioenergetic profile.
Oligomycin is an ATP synthase inhibitor and is used to semi-qunatitatively measure 
AT P p r o d u c t i o n a n d p r o t o n l e a k . F C C P ( c a r b o n y l c y a n i d e - p -
trifluoromethoxyphenylhydrazone) measures the maximal oxygen consumption rate 
of cellular mitochondria.  OCR denotes oxygen consumption rate.The cocktail of 
antimycin/rotenone quantifies non-mitochondrial respiration rate within the assayed 
cells. 
Calculation of mitochondrial bioenergetics: 
Oxygen consumption rate (OCR) data for each well was normalised per mg/protein 
for chemical treatment. The spare respiratory capacity and coupling efficiencies were 
calculated from the oxygen consumption values according to the following formulae:
Spare respiratory capacity  = (FCCP/ Basal respiration OCR)*100
Coupling efficiency = 1 –	  (Oligomycin/Basal respiration OCR)
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4.2.2.1. Differentiation of 3T3-L1 preadipocytes (fibroblasts) to adipocytes:
Differentiation protocol:
3T3-L1 preadipocytes were seeded at 2x104/2ml in 6WP in growth media and incu-
bated at  37C, 5% CO2. Media was replaced every 48 hours (2ml per well). After 3 
days, 3T3-L1 preadipocytes reached confluency (100%).The next day, the media was 
changed from growth media (Day  0) to differentiation media (prewarmed to 37C, 2 
washes with phosphate buffered saline (PBS) at 37C, to remove residual growth me-
dia). After 48 hours (Day  2), cells were washed twice with PBS and placed in nutri-
tion media (Days 4-6) for 48 hours. Finally for the final days of 3T3-L1 differentia-
tion the cells were returned to growth media (Day  6-8). Differentiation protocol was 
completed on day 8. Any protein or RNA samples were harvested for further expres-
sion analyses. Individual protein samples (per well) were harvested by removing cul-
ture media, washing the monolayer twice with cold PBS, addition of RIPA lysis buffer 
(250μl), shaking incubation on ice, scraping and storage in eppendorfs (2 ml) at -20C 
until required. RNA samples were harvested by removing culture media, washing the 
monolayer twice with cold PBS, addition of Qiazol (250μl), shaking incubation on 
ice, scraping and storage in eppendorfs (2 ml) at -20C until required. RNA was ex-
tracted using RNeasy kit (Qiagen, see 2.1).
Growth media (GM):
DMEM  F12 supplemented with 10% foetal bovine serum (FBS), penicillin 
(100 U/ml), streptomycin (100 μg/ml) and L-glutamine (10mM).
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Differentiation media (DM, final concentrations, Promocell supplement mix)
DMEM  F12 supplemented with 10% foetal bovine serum (FBS), IBMX 44μg/ml), 
insulin (0.5μg/ml, human recombinant), dexamethasone (400ng/ml), d-Biotin (8 μg/
ml), L-thyroxine (9ng/ml) and Ciglitazone (3μg/ml).
Nutrition media (NM, Promocell supplement mix)
DMEM  F12 supplemented with 10% foetal bovine serum (FBS), insulin (0.5μg/ml, 
human recombinant), dexamethasone (400ng/ml), d-Biotin (8 μg/ml).
RIPA lysis buffer (1x RIPA lysis buffer (Millipore) containing protease inhibitor 
(Roche) and phosphatase inhibitor (100μl of 100mM  Sodium fluoride and 100μl of 
100mM Sodium vanadate, Sigma Aldrich),
4.2.2. Cytotoxicity of SB203580.
4.2.2.1. Principles of the MTT assay: A tetrazolium salt, 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) is used in a colorimetric assay to assess 
the affect of a compound on cell viability. Respiring cells promote the conversion of 
the tetrazolium dye MTT into an insoluble formazan through an enzyme based cataly-
sis involving NAD(P)H-dependent oxidoreductase. The conversion from MTT to 
formazan is accompanied by a colour change from yellow to purple. Cellular respira-
tion is quantified by  absorbance at 570nm, with purple indicating greater cellular res-
piration. 
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Figure 4.5. MTT assay 
The conversion from MTT to formazan is accompanied by  a colour change from yel-
low to purple. Cellular respiration is quantified by  absorbance at 570nm, with purple 
indicating greater cellular respiration. Figure from Ebada et al. Nature protocols 3. 
1820-1831 (2008).
This assay is performed to quantify the minimum concentration of a compound that 
cells can be exposed to, in order to elicit the compound’s functional role whilst pre-
serving the respiration of most of the cultured cells. The assay  was performed accord-
ing to the manufacturer’s protocol (Sigma Aldrich, M2128). Briefly the assay was per-
formed as follows;
4.2.2.2 Assay protocol: 2 days prior to the MTT assay, 3T3-L1 preadipocytes were 
plated into a 6 well plate at a density  of 1 x 105/ml. Once confluent, the media was 
removed and the cells were washed twice with PBS. Media was replaced with 0.2% 
BSA DMEM-F12 (2ml/well, no antibiotics). Cells were serum starved 3 hours before 
the assay. The working stock of MTT was 5mg/ml. (M2128, Sigma Aldrich) Control 
cells were treated with equivalent volumes of DMSO to that used to treat cells with 
SB203580 compound. Following incubation of the 3T3-L1 at  37°c and 5% CO2 for 0, 
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30 minutes, 1hr and 2 hours, cells were washed twice with PBS. MTT (20μg/well) 
was added to the wells and 3T3-L1 were incubated in the dark (due to the light sensi-
tive nature of MTT) for a further 4 hours at  37°c and 5% CO2. Cells were washed 
twice more with PBS and the formazan crystals were eluted in 2ml DMSO: Isopropa-
nol (1:1 ratio). 
4.2.2.3. Calculation of cytotoxicity: Absorbance was read at 570 nm. Background 
absorbance at 690 nm was subtracted from this reading. MTT incubated in the ab-
sence of cells was used to assess non-specific binding of dye to plastic which may in-
fluence the absorbance readings.  Cytotoxicity was determined as the difference in 
absorbance between control and SB203580 treated cells and was expressed as a per-
centage. Each value for cytotoxicity is an average of 8 measurements.
4.2.3. Gene expression analyses of adipocyte differentiation.
PPAR-γ (Mm01184322_m1) gene expression along with Oil red O lipid staining was 
used to determine the differentiation status of 3T3-L1 cells through normal differen-
tiation and p38 inhibitor treatment. 
4.2.4. Manipulation of p38 expression and mitochondrial bioenergetics. 
The XF24 Seahorse Bioanalyser was used to assay the effect of p38 on mitochondrial 
bioenergetics (see sections 4.2.1.2 to 4.2.1.3 for assay protocol and cell culture condi-
tions). Mitochondrial bioenergetics with p38 inhibition by SB203580 treatment was 
assessed in 3T3-L1 preadipocyte cells. Protein quantification was performed using 
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Biorad protein assay  (500-006, Biorad) and BSA as a standard (2mg/ml). The protein 
concentration given for each well is an average from triplicate measurements. 
4.2.5. Mitochondrial DNA content of 3T3-L1 preadipocytes.
Total DNA was extracted from 3T3-L1 preadipocytes using DNeasy kit (Qiagen) ac-
cording to the manufacturer’s protocol (see Figure 2.3 for DNA extraction protocol). 
RNase treatment was performed to prevent co-purification of RNA with genomic 
DNA. DNA quantification was performed using Nanodrop spectrophotometer The 
relative amounts of nuclear and mitochondrial DNA were determined by qPCR using 
20ng of isolated genomic DNA as a template. DNA was amplified using SYBR green 
in an ABI 7500 thermocycler (Life technologies) The abundance of each gene was 
defined as a ratio between mitochondrial threshold cycle (Ct) value and nuclear 
threshold cycle. Each sample was measured in duplicate against a mitochondrial (m)/
nuclear (n) DNA primer set. The following primer sequences were used: COXII; 
F o r w a r d 5 ’ - A AT T G C T C T C C C C T C T C TA C G - 3 a n d r e v e r s e 5 ’ -
G T A G C T T C A G T AT C AT T G G T G C - 3 ’ , R I P 1 4 0 F o r w a r d 5 ’ -
CGGCCTCGAAGGCGTGG-3’	   and reverse 5’-AAACGCACGTCAGTATCGTC-3’, 
ND2 and Beta-2-microglobulin as previously published in (Murholm, Dixen et al. 
2009) and (Wai, Ao et al. 2010) respectively. These primer sets were more appropriate 
than the CytB/Beta actin used in the human adipose tissue mitochondrial DNA ex-
pression analyses as their primer efficiency and melt curve analyses produced a single 
PCR product.
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4.2.6. Transfection of 3T3-L1. 
Plasmids transfected: pCDNA3.0-GFP (Ampicillin resistant, provided by Dr. Jürgen 
Muller, University of Warwick) and MKK6 overexpression (mitogen activated protein 
kinase kinase 6, human MKK6 (Glu) Addgene plasmid 13518; provided by Roger 
Davis from the Addgene repository; details of the molecular cloning and construction 
of these plasmid expression vectors are published in their paper (Raingeaud, Whit-
marsh et al. 1996)). MKK6(Glu) is the replacment of Ser207 and Thr211 from the 
wildtype MKK6 with Glu. MKK6 or MAP2K6 (mitogen-activated protein kinase ki-
nase 6) is a member of the dual specificity protein kinase family, which functions as a 
mitogen-activated protein (MAP) kinase kinase. MKK6 phosphorylates and activates 
p38 MAP kinase and is an essential component  of p38 MAP kinase mediated signal 
transduction pathway. Constitutive over-expression of MKK6 activates p38 kinase 
activity. Therefore, this construct was used to activate p38.
3T3-L1 preadipocytes were seeded at a density 1.25x105/ml in 6 well plates 
and maintained in 10% FBS (antibiotic free, 2mM  L-glutamine, 5% CO2 and 37°c). 
Cells were transfected at 70% confluency with 5μg plasmid (2.5μg each plasmid, 
where cells were co-transfected with GFP) and Lipofectamine 2000 (Invitrogen) us-
ing manufacturer’s protocol. Briefly, plasmid DNA and Lipofectamine complexes 
were incubated to allow complex formation (1:2 ratio Plasmid DNA: Lipofectamine, 
45 minutes room temperature incubation in Optimem reduced serum media). 
 Media in 3T3-L1 was replaced 4 hours after transfection with fresh 10% 
growth media (FBS, antibiotic free). Cells were harvested 48 hours post transfection. 
Mitochondrial fusion and fission gene expressions were analysed by  qRT-PCR as de-
scribed in methods section of the bariatric chapter 2.2.3 and 2.2.4 . 
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4.2.7.1. Mitochondrial morphology: Effects of p38 inhibition by SB203580.
3T3-L1 were seeded at a density 1.25x105/ml in glass bottomed petri dishes (35mm 
collagen coated, γ-irradiated, glass bottomed petri dishes, Matex corporation) and 
maintained in 10% FBS (antibiotic free, 2mM L-glutamine, 5% CO2 and 37°c). Cells 
were washed twice with 0.2% BSA DMEM to remove residual serum and allowed to 
recover for an hour (5% CO2 and 37°c) prior to treatment or mitochondrial labelling. 
Image acquisition: Labelling of mitochondria was performed using Mitotracker Red 
(250nM, 30 minutes). Images were captured as a time-lapse series on Leiss 63x lens. 
10 fields were selected per petri dish and mitochondrial morphology was assessed by 
field images taken across 3 petri dishes. 
Image processing: Within ImageJ, images were processed through sharpening; the 
location of edges feature and the image was despeckled. A binary image generated 
automatically from the original image using the analyse particle macro provided a 
semi quantitative determination of mitochondrial size and morphology using the area 
measurement of neighbouring pixel (μm2) and test  data set of manually defined, by 
human inspection, mitochondrial morphologies. For each of the 6 mitochondrial sub-
types, Peng et al wrote an algorithm to define its distinct morphological features, 
thereby allowing future automatic characterisation of different mitochondrial subtypes 
from a confocal microscopy image. Prior to each treatment, 10 fields were captured 
for DMSO treated 3T3-L1. Following addition of SB203580, 3T3-L1 were incubated 
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for 15 minutes prior to time-lapse acquisitions. Unpaired t tests were performed to 
assess statistical significance of p38 inhibition.
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Figure 4.6. Proposed model for the generation of mitochondrial morphological 
subtypes.
Small globules generated during mitosis through end-to-end fusion become tubules 
following cell division (A). Nevertheless, not all of these small globules progress to 
form simple tubules at  the end of cell division (B). In the event of insufficient genome 
copies within mitochondria they may be shuttled towards mitophagy to remove these 
from the population owing to their lower mitochondrial proofreading and subsequent 
accumulation of mutations (C). Twisted tubules may  be generated through microtu-
bule disassembly of tubules or through intra-mitochondrial fusion of twisted tubules 
to form loops. Through enhanced mitochondrial recruitment of Drp1, small globules 
may be generated from division of tubules (D). Figure from and legend based on 
(Peng, Lin et al. 2011).
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4.2.7.2. Image analysis of mitochondrial morphology in 3T3-L1 by time-lapse 
confocal microscopy.
Mitochondrial morphology was assessed and quantified using image processing soft-
ware. Within ImageJ (NIH), the time-lapse video was separated into a series of step-
wise stills. At each given position of the image, the individual intensity of all pixels 
was measured across the entire viewing field. A binary image of mitochondria was 
generated for each time frame through image processing within ImageJ. Using the “Analyse particles”	  Macro, the total number of mitochondria, average mitochondrial 
size and total mitochondria area were quantified. To address the question of mito-
chondrial motility, a sequentially subtraction protocol and median filter were used 
across the entire timeframe. Each of these images was subjected to quantification of 
pixel intensities. Any change in pixel intensity, above or below maximum pixel inten-
sity was recorded for that time point and given a value from 0 to 1. 0 corresponded to 
no movement, whilst 1 indicated movement of the mitochondria outside the bounds of 
that pixel. To facilitate multiple comparisons of time frames and different cell treat-
ments (DMSO or SB203580 treated), the index of motility was normalised to account 
for the total mitochondrial area and averaged over the first minute of imaging. 
Meanwhile, detailed morphological analysis required additional classification and im-
age processing. The original images were segmented in MicroP. This program written 
in Matlab and kindly donated to by Dr. J.Y Peng et al (Peng, Lin et al. 2011), enabled 
automatic classification of mitochondria into one of six subtypes; small globules, 
large globules, straight tubules, twisted tubules, loops and branched tubules. The sub-
types were colour coded from the segmented image file to generate a new object clas-
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sification image. The colours assigned were; blue: small globules, yellow: large/
swollen globules, green: straight tubules, orange: twisted tubules, purple: twisted tu-
bules and red: loops. The relative abundance of each subtype was expressed as a per-
centage of the total mitochondrial population. Morphological analyses were used to 




4.3.1. p38 and differentiation.
4.3.1.1. Triglyceride accumulates through adipocyte differentiation.
Triglyceride accumulation was semi quantitatively assessed by Oil red O staining. 
Lipid accumulation in the mature adipocytes (D4 onwards) was significantly higher 
compared to the preadipocytes of D0 (Figure 4.7. D4 vs D0; 2.4±0.3 fold, p = 0.005, 
D6 vs D0; 1.7±0.4 fold p = 0.0002 and D8 vs D0; 2.3±0.6 fold, p = 0.02).
120
Figure 4.7. Triglyceride accumulates with adipocyte differentiation.
Adipocyte differentiation (3T3-L1) is accompanied by an increase in triglyceride ac-
cumulation. Images of Oil Red O (ORO) stained 3T3-L1 were taken at 20x magnifi-
cation (A). Red indicates lipid accumulation. ORO absorbance values were measured 
at A595nm to semi quantitatively  determine triglyceride accumulation (B). Unpaired t-
tests were performed to assess the statistical significance of changes in ORO staining 
relative to Day 0 (n = 3 per day). Statistical significance was defined as a p  < 0.05*. 
p < 0.05*, p  < 0.01** and p < 0.001***. AU denotes arbitrary units, as the data is ex-
pressed as fold change in ORO staining relative to day 0. Data are given as mean ±	  
S.E.M.
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4.3.1.2 Effect of p38 inhibition through 3T3-L1 differentiation
SB203580 was utilised to inhibit  p38 throughout differentiation from preadipocytes to 
fully  differentiated 3T3-L1 (Day 0 (D0) being the day differentiation was initiated and 
when preadipocytes were 100% confluent adipocytes up to day 8 (D8). 
mRNA expression of PPAR-γ, a regulator of  adipocyte differentiation, was 
used to characterise the effect of p38 inhibition on adipocyte maturation. On D2-D6, 
PPAR-γ expression was significantly lower in p38-inhibited cells compared to DMSO 
treated controls (Figure 4.8. D2; 0.83±0.01 relative fold, p = 0.01 and D4 0.27±0.07 
relative fold; p = 0.01). 
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Figure 4.8. Effect of p38 inhibition through 3T3 differentiation.
mRNA expression of PPAR-γ involved in mitochondrial differentiation was analysed 
and compared against a DMSO control in chronically p38 inhibited 3T3s. Media con-
taining 10μM  SB203580 (SB) was changed every 24 throughout differentiation (day 
0-8). All experiments were performed in triplicate. Unpaired t-tests were performed to 
assess the statistical significance of changes in gene expression of 3T3 differentiation 
relative to day 0. Statistical significance was defined as a p < 0.05*. p < 0.05*, p < 
0.01** and p < 0.001***. AU denotes arbitrary  units, as the data is expressed as fold 
change in PPAR-γ	  mRNA expression relative to day  0. Data are given as mean ±	  
S.E.M.
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4.3.1.3 Mitochondrial dynamics throughout adipocyte differentiation 
Fis1 mRNA expression increased significantly and steadily from D2, peaking at D8 
through 3T3-L1 differentiation (Figure 4.9; D8 vs D0; 6.2±1 fold, p  < 0.001). Mfn2 
mRNA expression also steadily  and significantly  increased up  to D8 as differentiation 
progressed (Figure 4.9. (D4 vs D0; 2.5±0.3 relative fold, p = 0.002, D6 vs D0; 
6.0±0.3 fold, p = 0.003). 
In summary, markers of mitochondrial fusion and fission gene expression are 
dynamic in nature and consistent with previous reports (Ducluzeau, Priou et al. 2011), 
with their expressions peaking at the later stages of 3T3-L1 differentiation.
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Figure 4.9.  Markers of mitochondrial dynamics expression through adipocyte 
differentiation. 
mRNA expression of markers of mitochondrial fission: Fis1 (A) and fusion: Mfn2 (B) 
were measured throughout 3T3-L1 differentiation. All experiments were performed in 
triplicate.Unpaired t-tests were performed to assess the statistical significance of 
changes in mitochondrial gene expression relative to day 0. Statistical significance 
was defined as a p  < 0.05* and p < 0.01**. p  < 0.05*. AU denotes arbitrary units, as 
the data is expressed as fold change in mRNA expression relative to day 0. Data are 
given as mean ±	  S.E.M.
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4.3.2. Effect of p38 inhibition on mitochondrial dynamics and abundance.
4.3.2.1. Timecourse optimisation for p38 inhibition.
Serum starved 3T3-L1 preadipocytes were treated for up to 4 hours with either 
DMSO or SB203580. SB203580, a p38 inhibitor was reconstituted in DMSO. An 
equivalent volume of DMSO was included in the control treated 3T3-L1. Protein ex-
pressions of phospho-p38, total p38 and beta actin were quantified. Phospho-p38 in-
hibition (p-p38) was most significantly  decreased after 1 hour (Figure 4.10. 
SB203580 1hr vs DMSO control, ~ 2 fold reduction, p < 0.0001). Furthermore, inhi-
bition of p-p38 expression was sustained up to 2 hours after treatment (Figure 4.10. 
SB203580 2hr vs DMSO control, 0.3 fold lower expression, p = 0.02). After 4 hours 
of SB203580 treatment, no significant change in p-p38 expression compared to 
DMSO treated 3T3-L1 was noted. 
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Figure 4.10. Timecourse of p38 inhibition.
3T3-L1 preadipocytes were used to optimise the cell culture conditions for chemical 
inhibition of p38 by  SB203580 (Calbiochem). Protein samples were collected at 0, 30, 
60 and 120 minutes after SB incubation (n = 3, serum starved). Controls were treated 
with an equivalent volume of DMSO. Unpaired t-test analyses were used to determine 
the statistical significance of p38 inhibition by SB203580 in 3T3-L1 relative to 
DMSO treated controls. Statistical significance was defined as a p < 0.05* and p < 
0.001***. AU denotes arbitrary  units, as the data is expressed as fold change in phos-
pho (p-p38) expression relative to DMSO treatment at timepoint 0. Data are given as 
a mean ±	  S.E.M.
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4.3.2.2. Cytotoxicity assessment of the p38 inhibitor, SB203580.
The effect of both p38 inhibitor concentration and treatment timecourse were evalu-
ated in 3T3-L1 preadipocytes. At each timepoint, a new DMSO control was included. 
Statistical analysis using an unpaired t-test and assuming non equal variance, revealed 
no significant reduction in cell respiration as assessed by  the MTT assay, after 4 hours 
and across a concentration range of 2.5 to SB15μM  were used (Figure 4.11; DMSO 
control; 100±12%, SB2.5μM; 107±19% p < 0.25, SB5μM; 109±18% p  < 0.23, 
SB10μM; 106±26%, p<0.40 and SB15μM; 122±36% p < 0.35). 
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Figure 4.11. Cytotoxicity of the p38 inhibitor, SB203580.
3T3-L1 preadipocytes were used to define the cytotoxicity of SB203580 (Calbio-
chem). Confluent 3T3 preadipocytes were serum starved for 3 hours before being 
treated with 10μM of SB203580 for 2 hours (n = 8). Controls were treated with an 
equivalent volume of DMSO  (n = 8). Cytotoxicity was expressed as a percentage of 
the ratio of SB203580 treated absorbance/control absorbance * 100. Unpaired t-test 
analyses were used to determine the statistical significance of any  cytotoxic effects of 
SB203580 on 3T3-L1. p  < 0.05* was considered statistically  significant. Data are 
given as a mean ±	  S.E.M.
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4.3.2.3. Effect of p38 inhibition by SB203580 on markers of mitochondrial fis-
sion. 
Acute p38 inhibition by SB203580 was carried out 3T3-L1 preadipocytes and total 
protein collected every 30 minutes up to 2 hours. Statistical analysis revealed a sig-
nificant reduction in Fis1 protein expression up to 2 hours after treatment (Figure 
4.12. 30 minutes of SB203580 vs DMSO control; 0.69±	  0.01 fold, p < 0.001, 60 min-
utes of SB203580 vs DMSO control; 0.64 ±	  0.02 fold, p < 0.001 and 120 minutes of 
SB203580 vs DMSO control; 0.49 ±	  0.009 fold), p < 0.001).
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Figure 4.12. Fis1 protein expression decreases significantly following p38 
inhibition. 
3T3-L1 preadipocytes were seeded at  2 x 104/well and grown until confluent (5% 
CO2, 370c). Cells were treated with either SB203580 (10μM) or DMSO (control) for 
up to 2 hours. 20μg of protein was loaded per well. Beta actin was used as a loading 
control. n = 3 per treatment. Unpaired t-test analyses were carried out to determine the 
effect of p38 inhibition on Fis1 expression. Statistical significance was confirmed if p 
< 0.05*.  p < 0.001***. VC denotes DMSO 2hr vehicle control. AU denotes arbitrary 
units, as the data is expressed as fold change in Fis1 protein expression relative to 




4.3.2.4 Effect of p38 inhibition by SB203580 on markers of mitochondrial fusion. 
Mfn2 protein expression was statistically  decreased by  SB203580 treatment (Figure 
4.13; SB30’; 1.2±0.08 fold p  = 0.09 and SB60’; 1.6±0.75 fold p  = 0.4). In summary, 
acute p38 inhibition by SB203580 significantly decreased Mfn2 expression.
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Figure 4.13. Mfn2 protein expression decreases significantly following p38 inhibi-
tion.
3T3-L1 preadipocytes were seeded at  2 x 104/well and grown until confluent (5% 
CO2, 370c). Cells were treated with either SB203580 (10μM) or DMSO (control cells 
only) for up to 2 hours. 20μg of protein was loaded per well. Beta actin was used as a 
loading control (A). n = 3 per treatment. Unpaired t-test analyses were carried out to 
determine the effect of p38 inhibition on Mfn2 expression (B)..Statistical significance 
was confirmed if p  < 0.05*, p < 0.01** and p < 0.001***. VC denotes DMSO 2hr ve-
hicle control. AU denotes arbitrary units, as the data is expressed as fold change in 
Mfn2 protein expression relative to DMSO treatment at timepoint 0. Data are given as 
a mean ±	  S.E.M.
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4.3.2.5. Effect of p38 inhibition on mitochondrial copy number.
Mitochondrial copy number was assessed in p38-inhibited 3T3-L1 preadipocytes by 
two genomic DNA methods. The results expressed as a ratio between mitochondrial 
and nuclear genomic DNA indicated no statistically significant change in mitochon-
drial DNA content as a result of p38 inhibition which was expected because this is 
only acute treatment and by  2 hours the number of mitochondrial DNA content starts 
declining (Figure 4.14. ND1/B2M; 120’	  SB203580, 1.0±0.01 relative to control, p < 
0.09 and COXII/RIP140; 120’	  SB203580, 0.92±0.05, p < 0.09). 
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Figure 4.14. Mitochondrial DNA content remained unchanged following p38 in-
hibition.
3T3-L1 preadipocytes were treated with SB (10μM) or DMSO (control cells) for up 
to 2 hours. Mitochondrial DNA content was assessed by two primer sets (expressed as 
mitochondrial/nuclear primer sets; ND2/B2M and COXII/RIP140). Each treatment 
was assayed three times for each primer set. The data presented here, represent  the 
average of these triplicate readings; all data were non significant.AU denotes arbitrary 
units, as the data is expressed as relative mitochondrial/nuclear gDNA ratio at time-
point 0 min. Data are given as a mean ±	  S.E.M.
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4.3.3. Effect of p38 inhibition on mitochondrial bioenergetics.
4.3.3.1 Optimisation of Seahorse mitochondrial bioenergetics assay; cell density, 
culturing conditions, concentration of stress test reagents.
Preadipocytes were seeded at 4 densities; 1 x 104, 2 x 104, 1x105 and 1x106/well. The 
optimal seeding density  was 2 x 104, as evidenced by a single monolayer and average 
oxygen consumption rate (OCR) values of 276±79 pmol/02/min.  The optimal stress 
test reagent concentrations, as defined by  the changes in OCR were Oligomycin 1μM, 
FCCP 0.5μM  and antimycin/rotenone 1μM. All future seahorse mitochondrial bio-
energetics assays were treated with these optimised stress test concentrations. Un-
treated cells were included to assess the basal OCR throughout the seahorse assay 
(Figure 4.14).
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Figure 4.15. Optimisation of seahorse mitochondrial bioenergetics assay; cell 
density, culturing conditions, concentration of stress test reagents.
Oxygen consumption rates (OCR) of 3T3-L1 preadipocytes, given as the standard 
output measurement from the mitochondrial bioenergetics assay were normalised per 
mg of protein. This was acheived through cell lysis with RIPA lysis buffer, scraping of 
the monolayer of each well individually  and performing of a BioRad protein assay. 
Using a bovine serum albumin stock (BSA, 2mg/ml) a standard curve of BSA concen-
tration against absorbance (	  A595nm, at 0.25mg/ml increments). Based on the absor-
bance values of each cell lysate, the BSA standard curve was used to determine the 
protein concentration of each well. As a result, the OCR rates together with the known 
protein concentrations were used to normalise all the OCR data to per mg. 3T3-L1 
adipocytes were used to assess basal mitochondrial respiratory rate. Statistical signifi-
cance was confirmed if p < 0.05*, p < 0.01** and p < 0.001***. Unpaired t tests were 
used to assess for statistical significance.
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4.3.3.2. p38 inhibition and mitochondrial bioenergetics.
p38 was inhibited by the previously characterised p38 inhibitor, SB203580.The spare 
respiratory capacity  (SRC) of 3T3-L1 preadipocytes decreased in a dose-dependent 
manner, within the concentration range of 0-15μM SB203580. The SRC of the adipo-
cytes was significantly decreased between the SB203580 concentrations 7.5 to 15μM 
(Figure 4.15. SB 7.5μM; SRC, 191±5 % vs 242±7% ctrl p  < 0.01, SB 10μM; SRC 
145±34% vs ctrl 242±7%, p < 0.02 and SB 15μM; SRC 117±52% vs 236±7% ctrl, p 
< 0.024). The coupling efficiency  was significantly  decreased in adipocytes treated 
with 10μM of the p38 inhibitor compared to control cells. (Figure 4.15. C.E; SB 
10μM  81±0.009% vs 86±0.004% ctrl, p<0.02, SB 15μM 80±0.05% vs 86±0.004% 
ctrl, p < 0.08).
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Figure 4.16. Inhibition of p38 reduces mitochondrial efficiency.
3T3-L1 preadipocyte spare respiratory capacity  is calculated by maximal oxygen con-
sumption (FCCP)/basal respiration. Coupling efficiency (C.E), is calculated by 1 –	  
(Oligomycin or SB 10μM treated)/(Basal respiration). n = 5 per treatment. Using a 
bovine serum albumin stock (BSA, 2mg/ml) a standard curve of BSA concentration 
against absorbance (A595nm, at 0.25mg/ml increments). Based on the absorbance 
values of each cell lysate, the BSA standard curve was used to determine the protein 
concentration of each well. As a result, the OCR rates together with the known protein 
concentrations were used to normalise all the OCR data to per mg.  Statistical signifi-
cance was confirmed if p  < 0.05*. Unpaired t tests were used to assess for statistical 
significance.
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4.3.3.3. Optimisation of MKK6(Glu) transfection in 3T3-L1. 
MKK6 or MAP2K6 (mitogen-activated protein kinase kinase 6) is a member of the 
dual specificity protein kinase family, which functions as a mitogen-activated protein 
(MAP) kinase kinase. MKK6 phosphorylates and activates p38 MAP kinase and is an 
essential component of p38 MAP kinase mediated signal transduction pathway. Con-
stitutive over-expression of MKK6 activates p38 kinase activity. Therefore, this con-
struct was used to activate p38.  Transfection of 3T3-L1 preadipocytes with either 
1.0μg or 2.5μg of pCDNA3-GFP and pCDNA3-Flag MKK6(Glu) overexpression 
plasmid resulted in a statistically significant increase in Mfn2 mRNA expression of 
2.9±0.10 and 3.9±0.12 fold respectively compared to GFP control plasmid alone 
(Figure 4.16. 1.0μg GFP/MKK6; p  <0.01 and 2.5μg GFP/MKK6; p <0.05). Plasmid 
pCDNA3-Flag MKK6 (Glu) which contains insert MKK6 (Glu) was constructed in 
Dr. Roger Davis's lab and was obtained from Addgene (Raingeaud, Whitmarsh et al. 
1996). 
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Figure 4.17. Optimisation of MKK6 (Glu) transfection in 3T3-L1 preadipocytes.
MKK6 or MAP2K6 (mitogen-activated protein kinase kinase 6) is a member of the 
dual specificity protein kinase family, which functions as a mitogen-activated protein 
(MAP) kinase kinase. MKK6 phosphorylates and activates p38 MAP kinase and is an 
essential component of p38 MAP kinase mediated signal transduction pathway. Con-
stitutive over-expression of MKK6 activates p38 kinase activity. Lipofectamine 2000: 
plasmid DNA complex ratios 2:1 was used for transfection. 3T3-L1 preadipocytes 
were transiently  co-transfected in serum free MEM with MKK6(Glu)/eGFP with 0.5, 
1.0 or 2.5μg of plasmid. Control plasmid’s contained the eGFP vector alone. After 4 
hours the transfection cocktail was removed and replaced with 10% growth media. 
Cells were harvested 48 hours after transfection. Each plasmid condition was exam-
ined in 5 assays. AU denotes arbitrary units, as the data is expressed as relative Mfn2 
mRNA expression in eGFP control plasmid. UT denotes untransfected and eGFP 
(green fluorescent protein, control plasmid). MKK6 (Glu) constitutvely activates p38. 
Data are given as a mean ±	  S.E.M.Statistical significance was confirmed if p  < 0.05*. 
p < 0.01**. Unpaired t tests were used to assess for statistical significance.
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4.3.3.4. Effect of p38 activation by MKK6 (Glu), on markers of mitochondrial 
fission and fusion.
mRNA expression of Fis1 increased following MKK6 (Glu) transfection (Figure 4.18. 
2.5μg MKK6; Fis1 1.7±0.13 fold increase, p  = 0.02). MKK6 (Glu) transfection sig-
nificantly enhanced Mfn2 expression (Figure 4.18. 2.5μg MKK6; 3.9±0.24 fold in-
crease, p < 0.01). 
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Figure 4.18.Transfection of MKK6 (Glu) into 3T3-L1 preadipocytes enhances 
mRNA expression of mitochondrial fusion (A) and fission (B) markers 
MKK6 or MAP2K6 (mitogen-activated protein kinase kinase 6) is a member of the 
dual specificity protein kinase family, which functions as a mitogen-activated protein 
(MAP) kinase kinase. MKK6 phosphorylates and activates p38 MAP kinase and is an 
essential component of p38 MAP kinase mediated signal transduction pathway. Con-
stitutive over-expression of MKK6 activates p38 kinase activity. 3T3-L1 preadipo-
cytes were transiently transfected with 2μg MKK6 (Glu)/eGFP or pCDNA3.1 eGFP 
plasmid. The effect of genetic overexpression of MKK6, on markers of mitochondrial 
fission Fis1 and fusion Mfn2 were assessed by mRNA expression. 6 samples of 
MKK6 (Glu), 6 samples of eGFP (control plasmid) and 6 samples of untransfected 
controls (UT) were collected.  AU denotes arbitrary units, as the data is expressed as 
relative Mfn2/Fis1 mRNA expression in eGFP control plasmids.  Data are given as a 
mean ±	  S.E.M. Statistical significance was confirmed if p  < 0.05*. p < 0.01**. Un-
paired t tests were used to assess for statistical significance.
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4.3.3.5. Effect of acute p38 inhibition on mitochondrial size and abundance.
The average size of mitochondria significantly reduced in p38 inhibited cells com-
pared to DMSO control treated cells (Figure 4.18. SB203580 treated vs Ctrl; 
38μm2±7 vs 76μm2±23, p < 0.04, n = 3 plates/average of 3 image fields per plate). 
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Figure 4.19. Effect of acute p38 inhibition on mitochondrial size and abundance. 
3T3-L1 preadipocytes were treated with SB (10μM) or DMSO (control cells) for 20 
minutes. The average size of mitochondria was assessed in fixed 3T3-L1 cells using 
the analyse particles macro to identify  edges of mitochondria amongst MitoRed la-
belled mitochondria in a 2D confocal microscopy image. The data presented here, 
represent the average of 10 fields of view from 3 petri dishes. Data are given as a 
mean ±	  S.E.M. Statistical significance is indicated where unpaired t-test analyses 
value are p < 0.05*.
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4.3.3.6. Effect of acute p38 inhibition on mitochondrial morphology.
The abundance of the 6 mitochondrial subtypes (small globule, large globule, straight 
tubule, twisted tubule, loops and branched tubules) were affected by p38 inhibition. In 
particular, analysis of the time-lapse live microscopy videos revealed a significant re-
duction in the abundance of small globules in p38 inhibited 3T3-L1 preadipocytes 
compared to DMSO control counterparts (Table 3. Small globules; average of 87% 
control time lapse images compared to 54% in SB203580 treated preadipocytes, p < 
0.05). Whilst a marginal increase was noted in the straight tubule population after p38 
inhibition, this relationship  was non-significant (Table 3. Control; 7.3 vs 12 p38 inhib-
ited, p < 0.05). The population of twisted tubules remained unchanged by p38 inhibi-
tion. Perhaps the most striking changes in mitochondrial morphology were the exten-
sive enhancement of branched tubules (Table 3. branches tubules; control vs p38 in-
hibited, 4% vs 28%, p < 0.05) and the appearance of a loop population in p38 inhib-
ited cells undetected within the control 3T3-L1 mitochondrial population (Table 3. 
SB203580 treated; Loops, 5% vs undetected in control cells). Considering these live 
confocal imaging data in the context of the model proposed for the generation of mi-
tochondrial subtypes (Figure 4.6), control cells appear to be in a mitochondrial fission 




































































































































































































































































































































Figure 4.20. Effect of p38 inhibition on mitochondrial morphology subtypes.
Automated analysis of changes in mitochondrial size and abundance using the analyse 
particles and micro-P macro in Matlab. Micro-P macro was kindly provided by J.Peng 
and colleagues for use in mitochondrial subtype anaylsis. 6 petri confocal glass bot-
tomed dishes per condition (3 for live imaging) were cultured for imaging of control 
or 20 minutes SB203580 treated 3T3 preadipocytes. Both live and fixed cells were 
assessed. Fixed and live cells were considered separately for analysis. Values for mi-
tochondrial size and abundance are representative of an average across 3 petri dishes ±	  S.D. The subtypes were colour coded as; blue: small globules, yellow: large/swollen 




Recent data from studies conducted in skeletal muscle have demonstrated a link be-
tween obesity and mitochondrial dynamics (Huang, Eriksson et al. 1999, Kelley, He 
et al. 2002, Russell, Foletta et al. 2014). Whilst mitochondrial dynamics have been 
more extensively  characterised in skeletal muscle, studies in adipose tissue are lim-
ited. In recent years, the central role of adipose tissue in controlling energy  metabo-
lism and the significant impact of balancing energy homeostasis (Rosen and Spiegel-
man 2006) on mitochondrial function has become better understood. Mitochondrial 
function is regulated through biogenesis and morphology. Regulation of mitochon-
drial morphology is orchestrated by mitochondrial dynamics (Okamoto and Shaw 
2005, Huang, Galloway  et al. 2011). A clear connection between mitochondrial dy-
namics and health is demonstrated by the observation that mammalian cells devoid of 
mitochondrial fusion display stunted growth rates and diminished respiratory capacity 
(Legros, Lombes et al. 2002, Huang, Galloway et al. 2011). Furthermore, chemical 
inhibitors of mitochondrial fission, Mdivi, an inhibitor of mitochondrial fission,has 
been shown to attenuate phosphorylation of p38 within the skeletal muscle of ob/ob 
mice (Jheng, Tsai et al. 2012). Together these observations provide preliminary evi-
dence, to support further exploration of the potential role of p38 in regulating mito-
chondrial dynamics. 
The results of the present study identified strongly suggest  that  p38 is involved 
in mitochondrial dynamics. A robust and well-defined model system, 3T3-L1, a 
murine preadipocyte cell line was used (Todaro and Green 1963) due to its well-
characterised heterogeneous phenotype together with its flexibility  to inhibit or acti-
vate differentation and assess its effect on metabolic function. Furthermore, the 
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breadth of previous studies involving investigation of adipocyte differentation and 
inhibitor studies allows for comparison, contrast and extension of our studies with 
those previously published. The mitogen activated protein kinase gene (MAPK),  p38 
has been implicated in the accumulation of triglyceride in differentiating adipocytes 
(Kita, Nishida et al. 2009) and is an essential gene required for adipogenesis (Engel-
man, Berg et al. 1999). 
 Gene expression analyses of p38 (Figure 4.7) and markers of mitochondrial 
dynamics (Fis1 and Mfn2, Figure 4.9) throughout 3T3-L1 differentiation were consis-
tent with those previously reported (Ducluzeau, Priou et al. 2011). Phospho-p38 is 
known to rapidly decrease from its peak in the early  stages of differentiation to barely 
detectable levels at  the terminal stages of differentiation (Engelman, Lisanti et al. 
1998). Moreover, analysis of mitochondrial dynamics gene expression was consistent 
with Ducluzeau et al who concluded that adipocyte differentiation corresponded with 
an increase in expression of Mfn2 and Fis1 genes. Markers of mitochondrial fusion, 
Mfn2 (Bach, Naon et al. 2005) and fission, Fis1 (James, Parone et al. 2003, Lee, 
Jeong et al. 2004, Stojanovski, Koutsopoulos et al. 2004) have been documented to 
assist mitochondrial remodelling during cellular differentiation (Kita, Nishida et al. 
2009). Collectively, these observations provide evidence for a novel functional link 
between p38 and the coordination of mitochondrial dynamics. PPAR-γ, is highly ex-
pressed within adipose tissue (Medina-Gomez, Gray et al. 2007, Lodhi, Yin et al. 
2012).Given its established role in adipocyte differentiation (Siersbaek, Nielsen et al. 
2010), inhibition of p38, which prevents adipogenesis, would be predicted to corre-
spond with a significant reduction of PPAR-γ mRNA expression . As expected, 
PPAR-γ expression was significantly  lower in 3T3-L1 treated with SB203580 
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throughout differentiation (Figure 4.8). Thus, as a result of failure of 3T3-L1 to dif-
ferentiate, lipid accumulation was significantly stunted and cells maintained a more 
fibroblastic phenotype (Faust, Schmitt et al. 2012).
 SB203580, a p38α and β isoform inhibitor was assayed to assess the duration 
of p-p38 inhibition together with its cytotoxicity in 3T3-L1 preadipocytes (Badger, 
Bradbeer et al. 1996). p-p38 expression was significantly  decreased in our 3T3-L1 
preadipocytes, after incubating for 30 minutes to an hour with SB203580 (10μM, 
Figure 4.10). This was accompanied by no significant reduction in mitochondrial 
DNA content(Figure 4.11). However, markers of mitochondrial fission and fu-
sion,Fis1 and Mfn2 respectively, decreased significantly  in protein expression follow-
ing this acute p38 inhibition (Figures 4.12 and 4.13). Given the inability of mitochon-
dria to swiftly  reverse mutations and DNA damage induced by  chemical (e.g. drug 
compounds) or environmental factors (UV or stress induced damage), mitochondrial 
health is frequently challenged, and mitochondria are required to detect and remove 
damaged mitochondria (Mercer, Neph et al. 2011). Mitochondrial bioenergetics is in-
strumental in maintaining a mitochondrion’s role as the energy provider for cells 
(Tseng, Cypess et al. 2010). In order to address whether mitochondrial bioenergetics 
was reduced following p38 inhibition, the spare respiratory  capacities and coupling 
efficiencies of 3T3-L1 preadipocytes treated with or without SB203580 were com-
pared. Considering the significant reduction in Fis1 expression in p38 inhibited 3T3-
L1 preadipocytes, it would be anticipated that mitochondrial bioenergetics may  be 
negatively affected. Respiration together with parallel measurements of membrane 
potential offers extensive quantitative data, functional perspectives and may  identify 
the site of p38 action and downstream effects of mitochondrial dysfunction (Zhuang, 
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Demirs et al. 2000, Brand and Nicholls 2011). Spare respiratory  capacity  significantly 
decreased in a dose-dependent manner with SB203580 (Figure 4.15). In conjunction, 
3T3-L1 preadipocytes treated with SB203580 at 10μM experienced a significant re-
duction in their mitochondrial coupling efficiency (Figure 4.15). Taken together, 
whilst no change in mitochondrial DNA content was observed, mitochondria were 
respiring closer to their maximum oxygen consumption rate. Consistent  respiration 
close to the SRC of the mitochondria would generate additional mitochondrial stress 
and increase the likelihood of mitochondrial damage. One example of mitochondrial 
damage is oxidative stress, where greater levels of reactive oxygen species (ROS) are 
generated through formation of radical molecules (e.g. superoxide anion, single ion 
form of oxygen and is produced in the electron transport  chain) above those which 
can be neutralised through anti-oxidants (e.g. superoxide dismutase, catalyse the 
breakdown of the superoxide anion into oxygen and hydrogen peroxide) (Lodo et al, 
2010).
 Finally, MKK6 overexpression vector (MKK6 (Glu) (Raingeaud, Whitmarsh 
et al. 1996, Enslen, Raingeaud et al. 1998, Remy, Risco et al. 2010)) was transfected 
into 3T3-L1 preadipocytes (Figure 4.16). Preadipocytes were selected, as the transfec-
tion efficiency  is greater than that of differentiated adipocytes. This transfection study 
complemented the pharmacological inhibition of p38α and β by SB203580. MKK6, 
as a constitutive activator of p38, is sufficient to stimulate differentiation without the 
requirement for differentiating factors, insulin, dexamethasone and 1-methyl-3-(2-
methylpropyl)-7H-purine-2,6-dione (IBMX) and has been confirmed by other re-
searchers to enhance p38 activity. As a novel extension of this work, I characterised 
the effect  of MKK6 on the expression of markers of mitochondrial dynamics. Mfn2 
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mRNA expression quadrupled in MKK6(Glu) transfected preadipocytes, whilst Fis1 
expression doubled (Figure 4.17). Mitochondrial fusion has been shown to be critical 
in the control of the mitochondrial life cycle,as selective fusion is a pre-requisite for 
subsequent cycles of fission (Twig et al, 2008). As such the greater enhancement of 
markers of mitochondrial fusion may  represent an additional quality control mecha-
nism to prime the mitochondria that a larger population of mitochondria will be cy-
cling through a cell and ensure that an enhancement in the expression of mitochon-
drial dynamics genes and metabolism does not occur at the expense of mitochondrial 
quality.Exactly how this is acheived is unclear at present, but cross-talk signalling be-
tween the nucleus and mitochondria may play a role.
 Finally, the effect of p38 on mitochondrial morphology was assessed through 
live confocal microscopy  of 3T3-L1 preadipocytes with and without p38 inhibition by 
SB203580. Following p38 inhibition, the average size of mitochondria significantly 
reduced compared to DMSO controls (Figure 4.18). Furthermore, the morphological 
subtypes were altered by p38 inhibition. 20 minutes of p38 inhibition was sufficient 
not only to lower the abundance of small globules but also to increase the number of 
straight tubules and generate previously unseen loops (Table 3). Based on the model 
proposed by Peng et al (Figure 4.6) the appearance of mitochondrial loops together 
with the reduction of small globules and increase in straight tubules may signify tha t 
p38 inhibition shifts the balance of mitochondrial dynamics towards a fusion domi-
nant phenotype. A fusion dominant phenotype would like translate into a less metab-
olically active mitochondrial population, as over time mutations which occur naturally 
throughout the mitochondrial life cycle, would not be repaired as swiftly as those un-
dergoing regular mitochondrial fission. As p38 inhibition was shown to reduce mito-
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chondrial size, the snapshot images captured by time lapse confocal microscopy may 
represent a timepoint within mitochondrial dynamics, immediately  prior to mitochon-
drial fission identified by the analyse particles ImageJ analysis. 
 In conclusion, our present findings strongly suggest that p38 regulates mito-
chondrial dynamics. Further studies involving assessment of the rate of mitochondrial 
dynamics and bioenergetics in MKK6 transfected 3T3-L1 and human preadipocyte 
models will be required to provide additional support to our work.
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Chapter 5: 
Selection and assessment of p38 α and β isoform se-




Mitogen activated protein kinases (MAPK) have been preserved throughout evolu-
tion. The abundance of these MAPKs from yeast to mammals reflects their significant 
role within cells. One of the best characterised of the 14 human MAPKs is p38 (Lee, 
Kumar et al. 2000, Cohen 2002, Metz, Johnson et al. 2011).
5.1.2 Role of p38 MAPK pathway.
F i g- u r e 
5.1. Roles of the p38 MAPK pathway. 
A variety of stimuli, mainly stress stimuli, activate p38 MAPK through complex ki-
nase cascades including a MAP3K that phosphorylates a MAP2K that, in turn, phos-
phorylates p38 MAPK. Cellular intermediates, like GTPases, receptor adapter pro-
teins or cell cycle checkpoint  proteins, among others, transmit the stimulus to the ki-
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nase cascades. Once activated, the different p38 MAPK either phosphorylates cyto-
plasmic targets or translocate into the nucleus leading to the regulation of transcrip-
tion factors involved in cellular responses. MKK6 is the major activator of all p38 
MAPK isoforms, while MKK3 and MKK4 are more specific and can only activate 
some isoforms. Legend and figure originally created by Almudena Porras and Carmen 
Guerrero.http://atlasgeneticsoncology.org/Deep/MAPK14-p38ainCancerID20089.htm
l.
5.1.3. p38 isoforms and abundance.
Four p38 isoforms have been identified within mammalian cells. The structural simi-
larity and tissue specificity  distinguish between these isoforms (Lee, Kumar et al. 
2000). Whilst, α and β isoforms are ubiquitously expressed, δ and γ are selectively 
expressed in only a few tissue types (Risco and Cuenda 2012). p38γ is found mainly 
in skeletal muscle and δ predominates in testes, pancreas and small intestine (Cuad-
rado and Nebreda 2010). Furthermore, p38α and p38β, which share similar tissue lo-
calisation, are 75% homologous (Badrinarayan and Sastry 2011). In contrast, p38γ 
and p38δ are more restricted in their tissue localisations and share 57% and 63% ho-
mology to p38α (Enslen, Raingeaud et al. 1998, Enslen, Brancho et al. 2000).
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Figure 5.2. Sequence homology of p38  isoforms.
Multiple sequence alignment of amino acid sequence of p38 isoforms. Abbreviations 
of amino acids are as follows: A: alanine, D: aspartic acid, E: glutamic acid, F: phen-
ylalanine, G: glycine, H: histidine, I: isoleucine, K: lysine, L: leucine, M: methionine, 
N: asparagine, P: proline, Q: glutamine, R: arginine, S: serine, T: threonine, V: valine, 
W: tryptophan, Y: tyrosine. DFG motif are the key amino acid residues contained with 
the p38 activation loop. ATP is the location of the ATP binding pocket. TXY are the 
conserved threonine and tyrosine kinase residues responsible for the activity of the 
MAPK. Uniprot preference numbers: human p38α (Q16539), mouse p38α (P47811), 
human p38β (Q15759), human p38δ (O15264) and human MK2 (P49137).
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5.1.4 Structural features and activation of MAPK’s.
p38 has two domains, ATP binding site (catalytic site) and a docking domain. p38 ki-
nase activation occurs at  the C-terminal activation loop  (Wang, Canagarajah et al. 
1998). Located within this activation loop are two phosphorylation sites, Tyr182 and 
Thr180 (Lee, Kumar et al. 2000). Following activation of p38 the docking motif coor-
dinates interaction with substrates of p38. Occurring outside the p38 ATP active site, 
this motif is most commonly referred to as DEJL or “D motifs”	  (Akella, Min et  al. 
2010). The p38α substrate MK2, and phosphatases have been shown to interact  with 
DEJL motifs (Akella, Min et al. 2010).
Figure 5.3. Structural specificity, substrates and mechanism of action of p38 re-
ceptor isoforms. A) The basic catalytic cycle for substrate phosphorylation by a ki-
nase. Starting top left, ATP binds to the active site of the kinase. This is followed by 
binding of the substrate to the active site. Once bound, the γ-phosphate of ATP (red) is 
transferred to a Ser, Thr or Tyr residue of the substrate. After phosphorylation, the 
substrate is released from the kinase. The last step  shown is the release of ADP from 
the active site. B) p38 consists of a catalytic cleft and an active site, which binds ATP. 
p38 activity requires dual phosphorylation at the threonine residue 180 (pT180, not 
T160 which is a typo in figure) and tyrosine 182 residue. Figure and legend taken 
from (Ubersax and Ferrell 2007).
	  	  B.	  	  A.
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Figure 5.4. Crystal structure of the human p38α MAPK.
Crystal structure of p38α MAPK presented at 2.5 Å	   resolution. The ATP molecule in 
its binding site is depicted in purple. The green molecule (1) is an ATP competitive 
p38 inhibitor.	   Beta strands are shown in blue, α-helices in yellow and the connecting 
loops in purple. The small lobe	  . Figure taken from (Pargellis, Tong et al. 2002).
5.1.5. Regulation of p38 activation.
Through site directed mutagenesis studies of human p38α, Thr180 was found to be 
necessary  for catalysis whilst Tyr182 may be required for substrate recognition (Lis-
nock, Tebben et al. 1998). Furthermore, human p38 kinase activity was 10-20 fold 
higher in dual phosphorylated p38α compared to singly phosphorylated p38 at Thr180 
alone (Whitmarsh and Davis 1999, Weston, Lambright et al. 2002). In addition to the 
phosphorylation status of p38, the nature of activation signal also influences the dura-
tion of activation (Mansour, Resing et al. 1994). Under normal homeostatic condi-
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tions, p38 MAPK activation levels are low (Brancho, Tanaka et al. 2003). In response 
to changes in the extracellular environment, e.g. LPS stimulation, p38 MAPK path-
way is transiently activated (Han, Lee et al. 1994). Given the role of p38 MAPK ac-
tivity, in cell proliferation, it is vital that p38 is only activated where necessary 
(Sharma, He et al. 2003, Faust, Schmitt et al. 2012). The level of p38 activation is 
tightly and finely controlled by  a series of negative feedback mechanisms and serine 
and threonine phosphatases (Dickinson and Keyse 2006). Multiple phosphatases are 
capable of acting on a single kinase (Saxena and Mustelin 2000, Risco and Cuenda 
2012). 
5.1.5.1. Dissecting the role of key amino acids in p38 catalytic activity and substrate 
binding.
Crystal structures between p38α and its substrates have shown that they interact pri-
marily within the hydrophobic docking groove (Jiang, Li et  al. 1997, Kumar, McDon-
nell et al. 1997, Cohen and Knebel 2006). This observation has been complemented 
by crystallographic determination of p38 and a p38 α/β inhibitor SB203580 (Eyers, 
Craxton et al. 1998, Davies, Reddy et al. 2000). 
5.1.5.2 SB203580: Binding mode within p38α MAPK
SB203580 has a central imidazole core connected to three rings (Wang, Canagarajah 
et al. 1998) forming a shape similar to a propeller. The pyridine ring of SB203580, 
overlaps part of the ATP binding within p38α (Tong, Pav et al. 1997). Both the ade-
nine ring of ATP and the pyridine ring of SB203580 occupy the same site within the 
ATP binding pocket. SB203580 elicits its ATP competitive action by steric hindrance 
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by preventing the adenine ring of ATP from accessing the ATP binding site (Gum, 
McLaughlin et al. 1998). Through this conformation, a hydrogen bond is created be-
tween the amide of Met109 in p38α and the nitrogen of pyridine ring of SB203580 
(Tong, Pav et al. 1997).This interaction is analogous to the hydrogen bond between 
adenine of ATP and amide of Met109 in p38α. 
Figure 5.5. p38α inhibitor,  SB203580 molecule alone (A) and complexed within 
the p38α crystal structure (B). SB203580 is a p38α and β inhibitor shown here in 
2D (A) and as a ribbon representation, in complex with the human p38α (B) (PDB: 
1a9u). 2D structure depicted was taken from cell signalling technology website (URL; 
http://www.cellsignal.com/product/productDetail.jsp?productId=5633) 
Only a small portion of SB203580 interacts directly with amino acids present in the 
ATP binding site (Wilson, McCaffrey et al. 1997). Adjacent  to the ATP binding site, a 
small hydrophobic groove is created by  the presence of Thr106 residue on a small side 
	  	  B.	  	  A.
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chain. The 4-fluorophenyl ring of SB binds within this groove (Tong, Pav et al. 1997). 
In spite of, SB203580’s ATP competitive inhibitor activity, the most significant inter-
action of this compound occurs between this Thr106 of p38α and SB (Wilson, McCaf-
frey et al. 1997). Site directed mutagenesis to a more hydrophobic and bulkier amino 
acid side chain at position 106, created a p38α MAPK insensitive to SB203580 (Ey-
ers, Craxton et al. 1998).
5.1.6 DFG in vs. out inhibitors.
5.1.6.1 Design of p38 inhibitors: DFG-in versus DFG-out inhibitors.
The key  structural differences between p38 isoforms exist at the ATP binding pocket. 
In p38α and β,these isoforms share the same three residues (Thr106, His107, 
Leu108). In the more distant homologs p38δ or γ however, these amino acids are dif-
ferent (Met106, Pro107 and Phe108). Site directed mutagenesis studies in yeast and 
bacteria, have shown that a single change from Met106 to Thr106 in isoforms p38δ or γ 
is sufficient to confer sensitivity to SB203580 (Eyers, Craxton et al. 1998, Gum, 
McLaughlin et al. 1998). Another key structural difference between the more closely 
related p38α and β is located within the hydrophobic binding pocket (Cohen 2002). 
The relative orientation of the N- and C- terminals in p38β results in a smaller hydro-
phobic binding pocket for substrates. The effect of mutating residue 106 in wild type 
p38α was assessed by enzyme based kinase assays (Davies, Reddy et al. 2000). Sub-
stitution of Thr for Glutamine (Gln) increased the Km for ATP by 17 fold relative to 
the wild type enzyme (Kumar, Jiang et al. 1999, Lee, Kumar et al. 2000). Glutamine 
is a more hydrophilic and larger amino acid than Threonine. Furthermore, the small 
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size and hydrophobic nature of the native pocket, would have been expected to reduce 
the ATP binding affinity in the resulting p38α mutant (Ross, Armstrong et al. 2002).
 
The first generation of p38 inhibitors were optimised as competitive ATP inhibitors. 
As many kinases have an ATP binding site, undesirable off target/non-selective effects 
against other kinases can result  from ATP competitive inhibitors. In an attempt to 
overcome this issue, three key residues located in the activation loop of p38α (D, As-
partic acid, F, Phenylalanine and G, Glycine) became the target motif for a new class 
of p38 inhibitors e.g BIRB-796 (Pargellis, Tong et al. 2002). In an unbound state, the 
DFG motif assumes a	  ‘DFG-in’	  conformation.
5.1.6.2. Solution state NMR spectroscopy
Magnetic properties of spin exist in the isotopes (1H and 13C) due to additional neu-
trons compared to protons, which are balanced in the cases of 2H and 12C (classified 
in the periodic table). The principle of NMR, is that in the presence of a magentic 
field, isotopes with additional neutrons (1H and 13C) absorb electromagnetic radia-
tion at a defined frequency for that isotope (Slichter,C.P. 1990). Furthermore, the 
strength of the magnetic field can alter the intensity  of the signal at this frequency. 
Those nuclei which orientate in the opposing direction to the applied magnetic field 
are of a higher energy state than those which align with the magnetic field (Grant,D.M 
and Harris,R.K. 1996).
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Figure 5.6. Principles of Nuclear Magnetic Resonance.
Figure taken from http://chem.ch.huji.ac.il/nmr/whatisnmr/whatisnmr.html.	  Upon ab-
sorption of the electromagnetic radiation, the sample is excited using a radio fre-
quency  pulse. Electrons within each nuclei, create a local magnetic field to shield the 
protons from the externally applied magnetic field. The shielding effects due to the 
movement of protons has been extensively characterised and are used to provide 
structural information about a compound. Once the magnetic field is removed, the 
absorbed electromagnetic radiation (resonance) is released (http:/ / 
www2.chemistry.msu.edu/faculty/reusch/VirtTxtJml/Spectrpy/nmr/nmr1.htm). The 
degradation of this absorbed electromagnetic radiation corresponds to a return in the 
energetic status of the nuclei to ground state and the spin state of the individual nuclei 
are balanced and neutral. The interconnection of atomic nuclei and application of a 
magnetic field allows a distinctive spectra similiar to a ‘molecular fingerprint’ to be 
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generated. Therefore, this spectra enables the identity of chemical substances to be 
confirmed. In the case of ligand binding to p38α, solution state NMR revealed that 
the DFG motif shifts to a ‘DFG-out’ conformation (Vogtherr, Saxena et al. 2006).
Figure 5.7. Energy profile of nuclei in NMR.
H in green indicates the direction of the externally applied magnetic field. E indicates 
the energy status of each atomic nuclei spin state. In the ground state,, shown on the
left, with no magnetic field applied, the difference in energy is zero. Upon application 
of an magnetic field, those atomic nuclei in red, are orientated in the opposing direc-
tion to the applied magnetic field. Therefore these excited nuclei have a higher ener-
getic profile than the ground state. Conversely, those nuclei whose spin is orientated 
in the same direction as the applied field, have a lower energy profile in their excited 
state. The greater the strength of the magnetic field applied, the greater the energy  dif-
ference between the aligned and non aligned spins of the nuclei (http:// 
www2.chemistry.msu.edu/faculty/reusch/VirtTxtJml/Spectrpy/nmr/nmr1.htm).
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Solution state NMR revealed that following ligand binding to p38α, the DFG motif 
shifts to a	  ‘DFG-out’	  conformation (Vogtherr, Saxena et al. 2006).
Figure 5.8. Conformational difference in binding mode between DFG-in vs DFG-
out inhibitors.
Crystal structure of p38 complexed with BIRB-796 (2.1 Å	   resolution; Rfactor= 0.241; 
Rfree=0.279, DFG-out inhibitor). DFG (is an abbreviation denoting the amino acids, 
asparatic acid (D), phenylalanine (F) and glycine (G)). SB203580, a DFG-in inhibitor, 
is presented within the binding pocket as a reference. Shown is a molecular-­‐surface 
representation of p38 with the main chain of the DFG motif highlighted in red (DFG-­‐
in conformation) and blue (DFG-­‐out conformation). Phe 169 and BIRB-796 are 
shown as stick representations and are color coded in red (DFG-­‐in) and blue (DFG-­‐
out). In the DFG-­‐in form, the side chain of Phe 169 resides in a hydrophobic pocket, 
whereas it points outwards in the DFG-­‐out form. They observed approximate occu-
pancies of 50 % for the DFG-­‐in and DFG-­‐out conformations in the ensemble average 
of the crystal. Figure and legend taken from (Vogtherr, Saxena et al. 2006).
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5.1.6.3. Substrate binding to p38α 
p38 substrate binding occurs at the DFG motif within the activation loop of p38α. 
Three conformational modes of p38α exist: inactive unbound to ATP (ligand), phos-
phorylated (Tyr182 and Thr180) but not  activated and fully activated p38α-ATP-MK2 
(White, Pargellis et al. 2007). Structural differences at the activation loop accompany 
the distinct DFG modes between unbound-p38 and AMP-PNP-p38α kinase (non hy-
drolysable ATP analogue). Ligand binding was shown to correspond to the conversion 
of the activation loop from DFG-in to DFG-out conformation. 
Figure 5.10. Binding modes of two different types of p38 MAPK inhibitors, 
Type I, ATP site binders (a) and (b) Type II, DFG-out inhibitors.  Compounds which 
belong to group (a) involve activation of the ATP site inhibitor with the hinge region; 
the F169 in the DFG-in conformation blocks the hydrophobic pockets (termed HPI 
and HPII in the figure above). In contrast (b) the designed type II inhibitor comforta-
bly occupies the larger area of the active site created by the 1200 turn of F169 leading 
to the transition into a DFG-out conformation and opening of the hydrophobic back 
pockets, HPI and II. A small M109-G110 flip is also observed. The designed type II 
p38 MAP kinase inhibitor interacts with the hinge region (head), DFG-loop (linker), 
and hydrophobic pocket (tail). Green compound is SB203580 . Figure and legend 
taken from (Badrinarayan and Sastry 2011).
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5.1.6.4. BIRB-796: DFG-out p38 inhibitor.
Due to the action of BIRB-796, interconversion of DFG-out back to DFG-in is pre-
vented (Moffett, Konteatis et al. 2011). Solution NMR analysis of BIRB-796 action 
on p38α revealed the presence of an NMR signal corresponding to Phe169 (Vogtherr, 
Saxena et al. 2006). This Phe169 residue is usually  located within a hydrophobic 
pocket, in a site proximal to the ATP binding site (Vogtherr, Saxena et al. 2006). Fur-
thermore, this residue only becomes accessible when the activation loop is in DFG-
out conformation (Badrinarayan and Sastry 2011). BIRB-796, can block both p38 ac-
tivity and activation. DFG-in binders such as SB203580 do not interfere with p38 ac-
tivation and formation of DFG loop does not  affect their binding (Kumar, Jiang et al. 
1999).
Figure 5.11. Kinetic scheme for the conformational exchange of the DFG motif.
In the apo protein (unbound ligand state), the DFG-­‐in and DFG-­‐out forms are in slow 
(kHz) conformational exchange. Ligand BIRB-796 binds to the DFG-­‐out conforma-
tion and freezes the conformational equilibrium in a defined state. Ligands such as 
SB203580 leave the DFG equilibrium unaffected. Figure and legend taken from 
(Vogtherr, Saxena et al. 2006). 
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Solution state NMR enabled determination of the equilibrium constants for DFG in-
terconversion (Vogtherr, Saxena et al. 2006).Investigation of the rates of DFG-in and 
DFG-out binding kinetics revealed that DFG-in inhibitors e.g SB203580 were mainly 
a diffusion controlled (Vogtherr, Saxena et al. 2006). The 2-fold lower magnitude ob-
served for DFG-out inhibitors of similar molecular size, suggested an alternative 
mechanism of action (Vogtherr, Saxena et al. 2006). Kinetic analysis of BIRB-796 
revealed a half-life of dissociation for p38 MAPK of 23 hours. The molecular basis 
for the enhanced affinity and association of BIRB-796 with p38 kinase resides in its 
morpholino substituent. Structural analysis of hydrogen bonding interactions between 
this BIRB-796 and an amide at position 109 of MAPK’s main chain has been pro-
posed to stabilise this interaction (Vogtherr, Saxena et al. 2006).
5.2 Drug design.
Drug design is concerned with the development of orally active, efficacious, bioavail-
able, safe and compounds which can be easily formulated into a drug.	  	  Bioavailability, 
safety  (non-toxic) and formulation ease are together what we might call ‘drug-like 
properties’.	   	  The challenge of drug design is to find molecules that bind to and affect 
the target protein while maintaining good drug-like properties.  At the early  stages of 
drug design, screening large compound libraries for drugability  is prohibitively ex-
pensive and time consuming. Therefore,	  Lipinski’s rules are one of the simple means 
of assessing the physical properties of compounds.	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5.2.1. Lipinski’s  rule of 5 (Lipinski 1997):
Compounds fulfilling the rule-of-5 criteria have a greater chance of being an orally 
bioavailable drug. Details of the rule of five criteria are given below:
•A compound’s molecular weight is less than 500 g/mol.
•The compound's lipophilicity, expressed as a quantity known as logP (the loga-
rithm of the partition coefficient between water and 1-octanol), is less than 5.
•The number of groups in the molecule that  can donate hydrogen atoms to hydro-
gen bonds (usually the sum of hydroxyl and amine groups in a drug molecule) 
is less than 5.
•The number of groups that can accept hydrogen atoms to form hydrogen bonds 
(estimated by the sum of oxygen and nitrogen atoms) is less than 10.
Identifying new compounds or ‘hits’	  requires numerous drug design methodologies. 
Effective application of quantitative structure activity  relationship  (QSAR) requires 
a continuous and smooth functional relationship to exist  between numerical de-
scriptors and a property e.g. inhibitory activity  against p38 (Walker, Jaworska et  al. 
2003, Fliri, Loging et al. 2009). Within large datasets, these requirements may not 
be upheld. In order to circumvent situations where a smooth functional relationship 
may not exist between numerical descriptors and a desired chemical property e.g. 
kinase inhibitory activity, compounds may be subdivided either by clustering by 
chemical structure or creation of a smaller dataset of compounds with a common 
and similar mechanism of activity (Gillet, Willett  et al. 2003). Therefore, through 
the introduction of multiple smaller datasets from a single larger dataset, may allow 
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outliers, that were non-homogeneous with the rest of the larger dataset to be use-
fully  incorporated and included as part of the overall QSAR analysis. In the context 
of p38 kinase inhibitors, the advantages and the limitations of each approach will be 
discussed. 
5.2.2. Toxicology and bioavailability considerations in drug design.
Compounds identified through modelling should be evaluated for their proposed toxi-
cology  and drugability. Toxicology can be estimated based on the functional groups 
contained within compounds and previous drug design projects (Metz, Johnson et al. 
2011). These can predict the potential route of ADME (Absorption, Distribution, Me-
tabolism and Excretion) (Butina, Segall et al. 2002). 
In order to improve the drugability of the compounds, chemical subgroups with a 
lower hydrophobic character were substituted in place of the napthyl and tolyl rings 
previously  included within the drug-like compound (Moffett, Konteatis et al. 2011). 
Evaluation of previously published inhibitors, SB203580 and BIRB-796 was initially 
undertaken using fragment based drug design (Jiang, Li et al. 1997, Moffett, Kontea-
tis et al. 2011). This involved selecting either thiophene urea and pyrazole urea as the 
core chemical scaffolds. The side chains are constructed around the central core  pro-
ducing a novel putative p38 inhibitor. Newly  created putative p38 inhibitors are com-
putationally assessed for their binding affinity to its drug target, the p38α. Throughout 
this process, the abundance and strength of the molecular docking interactions are 
considered between the substrate and the new drug candidate.
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A number of key  principles underlie drug design and assessment of their potential 
drug like activity.
5.2.3. Selection of compounds with putative inhibitory activity against p38.
5.2.3.1.  Descriptor selection. 
Descriptors were selected to enable a large database of compounds to be evaluated 
and identify compounds with drug-like activity. When presented with this scenario, 
descriptors offer the capability to cluster compounds according, for example, by their 
two-dimensional (2D) or three dimensional (3D) features (Bissantz, Kuhn et al. 
2010). Careful selection of descriptors is essential for accurate and meaningful analy-
sis of large datasets. Principle component analysis is used to capture those descriptors 
exhibiting the greatest variance within the dataset (Cohen 2002). However, most 
variation across the dataset does not always imply the most important descriptors 
(Macias, Mia et al. 2005, Gong, Cai et al. 2013, Li and Colosi 2013). Selection of the 
most appropriate descriptor is one that can distinguish between compounds that 
mimic or oppose vital biological and chemical interactions within ATP-p38 kinase 
interaction. 
Two key challenges to successful inhibitor design are those of specificity  and affinity 
for their target kinase. High sequence homology between the estimated 500 human 
kinases, commonly results in undesirable off target effects (Fabian, Biggs et al. 2005). 
In an attempt to address this, screening for a compound’s kinase activity against  rep-
resentatives of the different kinase subfamilies is vital (Enslen, Brancho et al. 2000, 
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Gill, Frederickson et  al. 2005). Screening an entire commercial database of up to a 
million compounds is impractical. Compound clustering and selection of those with 
proposed inhibitory  activity against p38 creates a more manageable panel of potential 
inhibitors to screen via in vitro kinase assays. Compounds can be clustered based on 
structural or chemical similarity (Sheridan and Kearsley  2002, Raghavendra and 
Maggiora 2007, Sheridan 2007, Gong, Cai et al. 2013). The outcome of cluster analy-
sis is influenced by  information content and user defined parameters e.g. descriptor 
selection (Macias, Mia et al. 2005, Li and Colosi 2013).
5.2.3.2. Structural similarity. 
Structural similarity of compounds can be clustered based on their 2D or 3D charac-
teristics. A major drawback of cluster analyses based on a 3D structural similarity, are 
the level of complexity that must be encapsulated by descriptors (Liu, Chen et al. 
2010). This includes, not only those feature descriptors required to define the 2D 
structure (the presence or absence of chemical groups) but also, the relative arrange-
ment of these structural groups with respect to each other and the environment in 
which they reside (Fliri, Loging et al. 2009). In addition, within 3D, compounds ex-
hibit spatial flexibility  (Gong, Cai et al. 2013). Therefore, in order to provide a suit-
able evaluation of a compound, multiple conformations of a single compound should 
be included into the dataset  prior to this drug’s subsequent evaluation by structural 
clustering. As such, the orders of magnitude of feature descriptors required above that 
of 2D structural definition generate a larger number of clusters each containing fewer 
compounds compared to 2D analysis (Bissantz, Kuhn et al. 2010). In essence, the 
computational expense and time required to produce and subsequently evaluate these 
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compounds during the virtual screening of compounds with its target receptor does 
not necessarily  translate into a greater selection of ‘hits’	  to compensate for the addi-
tional information provided by the 3D over the 2D structure. On balance, 2D offers a 
simple but effective method to define the structural information of individual com-
pounds within a large drug database. Three key elements that define a structure at a 
molecular level are configuration, conformation and constitution (Nikolova and Ja-
worska, 2003). In 2D analysis, all chemical groups present in compounds can be in-
corporated within a molecular fingerprint. A molecular fingerprint consists of a binary 
sequence of 1’s and 0’s indicating the presence or absence of different chemical sub-
structures. Typically these molecular fingerprints are over a 1000 digits in length 
(Swamidass and Baldi 2007). This molecular fingerprint represents the constitutional 
assignment of a molecule’s structure  (Swamidass and Baldi 2007). Despite its obvi-
ous simplicity, defining a compound by  the absence or presence of molecular sub-
structures is computationally inexpensive. Therefore, it is an attractive initial ap-
proach for assessing a compound collections’	  diversity. The topological descriptors 
that define a molecules’	  constitution include, degree of connectivity of an individual 
atom to others within the molecule, pharmacophore points, number of individual at-
oms, bonds or rings (Lisnock, Tebben et al. 1998, Bissantz, Kuhn et al. 2010). The 
structural key generated for each molecule can be clustered by various methods in-




5.3.1. Scaffold directed clustering.
The nature of the bond and atom linkage between the different substructures within a 
molecule is lost following fingerprint generation (Chuaqui, Deng et al. 2005). Due to 
the use of a single descriptor to capture the 2D features of a compound, it is not pos-
sible to reform the structure from a fingerprint (Xue, Godden et al. 2000). The topo-
logical descriptor value may not be unique between molecules (Xue, Godden et al. 
2000). Despite the different nature of two compounds it may help  to identify  key 
functional groups required for p38 kinase inhibitor-p38 kinase interaction. 
In 3D, the features of a molecule’s structure can be defined by  configuration and con-
formation (Nikolova and Jaworska, 2003). Configuration describes how atoms are 
linked to one another and the bond angles resulting from their arrangement (Nikolova 
and Jaworska, 2003). Finally, conformation is the spatial arrangement in 3D, of atoms 
from a molecule,which is most thermodynamically favourable i.e. lowest  energy  state 
(Nikolova and Jaworska, 2003).
	  5.3.2 Sphere exclusion clustering.
Often within drug discovery, the ability to rapidly  organise compounds into sets of 
clusters containing similar compounds is extremely useful when working with large 
datasets. One method by which this can be achieved is sphere exclusion clustering. 
This method enables broad sampling. Initially, a single compound is selected as the ‘seed’	  compound for a cluster (Bacha et al, 2007, Daylight Fingerprint Chemical In-
formation systems). The remaining compounds within the compound library which 
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display  chemical similarity are incorporated into this cluster. Any ‘hermit’, whose 
chemical identity differs from the rest of the dataset, remains separate from the gener-
ated cluster. Once all those compounds which match the chemical similarity of the 
initial cluster have been included within this cluster, a new initial ‘cluster centre’	  com-
pound is selected. With the exception of the compounds clustered in this first  cluster, 
all remaining compounds are included and the process is repeated. This continues it-
eratively until all compounds have either been clustered or are termed ‘hermits’	   i.e 
they do not successfully cluster with any of the generated cluster groups.
5.3.3. Compound library design.
An application of structure based drug design is the creation of a compound collection 
library. All compounds share a common scaffold core. A compound’s activity against 
a target kinase is assumed to derive from the nature of the functional groups surround-
ing its scaffold core (Friesner, Banks et al. 2004, Badrinarayan and Sastry 2011). The 
hallmarks of molecular fingerprinting are encompassed in their ability  to define the 
structural similarity  between pharmacophore groups (Swamidass and Baldi 2007). 
Defined as the neighbourhood principle, it assumes that those compounds with similar 
structural characteristics defined by their descriptors will exhibit similarity  in their 
activity (Nikolova and Jaworska, 2003). Furthermore, data assumption distributions 
underpin the use of structural features classification and measures of relative similar-
ity  between structures. The limitations, errors and potential bias introduced by these 
data assumptions should be considered carefully for their impact of compounds result-
ing descriptor based similarity analysis.
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5.3.4. Molecular docking of drug-like compounds into target receptor.
Co-crystallisation of compound and kinase are required to confirm the binding mode 
(Badger, Bradbeer et al. 1996, Gum, McLaughlin et al. 1998, Pargellis, Tong et al. 
2002). Furthermore, key amino acid interactions made between compound and kinase 
responsible for eliciting its function can be visualised. If the key residues within the 
kinase have already  been characterised e.g. p38 kinase, Thr106 and Met109 in p38α 
kinase, co-crystallisation of a new compound confirms if this binding mode is main-
tained (Bellon, Fitzgibbon et al. 1999, Walker, Jaworska et al. 2003).
5.3.5. Assessing drug-like compounds in the context of p38.
SB203580 was utilised throughout the course of this thesis to assess the effects of p38 
mediated regulation of mitochondrial dynamics. The model system for investigation 
of p38 regulation was the cell line 3T3L-1 adipocytes. The focus of this chapter is the 
selection of putative p38 inhibitors from the AZ compound collection. Computational 
modelling and assessment of the mitochondrial bioenergetics in the presence of these 
putative p38β inhibitors would lend additional evidence in support of the hypothesis 
that p38 is involved in the regulation of mitochondrial dynamics.
5.4. Methods.
5.4.1. X-ray crystallography structures of human and mouse p38 isoforms (α and β).
Crystal structures of p38 isoform (α and β) receptors were obtained from the protein 
database (PDB). 1KV2 (human p38 alpha, BIRB-796 co-crystallised, (Pargellis, Tong 
et al. 2002)), 1A9U (human p38 alpha, co-crystallised with SB203580, (Wang, 
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Canagarajah et al. 1998)), 3GP0 (p38 beta human with nitotinib,(Filippakopoulos , 
Malet, Coutard et al. 2009),  3GC8 (p38 beta human with dihydroquinazoline, (Patel, 
Cameron et al. 2009)), 2EWA (p38 alpha mouse co-crystallised with SB203580, 
(Vogtherr, Saxena et al. 2006)) and 2OZA (p38 alpha mouse and human MK2, 
(White, Pargellis et al. 2007)).
5.4.2. Hierarchical clustering of AZ p38 inhibitor actives compound database 
(Wards clustering).
An AstraZeneca FOYFI method (in-house developed software) was utilised to define 
the structural keys for 3259 compounds (Blomberg N 2009). These structural keys; 
created in a method similar to daylight fingerprinting which allows the presence or 
absence of predefined substructures and descriptors to be represented in a binary 
code. 1 refers to the presence and 0 to the absence of a defined substructure or de-
scriptor feature. within each compound. 3259 compounds were clustered using Wards 
clustering. This clustering was based on chemical similarity of the compounds’	  sub-
structures and descriptors. Tanimoto similarity e.g between two molecules A and B is 
calculated as the number of 1 bits (presence, using binary) divided by  the sum number 
of 1 bits in (a) and (b) minus those 1 bits which they share in common (c). Impor-
tantly, even if the result of this calculation is a value of 1, the molecules may not  be 
identical but simply  share similar substructures across their entire molecular structure. 
This methodology is most commonly  used with binary fingerprints (i.e. the presence, 
1 or absence of a substructure, 0). 
Similarity (A,B) = c / a + b - c 
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Conversely, the tanimoto distance is used to identify dissimilarity between a pair of 
molecules. Therefore, using this rationale, the shared absence of a substructure across 
a pair of molecules is taken to reflect a similarity between these two molecules. The 
range of distance values are 0 or positive. Importantly, smaller molecules often dis-
play  less tanimoto similarity. This is taken into account during the calculation of 
tanimoto distance as: 
Distance (A,B) = d / a + b - d
number of substructures shared between the two molecules (d) divided by the sum 
number of substructures in (a) and (b) minus (d). 
The tanimoto distance defined for the hierarchical clustering was 0.3. A tanimoto dis-
tance of 0.3 is equivalent to a tanimoto similarity  of 0.7 (Tanimoto Similarity = 1 –	  
tanimoto distance).
5.4.3. Selection of compounds from the AZ database: Two-dimensional clustering 
of putative p38 inhibitors based on their activity and chemical similarity (sphere 
exclusion).
Two-dimensional clustering was performed across the entire AZ compound collection 
(Figure 5.9). The compounds were clustered separately  by activity (activity across 
multiple kinases) or structure. The results were analysed together, to identify ‘hot-
spots’	  where clusters of compounds with similar structures and activities were located. 
For molecular docking studies, compound clusters from the larger AZ compound col-
lection were selected if their co-cluster contained at least 5 compounds. Furthermore, 
the inhibition of a given compound against p38 needed to be a minimum of 50%. 296 
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compounds met this criterion and were docked into 6 available p38 crystal structures 
respectively (1KV2, 1A9U, 3GPO, 3GC8, 2EWA and 2OZA). These 6 p38 structures 
represent both human and mouse p38 isoforms α (human; 1KV2 and 1a9u, mouse; 
2EWA. 2OZA) and β (human; 3GP0 and 3GC8) identified to date. Therefore, through 
assessment of both apo and drug-bound ligands with the p38 enabled predictions of 
the binding modes and key amino acid, H-bond and other short  distance interactions 
e.g van der Waals between a drug compound and p38, required to inhibit  further p38 
phosphorylation .
5.4.4. Docking interactions between p38 isoforms and inhibitors.
Crystal structures available from PDB were prepared in Schrodinger Maestro (a 
commercial computational modelling suite, only  accessible at AZ not at Warwick due 
to licensing costs)using the protein preparation wizard. 296 compounds from the hier-
archical clustering were docked into the p38 isoforms (α and β). Ligand docking fol-
lowing energy minimisation was performed using Glide 2.5. A maximium of 10,000 
conformations, an RMSD of 0.25Å	  and standard docking protocol were applied to all 
296 ligands. Explicit waters were included in the ATP binding site. Glide docking 
scores were normalised using the following equation: New score = (original glide 
score –	  mean glide score) -10. This enabled the glide scores defined to approximate a 
similar area of scoring space across all receptors. Strain correction terms were applied 
to the output glide docking score. 
 Input conformations were the same across all 6 p38 proteins tested.  All ligand 
pose scores (calculated from energy of binding, electrostatic or covalent bonding in-
teractions between the ligand and the protein) were mean-centred (to minimise the 
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lenth of the axis for the ligand pose scores, and limit the effect of any significant out-
liers) to allow cross-comparison between different input proteins.
5.4.5. Selection of putative p38 isoform selective inhibitors.
To assess the selectivity of a compound for a particular isoform of p38, the glide 
scores for that compound were assessed as follows:
Selectivity of a compound for p38 alpha = best p38 alpha / mean (best alpha, best p38 
beta, best p38 delta, best p38 gamma).
5.4.6. MTT Cytotoxicity assay.
2 days prior to the MTT assay, 3T3 preadipocytes were plated into a 6 well plate at a 
density  of 1 x 105/ml. Preadipocytes rather than differentiated adipocytes were used as 
the expression of phospho-p38 which we are trying to inhibit through treatment with 
AZ_0002 (putative p38 beta inhibitor) is more highly expressed in preadipocytes than 
adipocytes). Once confluent, the media was removed and the cells were washed twice 
with PBS. Media was replaced with 0.2% BSA DMEM (2ml/well, no antibiotics, so-
dium pyruvate supplemented). The cells were serum starved 3 hours before the assay. 
The working stock of Thiazolyl Blue Tetrazolium Bromide (MTT, M2128, Sigma 
Aldrich) was 5mg/ml dissolved in water. Control cells were treated with equivalent 
volumes of DMSO to those used to solubilise the AZ compound. Following incuba-
tion of the 3T3 preadipocytes at 37°c and 5% CO2 for 0, 30 minutes or 3 hours, cells 
were washed twice with PBS. MTT (20μl of 5mg/ml stock; final concentration is 
25μM/well) was added to the wells and 3T3 cells were incubated for a further 4 hours 
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at 37°c and 5% CO2. Cells were washed twice more with PBS and the formazan 
crystals were eluted in 2ml DMSO: Isopropanol (1:1 ratio). Absorbance was read at 
570 nm. Background absorbance at 690 nm was subtracted from this reading. MTT 
incubated at 37°c and 5% CO2 in the absence of cells was used to assess non-specific 
binding of dye to plastic which may influence the absorbance readings.  Cytotoxicity 
was determined as the difference in absorbance between control and AZ treated cells 
and was expressed as a percentage. Each value for cytotoxicity  is an average of tripli-
cate measurements.
5.4.7. Serial dilution of AZ_p38 compounds.
A working stock of 10mM was made for compound, AZ_0002 (putative p38β inhibi-
tor). This compound was compared against a reference compound, SB203580 10μM 
(IC50, 0.02μM, against p38α and β). The AZ compound was serially  diluted to a final 
concentration/well of 2.22 –	   0.0001μM (in DMSO) and assayed in duplicate. 
SB203580 was assayed alongside the AZ compound at a concentration of 10μM.
5.4.8. Mitochondrial bioenergetics assay.
3T3-L1 preadipocytes were seeded at 20,000/100μl per well into XF24 microplate. 
Preadipocytes were selected, as the basal phospho-p38 (p-p38) expression was sig-
nificantly high compared to differnetiated adipocytes but  also, we sought to identify  if 
p38 inhibition (following AZ_0002, putative p38 beta inhibitor) translated into any 
significant functional effect on mitochondria oxidative capacity. Once adhered, the 
3T3’s were incubated in a final volume of 250μl growth media. Cells were grown 
overnight at 370c, 5% CO2 in 10% FBS (Biosera, South American origin): DMEM/
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F12 (11039_054), 5ml Penicillin/Steptomycin (15140-122, 10,000 Units/ml Pencillin, 
10,000 μg/ml Streptomycin), 2mM  L-glutamine (25030-081). Cell culture reagents 
were purchased from Invitrogen. 
Mitochondrial stress reagents were purchased from Sigma Aldrich and prepared to a 
final concentration/well as follows: Oligomycin (1μM  75351), FCCP (0.5μM,C2920), 
Antimycin and Rotenone (1μM cocktail of both compounds, A8674 and R8875). 
SB203580 (10μM, Cell signalling technology), AZ_0002 (0.1 μM, 0.01μM and 
0.005μM), concentrations given in brackets are final stock concentrations assayed per 
well (see section 4.2.1.3, for detailed assay protocol and inhibitory activities of the 
stress reagents in oxidative phosphorylation). The final concentration that 3T3 preadi-
pocytes were treated with was 10 fold lower than the final stock concentration (0.01, 
0.001 and 0.0005μM respectively. The compound was provided by AstraZeneca, 
Alderley Edge, Cheshire). The XF24 Seahorse Bioanalyser was used to assay the ef-
fect of the predicted p38β isoform inhibitor on mitochondrial bioenergetics. 
5.4.9. Mitochondrial copy number determination (mtDNA/nDNA ratio).
Total DNA was extracted from 20,000 3T3-L1 using DNeasy kit  (Qiagen) following 
treatment for 0, 30 minutes, 3 hours with AZ putative isoform inhibitor (see Figure 
2.3). Control cells were treated with DMSO at equivalent  volume to inhibitor treated 
cells. 3T3 preadipocytes were treated with the highest concentration of AZ_p38β_in-
hibitor (0.1 μM) used in the mitochondrial bioenergetics assay. The relative amounts 
of nuclear (Beta 2 microglobulin, B2M or receptor-interacting protein 140; RIP140) 
and mitochondrial DNA (NADH-ubiquinone oxidoreductase chain 2; ND2 or Cy-
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cloxygenase II; COXII) were determined by qPCR with previously  published primer 
sequences (Murholm, Dixen et al. 2009, Wai, Ao et al. 2010). The two primer sets 
(ND2/B2M  and COXII/RIP140) were purchased from Invitrogen. COXII forward; 5’-
A A T T G C T C T C C C C T C T C T A C G - 3 ’ , C O X I I r e v e r s e ; 5 ’ -
G T A G C T T C A G T AT C AT T G G T G C - 3 ’ , R I P 1 4 0 f o r w a r d ; 5 ’ -
C G G C C T C G A A G G C G T G G - 3 ’ , R I P 1 4 0 r e v e r s e ; 5 ’ -
A A A C G C A C G T C A G T A T C G T C - 3 ’ , N D 2 f o r w a r d ; 5 ’ -
A G G G A T C C C A C T G C A C A T A G - 3 ’ , N D 2 r e v e r s e ; 5 ’ -
T G A G G G A T G G G T T G T A A G G A - 3 ’ , B 2 M  f o r w a r d ; 5 ’ -




5.5.1. Hierarchical clustering analyses of known p38 active’s within the AZ com-
pound collection.
Cluster analysis based on chemical similarity  of core scaffold structures within the 
AstraZeneca compound collection generated 16 clusters (Figures 5.12). 38 clusters 
were generated when the AZ compound collection was clustered based on their kinase 
activity profile (Figures 5.12). 
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Figure 5.12. Hierarchical clustering analyses of known p38 inhibitor compounds 
within the AZ collection. Chemical similarity of the core scaffold structures within 
AstraZeneca’s compound collection generated 16 clusters. 38 clusters were generated 
based on clustering compounds based on their kinase inhibition profile. The activity 
of these kinase inhibitors within the compound collection were available across a 
panel of 69 kinases including p38. Together with a tanimoto distance of 0.3, 38 clus-
ters were generated. 
16	  clusters
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5.5.2. Clustering based on p38 kinase activity from known database 
1069 compounds of the 3259 had full activity data against the entire 81 kinase assays 
including p38α (performed by colleages at AstraZeneca, AZ). These compounds were 
utilised as a training set for 2190 compounds which had some missing activity data. 
The chemical similarity of these compounds to the training set enabled missing data 
on kinase inhibition to be approximated through imputation. 3259 resulting kinase 
inhibition profiles were generated as a result of this imputation work (Figure 5.10). 
For molecular docking studies, compound clusters from the larger AZ compound col-
lection were selected if their co-cluster contained at least 5 compounds. Furthermore, 
for a compound to be considered for further exploration as a potential p38 inhibitor, 
the compound needed to reduce p38 kinase activity by  at least  50%, as determined by 
the kinase inhibition assay  (section 5.2.8). 296 compounds met this criterion and were 
docked into the 6 p38 protein structures respectively (1KV2, 1A9U, 3GPO, 3GC8, 
2EWA and 2OZA). 
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Figure 5.13. Two-dimensional clustering of compounds based on their chemical 
and kinase activity profile. Identification of compounds, which are present in the 
same chemical and activity cluster, were used to refine clustering of the compounds. 
The clusters selected for further investigation were required to contain at least 5 com-
pounds and have an inhibit  the p38 kinase activity  by at least 50%. From the initial 
4299 compounds, 296 were identified for further investigation.
38 clusters (inhibitory activity of compound)
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5.5.4 Isoform selectivity of AZ p38 inhibitors.
AZ0002 was selected as a putative p38β selective inhibitor based on its isoform selec-
tivity profile (Table 4). Glide docking scores of the putative p38β inhibitory com-
pound revealed a mean centred score of -8.54 for 3GPO (p38β) and -10.14 for 2EWA 
(p38α). Comparison of the glide docking scores of this compound with other isoforms 
revealed lower scores of -5.25 and -4.95 for the p38γ (1CM8) and δ (3COI) respec-
tively. Analysis of the relative isoform specificity score of the AZ_0002 compound 
was defined as 100% for p38β compared to 67 and 69% for p38γ and p38α respec-
tively.
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Table 4. p38 isoform selectivity of AZ compounds.
To assess the selectivity  of a compound for a particular isoform, the glide scores for 
that compound were assessed as follows:  Selectivity of a compound for p38 alpha = 
best p38 alpha / mean (best alpha, best p38 beta, best p38 delta, best p38 gamma).
Table 5. p38 kinase inhibition assay (performed by colleages at AstraZeneca).
AZ_p38 beta was known as AZ_0002 in our studies. The kinase inhibition assay was 
used to determine the IC50 for the AZ_p38 compounds. 
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5.5.5. Effect of AZ_0002 on mitochondrial DNA content.
Assessment of mitochondrial DNA content by two different mtDNA/nDNA assays 
(ND2/B2M  and COXII/RIP140, Figure 5.11) concluded that  treatment of preadipo-
cytes with up  to 0.1μM of AZ_0002 for 3 hours did not result in a statistically signifi-
cant change in mitochondrial DNA content, probably due to limited exposure.
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Figure 5.14. Treatment of 3T3-L1 preadipocytes with the putative p38β inhibitor, 
AZ_ 0002, resulted in no significant change in mitochondrial DNA content. 
3T3-L1 were treated with AZ_0002 (10μM) or DMSO (control cells) for up to 3 
hours. Mitochondrial DNA content was assessed by two primer sets (ND2/B2M and 
COXII/RIP140). Each treatment was assayed three times for each primer set. The data 
presented here, represent the average of these triplicate readings. All data were non 
significant.
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5.5.6. Effect of AZ_0002 on mitochondrial bioenergetics of 3T3-L1 preadipo-
cytes.
Spare respiratory capacity of 3T3-L1 preadipocytes is reduced following acute treat-
ment with putative inhibitor of p38β, AZ_0002. The relative impairment of the spare 
respiratory capacity with AZ_0002 was equivalent to that achieved by  10μM of 
SB203580 (Figure 5.15. p  < 0.05). Furthermore, the coupling efficiencies of mito-
chondria were significantly decreased following treatment of preadipocytes with ei-
ther 10μM of SB203580 or AZ_0002 (putative p38β inhibitor) at 0.01μM (Figure 
5.15. p < 0.05). Intriguingly, the level of statistical significance was greater in SB 
relative to DMSO controls compared to AZ_002  (putative p38β inhibitor) treated at 
0.01μM (Figure 5.15. p < 0.05).
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Figure 5.15. Spare respiratory capacities of the 3T3-L1 preadipocytes were 
markedly diminished in the presence of the putative p38β inhibitor, AZ_0002. 
20,000 cells were seeded into an XF24 Seahorse cell culture plate and grown over-
night at 370c, 5% C02. Following 30 minutes of pretreatment with an AZ_0002, mito-
chondrial bioenergetics were assessed using mitochondrial stress reagents (1μM 
Oligomycin, 0.5μM FCCP, 1μM Antimycin/Rotenone). Spare respiratory capacity 
presented above, is calculated by division of basal respiration from maximal oxygen 
consumption (FCCP uncoupled respiration). Oxygen consumption rates per well were 
normalised per mg of protein (O2/min/mg). Concentrations of AZ_p38 inhibitor cho-
sen were selected based on their IC50 in the p38 kinase activity assay (p38α 0.01μM).
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5.6. Discussion.
Hierarchical cluster analysis was utilised as a methodology to select putative isoform 
selective compounds. Initially  we sought to investigate the difference in the number 
of clusters that would be generated if chemical similarity or kinase activity were used 
to define the AstraZeneca (AZ) compound collection. A sub-group  of 3259 com-
pounds previously identified by AZ to have potential inhibitory  activity against ki-
nases including p38 were utilised within initial cluster analyses (Figure 5.12). Cluster-
ing of compounds based on their chemical similarity generated 16 clusters whilst  in-
hibitory activity profile against a range of kinases including p38 clustering of the core 
scaffold structures produced 38 clusters (Figure 5.13). 
Co-clustering of the AZ compounds by inhibitory activity against a panel of 
kinases and chemical similarity enabled us to reduce the likelihood of false positives. 
Furthermore, the overlapping of clusters in this manner assisted us in selecting com-
pounds with a greater probability of p38 inhibitory  activity. Within the sub-group of 
3259, a panel of 110 kinase assays had been performed to identify kinase activity pro-
file of these compounds. However, as inhibition data was not available across all 
compounds, the decision was taken to exclude given kinase inhibition assays (28/110 
assays) rather than compounds. This rationale was selected as we did not want to 
compromise chemical diversity  within the compound collection. 1069 compounds 
contained full kinase inhibition profiling across the 82 assays. These compounds were 
used as a training set and multivariate analysis was performed on these compounds. 
Following this analysis, the missing data pattern within the panel of 3259 compounds 
was identified and missing data was imputed.
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 Clusters selected for further investigation were required to contain at least 5 
compounds and have an inhibitory action against kinases of greater than 50%. 296 
compounds met these eligibility  criteria. The scaffold substructures contained within 
these 296 compounds were identified. Once identified, the core scaffold structures 
that exemplified these known AZ actives were used to identify  new compounds 
within the larger AZ compound database. Furthermore, Scifinder was used to search 
published compounds containing similar scaffold structures. Substructure searching 
enabled any previous biological knowledge of these scaffold cores within diabetes, 
inflammation and ER stress to be evaluated. Molecular docking was undertaken to 
postulate the nature and selectivity by which these compounds and predict how they 
may interact with the MAPK receptors, p38α and β. Following modelling of the puta-
tive amino acid interactions between the p38β and AZ_0002 inhibitor, we sought to 
investigate whether mitochondrial bioenergetics could be affected by this compound. 
In previous studies with SB203580 we identified that p38 inhibition resulted in a re-
duction in spare respiratory capacity  of 3T3-L1 preadipocytes (Chapter 4). The exten-
sive characterisation of amino acid interactions between p38α or β and SB revealed 
the essential amino acid interactions required for its inhibitory  kinase action. Thr106 
located within a small side chain in a small hydrophobic groove adjacent to the ATP 
binding site, is the critical amino acid interaction required between SB and p38α in 
order for it elicit  its inhibitory activity. Spare respiratory capacity diminished follow-
ing incubation of 3T3-L1 preadipocytes with the AZ_0002, p38β inhibitor (Figure 
5.15). Whilst, mitochondrial copy number was slightly reduced following 30 minutes 
of acute treatment with p38 inhibitor AZ_0002, it did not decline to a statistically  sig-
nificant degree as a more chronic treatment was probably required (Figure 5.14).
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Spare respiratory  capacity (SRC) is calculated by comparison of the oxygen 
consumption rate (OCR) in an uncoupled versus a closed normal oxidative phospho-
rylation. As the addition of FCCP, a mitochondrial uncoupler occurs after the 30 min-
utes, any changes observed in SRC were not due to changes in mitochondrial bio-
genesis. Furthermore, the dose dependent nature of the decline in SRC supports the 
view that changes in SRC are due to the effects of the addition of the compound and 
not other factors such as cell death (performed by AstraZeneca, data not shown). The 
concentrations selected reflected a range around the predetermined IC50. For assess-
ment of the effect of our AZ_0002, putative p38β inhibitor compound, final concen-
trations of 0.1, 0.01 (IC50 of the compound) and 0.005μM on mitochondrial bioener-
getics of 3T3-L1 preadipocytes were assayed. 
 In conclusion our study has highlighted that p38 can regulate mitochondrial 
function. Site directed mutagenesis studies would be required to complement and 
support the amino acid interactions modelled between p38 (β) and p38 β inhibitor.
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Chapter 6:
Overall discussion and conclusions
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6.0. Discussion.
The aim of this thesis was to understand the role of mitochondrial dynamics in obesity 
associated type 2 diabetes. To study this we used human adipose tissue from lean, 
overweight and obese individuals and observed that mitochondrial dynamics was dys-
regulated in adipose tissue of obese subjects compared to lean. To further understand 
the effect of obesity we used pre and post bariatric surgery  samples where the effect 
of weight loss and surgical procedure were studied in the regulation of mitochondrial 
dynamics.  The ultimate aim was to study how this important  system is regulated in 
adipose tissue. Our preliminary study  showed that p38 MAPK pathway may  have an 
important role in the regulation of mitochondrial dynamics, and therefore, the effect 
of this pathway on the regulation of mitochondrial fission and fusion was investigated 
using the 3T3-L1 murine cell line. 
6.1. Is mitochondrial dynamics differentially regulated in the subcutaneous adipose 
tissue of lean, overweight and obese individuals?
Chapter 2 describes the study of mitochondrial fusion and fission in human AbSc AT 
of lean, overweight and obese subjects. 
 Adipose tissue plays an important  role in the regulation of energy homeostasis 
and was used for the investigation of mitochondrial dynamics. It  also acts as an endo-
crine organ and depot for dietary nutritional excess, storing triglycerides within adi-
pocytes until they are required by the cell. The regulation of mitochondrial dynamics 
was studied by evaluating expression levels of markers of mitochondrial fission as well as 
fusion. This approach offers the ability to explore whether a single or multiple mitochon-
drial fission marker genes were altered by adiposity. Our data demonstrates that markers 
200
of mitochondrial fission increased with adiposity, as evidenced by the significantly  in-
creased expression levels of Fis1 in obese compared to lean controls (Figure 
2.4).Considering the opposing arm of mitochondrial dynamics next, markers of mito-
chondrial fusion genes (Opa1 and Mfn2) were significantly and positively correlated 
in AbSc AT of lean subjects (Figure 2.6). Conversely, in obese individuals no signifi-
cant correlation was present (Figure 2.6). This suggests a dysregulation of mitochon-
drial dynamics in obese, as a consequence mitochondrial health may be compromised 
leading to a reduction of mitochondrial bioenergetics.
 Our results clearly support previous studies, which indicate that markers of mito-
chondrial dynamics are affected by  adiposity and support the known essential role of op-
timal mitochondrial dynamics in preventing the development of mitochondrial dysfunc-
tion. Mitochondrial dynamics adapts to nutritional conditions working to maintain mi-
tochondrial health (Twig, Hyde et al. 2008). Conditions of nutritional excess are 
joined with fragmented mitochondria (Otera, Wang et  al. 2010). A limitation of our 
study which would require future investigation is the  assessment of the bioenergetic ca-
pacity and characterisation of the mitochondrial capacity and morphology in adipose tis-
sue from each individual to see how closely  our mitochondrial dynamics expression 
analyses reflect  mitochondrial function. 
  In summary, Chapter 2 concluded that markers of mitochondrial dynamics 
genes in human AbSc AT were differentially  expressed in lean, overweight and obese 
individuals. Adiposity was accompanied by an increase in expression of the mito-
chondrial fission (Fis1 and Drp1) and fusion (Opa1 and Mfn2) gene expression mark-
ers in AbSc AT.
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6.2. Is mitochondrial dynamics affected by weight loss or Bariatric Surgery in 
T2DM individuals?
Chapter 3 investigated mitochondrial dynamics within morbidly obese T2DM sub-
jects before and after undergoing elective bariatric surgery.
Mitochondrial dysfunction is known to commonly afflict those with T2DM and 
other metabolic disease such as cardiovascular disease (Sjostrom, Lindroos et al. 
2004, Ren, Pulakat et al. 2010). A key line of evidence for this hypothesis is that indi-
viduals with cardiac function mutations also present with compromised mitochondria 
and mutations within proteins controlling mitochondrial dynamics (Jung, Martins et 
al. 2008, Murray, Cole et al. 2008, Doenst, Pytel et al. 2010). 
Following the conclusion that mitochondrial dynamics was influenced by adipos-
ity, we investigated whether weight loss would have a positive effect on mitochon-
drial dynamics. To study this, adipose tissue was used from pre and post bariatric sur-
gery from patients who had significant weight loss 6 months post-surgery. 
Despite, indirect evidence of mitochondrial dysfunction, insulin resistance and 
adiposity, it is still unclear how these processes are connected at a molecular level. 
Bariatric surgery is one of the most successful methods to resolve insulin resistance 
(Levy, Fried et al. 2007, Buchwald, Estok et al. 2009, Carlsson, Peltonen et al. 2012, 
Nijhawan, Richards et al. 2013). Clinical observations have highlighted that the more 
extensive structural remodelling of the gastrointestinal tract during bariatric surgery, 
the more significant the correlation with diabetes resolution (Neff 2013). If a single 
surgical procedure can offer weight loss, diabetes remission and the redressing of mi-
tochondrial dynamics and thus enhance the metabolic activity often lost during obe-
sity, this would offer patients a distinct advantage as well as a clinical argument to-
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wards performing this surgical procedure over others available or providing medical 
care to manage the diabetes and obesity conditions.
Initial investigation of mitochondrial dynamics in subcutaneous adipose tissue 
before and after bariatric surgery  revealed that biliopancreatic diversion (BPD) sur-
geryhad the greatest  number of improvements in clinical parameters and differences 
in mitochondrial dynamics observed in the post-surgical AbSc AT samples. Consistent 
with previous studies, it was concluded that weight loss was most  likely to be respon-
sible for an individual’s remission of T2DM and other clinical improvements (Table 
2.) (Hotamisligil 2007, Bradley, Conte et al. 2012) (Figures 3.6 and 3.7). Other stud-
ies have concluded that 20% weight loss is necessary to result in a demonstrable im-
provement in the skeletal muscle insulin sensitivity of extremely obese people (Cam-
pos, Rabl et al. 2010, Lima, Pareja et al. 2010, Bradley, Conte et al. 2012). In agree-
ment with this, at 6 months after surgery all our patients had lost at least 20% of their 
pre-operative weight (Table 2). Thus far, our data clearly shows an overall reduction 
in the expression of markers of mitochondrial fission and fusion (Figures 3.2 and 3.5).
Similar to the adiposity study, a limitation of our study which would require 
future investigation is the assessment of the bioenergetic capacity and characterisation 
of the mitochondrial capacity  and morphology in adipose tissue from each individual 
to see how closely  our mitochondrial dynamics expression analyses reflect mitochon-
drial function.
In summary, this study provides a novel contribution to current knowledge 
within the field of diabetes and bariatric surgery. This study highlights that the re-
dressing on markers of mitochondrial dynamics expression in AbSc AT reflects a pos-
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sible mechanism through which mitochondrial dysfunction can be corrected following 
weight loss surgery.
6.3. Does p38 regulate mitochondrial dynamics? 
Chapter 4 characterised the expression profile of the phospho-p38 and mitochondrial 
dynamics genes during the differentiation of adipocytes. Phospho-p38 is known to 
rapidly decrease from its peak in the early stages of differentiation to barely detect-
able levels at  the terminal stages (Engelman, Lisanti et al. 1998). Phospho-p38 ex-
pression was modulated in 3T3-L1 by chemical inhibition SB203580 or activation by 
transfection of an MKK6 overexpression using MKK6(Glu), to determine its impact 
on mitochondrial dynamics. 
In recent years, the central role of adipose tissue in controlling energy  metabo-
lism and the significant impact of balancing energy homeostasis (Rosen and Spiegel-
man 2006) on mitochondrial function has become better understood. Mitochondrial 
function is regulated through biogenesis and morphology. Regulation of mitochon-
drial morphology is orchestrated by mitochondrial dynamics (Okamoto and Shaw 
2005, Huang, Galloway  et al. 2011). A clear connection between mitochondrial dy-
namics and health is demonstrated by the observation that mammalian cells devoid of 
mitochondrial fusion display stunted growth rates and diminished respiratory capacity 
(Legros, Lombes et al. 2002, Huang, Galloway et al. 2011).
SB203580, a p38α and β isoform inhibitor was assayed to assess the duration 
of p-p38 inhibition together with its cytotoxicity in 3T3-L1 preadipocytes (Badger, 
Bradbeer et al. 1996). p-p38 expression was significantly  decreased in our 3T3-L1 
preadipocytes, after incubating for 30 minutes to an hour with SB203580 (10μM, 
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Figure 4.10). This was accompanied by no significant reduction in mitochondrial 
DNA content (Figure 4.11). However, markers of mitochondrial fission and fusion, 
Fis1 and Mfn2 respectively, decreased significantly in protein expression following 
this acute p38 inhibition (Figures 4.12 and 4.13). Our present findings strongly sug-
gest a novel regulation of mitochondrial dynamics by p38. Inhibition of p38 resulted 
in diminished mitochondrial bioenergetic capacity  and thus a reduction in mitochon-
drial efficiency. A limitation of this study  is the lack of qunatification of the change in 
the rate of mitochondrial dynamics following p38 inhibition.In order to acheive quan-
titative values for mitochondrial dynamics requires pin point laser activation of a sin-
gle green fluorescent mitochondria within stably transfected cells. The majority of 
work in these quantitative experiments thus far has been performed in freshly isolated 
mouse (from sacrificied mice) or human adipocytes (needle biopsies) using a 2D-
scanning laser confocal microscope currently  unavailable within our department. The 
activation plane and specificity of the laser activation of a single GFP labelled mito-
chondria is beyond the capabilities of our confocal microscope.Therefore, in order to 
perform these experiments requires the development of a collaboration, which was 
not possible in our case due to insufficient time (the dynamics experiments were op-
timised and successful performed only a few weeks before the end of my experimen-
tal work) but could be arranged for future projects.Further studies involving assess-
ment of the rate of mitochondrial dynamics and bioenergetics in MKK6 transfected 
3T3-L1 and human preadipocyte models will be required to provide additional sup-
port to our work.
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6.4. Modelling and selection of putative p38 α and β isoform inhibitors.
p38 is known to interact with the putative inhibitors via 3 key amino acid interactions; 
Thr180, Tyr182 and Met109 (Adams, Boehm et al. 2001). Of the 3259 compounds 
clustered by chemical similarity of the compounds substructures, descriptors or activ-
ity, 296 compounds initially  met similar criteria to SB203580. The scaffold substruc-
tures contained within these 296 compounds were identified. Once identified, the core 
scaffold structures that exemplified these known AZ actives were used to identify new 
compounds within the larger AZ compound database. Molecular docking was under-
taken to postulate the nature and selectivity by which these compounds and predict 
how they may interact with the MAPK receptors, p38α and β. Following modelling of 
the putative amino acid interactions between the p38β and AZ_0002 inhibitor, we 
sought to investigate whether mitochondrial bioenergetics could be affected by this 
compound.
 In conclusion our study has highlighted that p38 can regulate mitochondrial 
function, as treatment of 3T3-L1 preadipocytes resulted in a significantly diminished 
spare respiratory capacity compared to DMSO treated controls. Whilst the increase is 
oxygen consumption rate in mitochondria occured following treatment with the p38 
inhibitor, looks promising if the duration of this enhancement could be selecively and 
acutely  activated, translation of this compound as an anti-obesity drug is unlikely. 
One of the main factors that would prevent its transition into future drug development 
is the risk of increasing cancer through manipulation of p38 signalling. Therefore, 
these studies were performed to evaluate the regulation of mitochondrial dynamics 
and the signal transduction processes that accompany it. An additional limitation of 
our study is that only one exemplar of putative p38 beta inhibitors was assayed within 
206
the mitochondrial bioenergetics assay. Given additional time, would have permitted 
the remaining 9 from the top 10 selected compounds to be individually  assayed. Site 
directed mutagenesis studies would be required to complement and support  the amino 
acid interactions modelled between p38 (β) and p38 β inhibitor. 
6.5. Conclusions.
This thesis sought to expand our knowledge and understanding of the actions of p38 
on mitochondrial dynamics in adipose tissue. The current studies have highlighted 
that markers of mitochondrial dynamics are upregulated in adiposity. Furthermore, 
assessment of the impact of bariatric surgery in morbidly obese T2DM  subjects con-
cluded that  weight loss rather than the surgical procedure alone resulted in  a reduc-
tion in the expression of mitochondrial fusion and fission markers. Together, the re-
sults presented in this thesis support previous reports that mitochondrial dynamics are 
critical to adapt and maintain metabolic health required to meet the energetic demands 
of the cells in which they reside. Our results extend our understanding of mitochon-
drial dynamics in adiposity through the novel finding that p38 is involved in the posi-
tive regulation of mitochondrial dynamics in adipocytes.
6.6. Future work.
The current studies have highlighted that  markers of mitochondrial dynamics are 
down regulated with adiposity and are positively regulated by p38 within 3T3-L1 
preadipocytes. Given additional time for this project, I would have liked to investigate 
the following concepts in more detail:
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• Confocal microscopy of mitochondrial dynamics in transfected with the con-
stitutively active MKK6(Glu) vector in preadipocytes
• Culturing of human adipocytes and p38 inhibition through genetic and phar-
macological mechanisms
• Effect of p38 on quality  control mechanisms; feedback responses between 
PQC and mitochondrial dynamics
• Investigate the mechanisms of cross-talk between ER and mitochondrial dy-
namics and how p38 inhibition impacts upon these.
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